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Type 2 diabetes is a well-established risk factor for cardiovascular disease, with the landmark 
Framingham study in the 1970’s reporting the incidence of heart failure is significantly higher 
in diabetic (DM) patients compared to non-diabetic (nDM) patients.  However the underlying 
mechanisms that link type 2 diabetes with heart failure are still unclear. Recent evidence has 
shown that diabetic patients and mouse models of diabetes have an up-regulation of 
calmodulin-dependent protein kinase delta (CaMKIIδ) activity. CaMKIIδ is a multifunctional 
serine-threonine kinase expressed as four different genes that generate four isoforms (αβγδ) 
and a number of splice variants. Within the myocardium δ is the predominant form, whilst a 
modest expression of γ has also been shown. Upon CaMKIIδ activation is involved in 
coordination of the ion channels and Ca2+ handling proteins involved in excitation-contraction 
and excitation-transcription coupling in the myocardium. Excessive CaMKIIδ activation in 
the myocardium has been linked with reduced myocardial performance due to disturbed Ca2+ 
handling. However this mechanism of reduced cardiac function and the involvement of 
CaMKIIδ has not been investigated in the diabetic heart. Therefore, this thesis set out to 
investigate the role of CaMKIIδ in the type 2 diabetic heart and the potential therapeutic role 
for CaMKIIδ inhibitors.  
 
To investigate whether CaMKIIδ activation is increased prior to systolic dysfunction in the 
type 2 diabetic heart western blots were carried out to measure the activation levels of 
CaMKIIδ in leptin-receptor-deficient 20-week-old male non-diabetic and type 2 diabetic 
Zucker diabetic fatty (ZDF) rats. Western blots confirmed that there was no change in 
expression of CaMKIIδ (0.95 ± 0.08 vs 1.15 ± 0.10, nDM (n=8) vs DM (n=8) but CaMKIIδ 
phosphorylation was significantly increased in the DM animals (0.77 ± 0.13 vs 1.40 ± 0.26) 
indicating that CaMKIIδ activation was increased in the type 2 diabetic ZDF heart prior to 
systolic dysfunction. The next step was to measure contraction and relaxation in the heart and 
the effects of CaMKIIδ inhibitors, KN93 and AIP. To do this small cardiac muscles 
(trabeculae) were isolated from the right ventricle free wall and stimulated at various 
frequencies. It was shown that the diabetic trabeculae had a reduced contractile force and 
speed of contraction and relaxation, but CaMKIIδ inhibition with both KN93 and AIP was 
able to reverse the impairments in contractility.  
 
To investigate the mechanisms behind the reduced contractility in the type 2 diabetic 
trabeculae and the effects of CaMKIIδ inhibition, cardiomyocytes were isolated from 18-19 
! iii 
week old male nDM (n=6) and DM (n=6) ZDF rats and loaded with Fluo-4AM and viewed 
under a confocal microscope to allow for the measurement of intracellular Ca2+ during and 
between transients. Measurements were completed in the presence of the CaMKIIδ inhibitors 
KN93 and AIP. It was observed that there was no alteration in Ca2+ homeostasis in the 
diabetic and non-diabetic cells during transients but it was altered between transients, as 
demonstrated by an increase in Ca2+ waves. CaMKIIδ inhibition with KN93 and AIP was able 
reduce this marker of pro-arrhythmic behaviour.  
 
To further interrogate the potential of CaMKIIδ inhibition as a therapeutic measure in the 
clinic the effects of chronic inhibition must be investigated. To do this a mouse model of type 
2 diabetes (db/db) (n=8) alongside nDM control mice (n=11) were injected with KN93 (10 
µmol/kg) every other day from the age of 14 to 18 weeks of age. At 18 weeks of age right 
ventricle tissue was taken for the measurement of cardiac fibrosis using Masson’s Trichrome 
stain. It was found that there was no difference in fibrotic remodelling between the DM and 
nDM right ventricular tissue (1.01% vs 1.05%), and also no effect of the CaMKIIδ inhibitor, 
KN93, on cardiac fibrosis (nDM= 1.24% vs DM= 0.93 %). Therefore indicating that chronic 
CaMKIIδ inhibition has no detrimental effects on inducing cardiac fibrosis in either the nDM 
or DM heart.  
 
Therefore the results from this study identify CaMKIIδ as a novel mediator of cardiac 
contractility in the type 2 diabetic heart, pre systolic dysfunction. The findings have suggested 
that altered Ca2+ handling may not be the only mechanism to attribute to for the reducing 
contractility in the diabetic heart, as Ca2+ homeostasis was not altered during transients. 
However pro-arrhythmic behaviour was increased in the isolated diabetic cardiac muscle and 
cardiomyocytes, which CaMKIIδ inhibition was able to reduce. Therefore providing evidence 
of the potential therapeutic role of CaMKIIδ, which can be built upon to further investigate its 
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1.1 Diabetic heart dysfunction 
 
Diabetes mellitus is an increasing epidemic worldwide, with over 8 million people newly 
diagnosed globally each year (Whiting et al., 2011). Recent projections predict an increase in 
people suffering from diabetes mellitus from 382 million in 2013 to 592 million by 2035 
(Guariguata et al., 2014). However these estimations only take into account factors such as 
urbanization and population ageing, and thus other factors such as obesity may drive the 
prevalence of diabetes even higher than predicted estimates (Guariguata et al., 2014; Whiting 
et al., 2011).  
 
Diabetes mellitus is a chronic disease characterised by the inability to maintain normal 
glucose homeostasis, which in turns leads to chronic hyperglycemia. Two forms of diabetes 
exist, but the two have different pathophysiological mechanisms. Type 1 diabetes (T1D) is an 
autoimmune disease directed against insulin-secreting β-cells of pancreatic islets, which leads 
to destruction of 80-90% of β-cells and ultimately to decreased insulin secretion (Daneman, 
2006). Type 2 diabetes (T2D) is induced via two main mechanisms: increased insulin 
requirements to maintain normal glycaemia due to the resistance of the peripheral tissue to the 
action of insulin, and also an inability of the β-cells to respond to the increased needs for 
insulin due to an alteration in insulin secretion (Cnop et al., 2005; Prentki & Nolan, 2006). 
Approximately 95% of diabetic cases are classified as T2D and, due to this high prevalence, 
T2D is the main focus of this thesis. 
 
Untreated or poorly controlled T2D is a serious threat for tissues and organs of the body, and 
one major risk factor for diabetic patients is an increased risk of cardiovascular disease. The 
landmark Framingham study many decades ago showed that the incidence of heart failure 
(HF) is twice as high in males with diabetes and five times higher in females with diabetes 
compared to age-matched control subjects (Kannel & McGee, 1979; Marwick, 2006). 
Approximately 80% of deaths in diabetic patients can be attributed to cardiovascular disease 
(Hayat et al., 2004). In 1972, Rubler et al. identified a direct link between diabetes and heart 
disease, termed ‘diabetic cardiomyopathy’ (DCM), and this pathology is independent of 
coronary artery disease (CAD), valvular or congenital heart disease, or hypertension. 
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Subsequent studies showed that diabetic patients have an increased lifetime risk of developing 
HF and increased risk of mortality from myocardial infarction (MI) (Malmberg & Ryden, 
1987). The term DCM has become widely accepted within the literature, whilst others have 
placed myocardial disease during diabetes under a broader term of ‘Diabetic Heart 
Dysfunction’ (DHD) (Marwick 2006; Asmal et al., 1980). DHD encompasses CAD or 
coronary heart disease (CHD); HF, cardiac autonomic neuropathy (CAN); and/or DCM 
(Rawal et al., 2014).  The term DHD will be used in this thesis to describe diabetic heart 
dysfunction induced by T2D.  
 
Despite cardiac dysfunction being a well-established consequence of T2D, there is no specific 
diabetic cardiac therapy available to patients. This is due to the fact that DHD is a 
multifactorial disease, which encompasses a number of molecular and cellular mechanisms 
that have been proposed to underlie the development of cardiac dysfunction. These 
mechanisms include fibrosis, inflammation, apoptotic and necrotic cell death, alterations to 
the renin angiotensin activation system, increased fatty acid utilization, lipotoxicity, 
mitochondrial dysfunction, altered myocardial insulin signalling, oxidative stress, autophagy, 
changes in microRNAs, and epigenetics (Fang et al., 2004; Poornima et al., 2006; Boudina & 
Abel, 2007; Bugger & Abel, 2014). This thesis focuses on impaired calcium (Ca2+) handling 
in T2D DHD, as Ca2+ is a critical ion involved in contraction and relaxation of the heart. 
Other mechanisms will be described later in this introductory chapter. 
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1.2 Cardiac calcium handling  
 
Ca2+ is an alkaline earth metal that, when present in water, forms a divalent cation. In all 
living cells Ca2+ plays a significant role acting as an intracellular messenger regulating a 
diverse range of cellular processes, such as muscle contraction, cell proliferation and gene 
transcription (reviewed in Bootman et al., 2001).!
 
During each cardiac cycle an electrical action potential produces a Ca2+ transient that triggers 
cardiomyocyte contraction, a process otherwise known as excitation-contraction coupling 
(ECC) (Bers, 2002). Ca2+ is a critical second messenger in cardiac muscle, and thus any 
alteration in the handling of Ca2+, or the intracellular Ca2+ concentration, will have major 
acute and chronic consequences on cardiac function (Hasenfuss, 1997 & 1998; Hasenfuss & 
Pieske, 2002).  
 
1.2.1. Action potentials in cardiomyocytes  
 
A cardiac action potential is created when there are differences in ion concentration between 
the interior and exterior of the cell. This is otherwise referred to as intracellular potential, 
which in turn then provides a specific electrical stimulus for excitable cells such as 
cardiomyocytes to contract (see Figure 1.1. for action potential schematic). The action 
potential in ventricular cardiomyocytes is composed of 5 phases (0-4). Phase 4 is the resting 
phase, in which the sodium (Na+) and Ca2+ channels are closed and, due to constant leak of 
potassium (K+) out of the cell, the membrane potential is set at -90 mV. This is followed by 
phase 0, otherwise known as depolarization. During phase 0 an action potential is triggered by 
a neighbouring ventricular cardiomyocyte and the membrane potential will rise above -90 
mV. Na+ leaks into the cell via the opening of Na+ channels one by one and the membrane 
potential eventually reaches a threshold. This generation of an inward Na+ current rapidly 
depolarizes the membrane potential to slightly above 0 mV for a transient period otherwise 
known as overshoot. At this point the Na+ channels close and the voltage-gated L-type Ca2+ 
channels (LTCC) open, causing a steady influx of Ca2+ down its concentration gradient. At 
this stage the membrane potential is slightly positive and the action potential moves into 
phase 1, known as early repolarization, in which the K+ channels open briefly. This outward 
flow of K+ returns the membrane potential to 0 mV. This is followed by phase 2 (plateau 
phase). Here the cardiomyocyte is still in a constant inward current of Ca2+ as the LTCC 
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remain open. K+ leaks out via the delayed rectifier K+ channels and down its concentration 
gradient. The inward current of Ca2+ and outflow of K+ are electrically balanced, and the 
membrane potential is maintained at a plateau just below 0 mV. The final repolarization is 
phase 3, in which the Ca2+ channels are inactivated and the membrane potential is brought 
back to its resting potential of -90 mV as the persistent outflow of K+ exceeds Ca2+ inflow and 
prepares the cell for a new cycle of depolarization. During this phase membrane ionic 
concentration is restored to normal levels as the sarcolemmal Na+-Ca2+ exchanger (NCX), 
Ca2+-ATPase and Na+-K+-ATPase restore Na+ and Ca2+ ions to the extracellular environment 





Figure 1.1 Ventricular cardiomyocyte action potential schematic. Phase 0, rapid 
depolarization; phase 1, early rapid depolarization; phase 2, plateau; phase 3, final rapid 
repolarization; phase 4, resting membrane potential. Black line indicates action 
potential. Blue line represents cytosolic [Ca2+] changes instigated by the action 
potential. Red line presents contraction and relaxation corresponding with the rise and 
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1.2.2 Calcium induced calcium release!
 
Contraction of the heart is mediated via a positive feedback mechanism known as Ca2+ 
induced Ca2+ release (CICR) (Fabiato & Fabiato, 1977; Bers, 2002). During depolarization 
the voltage-gated LTCC allow for an influx of Ca2+ into the cardiomyocyte. This triggers the 
release of a large pool of Ca2+ stored in the sarcoplasmic reticulum (SR) through the Ca2+ 
release channel, the ryanodine receptor (RYR2). The LTCC are located at the transverse 
tubules that form deep invaginations in the sarcolemma. Each LTCC that is positioned on the 
tubules delivers Ca2+ to 6-20 RYR2 causing activation and Ca2+ release into the cytosol 
(Lukyanenko et al., 1996). The Ca2+ that is released via CICR is then actively transported to 
the myofilament protein complex troponin, triggering a shift in tropomyosin and allowing 
myosin to bind to actin. Myosin attachment to the thin filaments causes a rapid shortening of 
the sarcomere resulting in systolic contraction of the cardiomyocyte. This process is otherwise 
known as cross bridge cycling (Landesberg & Sideman, 1994). See Figure 1.2 schematic for 
schematic of CICR during ECC. 
 
1.2.3 Cardiac relaxation  
 
Relaxation occurs when cytosolic Ca2+ concentration declines, and Ca2+ dissociates from 
troponin to allow for diastolic filling of the heart (Katz & Lorell, 2000). During relaxation, the 
SR retrieves Ca2+ through action of the SR Ca2+-ATPase (SERCA2a), which pumps the same 
amount of Ca2+ that was released during CICR back into the SR (Bers, 2000). The SERCA2a 
pump is modulated by the protein phospholamban (PLB), which when in a dephosphorylated 
state acts as natural inhibitor of SERCA2a pump activity (Tada & Katz, 1982). When PLB is 
phosphorylated the brake on SERCA2a activity is relieved, allowing for greater SR influx of 
Ca2+ and a faster rate of relaxation and diastolic filling. Ca2+ extrusion from the sarcolemma 
occurs via the NCX, where under normal conditions the removal of Ca2+ via the NCX 





















































Figure 1.2 Excitation contraction coupling. (1) An action potential is generated due to 
changes in the ion concentration either side of the plasma membrane, other referred to as 
intracellular potential. The action potential propagates down the t-tubule. At this stage the 
membrane potential is at -40 mV causing the L-type Ca2+ channel (LTCC) to open up and 
allow a steady influx of Ca2+ into the cell. (2) Entry of Ca2+ into the cell triggers further 
release of Ca2+ from the sarcoplasmic reticulum (SR) (CICR) via the ryanodine receptor 
(RyR2). Ca2+ then moves to the myofilaments where it binds to troponin to allow for 
contraction to occur. (3) Relaxation occurs when Ca2+ is removed and taken back up to the 
SR. Phosphorylation of phospholamban (PLB) releases inhibition of SERCA, increasing the 
rate of Ca2+ uptake back up into the SR. Ca2+ is also extruded from the cytosol of the cell via 
sarcolemmal Na+/Ca2+ exchange (NCX). (4) The mitochondria take up excess Ca2+ via the 
mitochondrial Ca2+ uniporter, which contributes to the regulation of ATP production. Ca2+ is 
removed from the mitochondria matrix via the NCX pump as 3+ Na ions are pumped into the 
matrix and one Ca2+ ion is pumped out. Numbers in red and blue are the relative percentages 
of Ca2+ flux per compartment for human (red) and rat (blue) in the ventricular cardiomyocyte 




1.2.1.4 Autonomic regulation of the heart  
 
The cardiac cycle of the heart is modified by the autonomous nervous system, which is 
composed of two branches, the sympathetic and parasympathetic bifurcations. The 
sympathetic nervous system acts to increase developed contractions (inotropy) and accelerate 
relaxation (lusitropy) in response to an increased work demand placed on the heart (Katz, 
2001). Noradrenaline released from the sympathetic nervous system activates β-adrenergic (β-
AR) receptors, which in turn activate a GTP-binding protein (Gs). The Gs stimulates the 
activation of adenylyl cyclase, which converts adenosine triphosphate (ATP) into a second 
messenger, cyclic adenosine-3’, 5’-cyclic monophosphate (cAMP) (Katz, 2001; Saucerman et 
al., 2003). This cascade leads to the activation of protein kinase A (PKA) and subsequent 
phosphorylation of LTCC (Gerhardstein et al., 1999) and RyR2 (Marx et al., 2000) to 
promote greater force of contraction. PKA also phosphorylates troponin I (TnI), and S16 on 
PLB (Sulakhe & Vo et al., 1995) to allow for faster crossbridge cycling and increased 
removal of cytosolic Ca2+ respectively, both of which accelerate relaxation. The 
parasympathetic input acts as an antagonist to the sympathetic nervous system as 
acetylcholine (ACh), a major neurotransmitter is released from the parasympathetic nerves 
which then binds to muscarinic ACh receptors (Mendelowitz, 1999) to reduce heart rate 




1.3 Impaired contractility and Ca2+ handling in the type 2 diabetic heart 
 
Reduced contractility in the diabetic heart in the absence of vascular injury was reported 
many decades ago (Fein et al., 1981; Penpargkul et al., 1980; Regan, 1983). The first 
hypothesis of the mechanism behind the reduced contractility was a disturbance in 
intracellular Ca2+ homeostasis (Dilmann, 1980; Penpargkul, 1981; Pierce & Dhalla, 1981). 
Since these studies in the 1980s numerous others have reported disturbed Ca2+ handling in the 
diabetic heart. However there still remains no consensus on the actual molecular mechanisms 
by which defects in Ca2+ handling are occurring. Those investigating Ca2+ handling at the 
isolated single cell level have reported contrasting findings, as some have shown the Ca2+ 
transient to be decreased (Noda et al., 1993; Prigent et al., 1997), increased (Howarth et al., 
2005) or unchanged (Yu et al., 1997). More recent studies have reported in T1D rodent 
models increased resting intracellular Ca2+ levels, attenuated SR Ca2+ release and reuptake, 
delayed recovery of the intracellular Ca2+ transient, reduced expression of SERCA2a and 
NCX exchanger, and compromised mitochondrial Ca2+ handling (Bers, 2000; Bugger & Abel, 
2014; Ye et al., 2003; Ye et al., 2004; Zhang & Chen, 2012). Similar findings have been 
observed in T2D db/db mice, that have decreased systolic and diastolic levels of Ca2+, 
decreased rates of Ca2+ decay, Ca2+ leak from the SR, and decreased SR Ca2+ load (Kralik et 
al., 2005; Bugger & Abel, 2009).  Figure 1.3 is a schematic adapted from Pierce & Russell 
(1997) illustrating the proposed mechanisms of altered Ca2+ handling in the diabetic heart. 
The current disparity in findings may be due to differences in animal models (T1D versus 
T2D) and experimental conditions, such as a stimulation frequencies and temperatures (Zhang 
et al., 2008).  
 
Investigations in human patients have also demonstrated impaired cardiac function and 
altered Ca2+ handling in the setting of the diabetic heart. Reuter et al. (2008) compared non-
diabetic and diabetic patients with CAD, but without signs of HF, and showed prolonged 
intracellular Ca2+ release in the non-failing myocardium of T2D patients. A recent study by 
Lamberts et al. (2014) reported a reduction in diastolic function in isolated trabeculae from 
right atrial appendages (RAA) of T2D patients (with CAD and without cardiac failure), 
demonstrated by a slower rate of relaxation, prolonged 50% relaxation time and, time 
constant of relaxation. Despite this impaired relaxation, the expression of SERCA2a protein 
was increased in the samples of the T2D patients, while expression of PLB was decreased. 
These observations suggest improved relaxation of the RAA, and the authors attributed these 
unexpected findings to a compensatory mechanism in response to increased levels of atrial 
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myocardial fibrosis, demonstrated by an elevated collagen deposition. Increased cardiac 
fibrosis would ultimately lead to increased myocardial stiffness and could eventually result in 
both systolic and diastolic dysfunction.  
 
Given the disparity in findings from the studies mentioned in the first paragraph of this 
section above that the diabetic heart has been reported to exist in both Ca2+ deficient or a Ca2+ 
overload state, and that its response to stimuli that alter [Ca2+]I is defective (Pierce & Russell, 
2007) indicate that more research is required to delineate the mechanisms that underpin 
altered Ca2+ handling and reduced contractility in the T2D heart. Studies investigating 
contractility in HF patients have pointed towards a protein kinase known as Ca2+/calmodulin 
dependent protein kinase II (CaMKII). CaMKII modulates a number of cardiac Ca2+ handling 
pathways, and inhibition of CaMKII in isolated cardiac muscle improves contractile 
performance. Therefore CaMKII has emerged as a potential candidate to investigate for its 















Figure 1.3 Proposed mechanisms of altered Ca2+ handling in the diabetic heart. Schematic adapted from Pierce et al. (1997). A Dysfunctional 
sarcoplasmic reticulum (SR) will result in depressed SR Ca2+ uptake leading to a slower rate of relaxation.  Depressed SR Ca2+ release due to reduced 
RyR2 activity leads to lower maximal tension generation. This dysfunction in SR Ca2+ reuptake and release will ultimately lead to a significantly 
reduced cardiac performance. B, Maintenance of Ca2+ homeostasis can be disturbed in diabetes. Any alterations to active Ca2+ transport via 
modifications to the NCX, as well as depressed passive Ca2+ buffering due to alterations in Ca2+ buffering proteins (NCX, SERCA, calmodulin, 
troponin C, Ca/Mg) can both disrupt Ca2+ flux resulting in reduced contractile performance and predisposition to myocardial injury.  
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1.4 Calcium/calmodulin dependent protein kinase II (CaMKII) 
 
CaMKII is a multifunctional serine-threonine kinase activated by increased intracellular Ca2+. 
It was first identified in the nervous system, where it is highly enriched and involved in 
learning and memory processing (Braun & Schulman, 1995; Hudmon & Schulman, 2002; 
Coultrap & Bayer, 2012; DeKoninck & Schulman, 1998). It has since been found to exist in 
almost all tissue types, including the heart (Kennedy & Greengard, 1981; Srinivasan et al., 
1994; Uemura et al., 1995). 
 
1.4.1 CaMKII isoforms 
 
CaMKII is expressed as four different genes that generate four isoforms (αβγδ) and a number 
of splice variants. Within the myocardium δ is the predominant form, whilst a modest 
expression of γ has also been shown (Braun & Schulman, 1995; Maier & Bers, 2002; Zhang 
& Brown, 2004). In neuronal tissue, α and β are the predominant isoforms (Hudmon and 
Schulman, 2002; Schworer et al., 1993). Despite the variance in tissue distribution of the 
isoforms all isoforms contain a highly conserved (92% similarity) N-terminal catalytic 
domain that promotes phosphorylation of target proteins to alter their function (Tobimatsu & 
Fujisawa, 1989).   
 
The predominant isoform in cardiac tissue, CaMKIIδ, is expressed as seven splice variants in 
the mammalian myocardium (Tombes et al., 2003). CaMKIIδB and CaMKIIδC are the two 
major splice variants expressed in the adult heart, where δB is largely compartmentalized to 
the nucleus due to an eleven amino acid nuclear localization sequence (NLS), while the 
cystolic δC isoform lacks a NLS (Edman & Schulamn, 1994; Srinivasan et al., 1994). Other 
variants for the heart (δF δG δH δI δJ) are thought to only be expressed during neonatal stages 
of development (Hoch et al., 1999). 
 
CaMKIIδB is involved in cardiac hypertrophy, where it activates the hypertrophic response 
gene atrial natriuretic peptide, brain natriuretic peptide and β-myosin heavy chain in response 
to phosphorylation of class II histone deacetylases (Little et al., 2007). The δB and δC have 
been shown to act in opposing ways on cardiomyocyte viability. Peng et al., (2010) showed 
that CaMKIIδB was shown to be antiapoptotic by phosphorylation of HSF1 and subsequent 
induction of HSP70. Whereas, CaMKIIδC is proapoptotic.  
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The main focus of this thesis is on CaMKIIδ and this will be referred to unless otherwise 
stated.  
!
1.4.2 CaMKII structure and activation 
 
The CaMKIIδ monomer consists of a catalytic domain, a regulatory domain, and an 
association domain (see Figure 1.4). The N-terminal catalytic domain contains the 2 ATP 
binding sites, 1 for ATP and 1 for the target protein in close proximity to ATP for transfer of 
a phosphate group to a target protein, whereas the regulatory domain contains the binding site 
for Ca2+/calmodulin (CaM) (Hudmon and Schulman, 2002). The function of the association 
domain is the assembly of the single monomers into large multimers of typically 12 subunits. 
Each of these monomers make up the dodecameric holoenzyme due to the association 































Figure 1.4 Structure of CaMKII!. A, CaMKIIδ is comprised of a catalytic, regulatory and association domain. The catalytic domain performs kinase 
function, the regulatory domain contains binding sites for Ca2+/CaM, and the association domain allows for the multimeric assembly of the 
holoenzyme. Possible variance in CaMKIIδ splice variants exon utilization between each isoform is illustrated (Adapted from Tombes et al., 2003). B, 
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Under normal conditions the catalytic and regulatory domains are closely associated, blocking 
substrate binding and resulting in autoinhibition of the kinase (Maier & Bers, 2002; Zhang & 
Brown, 2004; Braun & Schulman, 1995). When intracellular Ca2+ is elevated, CaM binds to 
CaMKIIδ and disrupts the association between the regulatory and catalytic domains, exposing 
the catalytic domain for substrate binding and relieving autoinhibition (Lin et al., 1987; Kelly 
et al., 1988). Prolonged Ca2+/CaM elevations at a high frequency, a hallmark of cardiac stress, 
modify CaMKIIδ into an autonomously active form via autophosphorylation at the T287 site 
(Bers, 2006) (see Figure 1.5). 
 
CaMKIIδ activity is also altered by oxidative stress. Erickson et al. (2008) identified a novel 
mechanism of CaMKIIδ activation by oxidation of a pair of methionines (M281/282) (Fig 1.4 
A) within the regulatory domain during heightened levels of oxidative stress. CaMKIIδ is 
therefore able to connect Ca2+ and redox signals to downstream cellular responses.  
 
CaMKIIδ has also been shown to be activated during hyperglycemia via O-GlcNAcylation 
(O-GlcNAc) modification at S279. Erickson et al. (2013) reported that, in animal models of 
elevated glucose concentrations that mimic conditions observed in diabetic patients, 
hyperglycemia was sufficient to activate CaMKIIδ and result in potentially fatal arrhythmic 
events, in particular premature ventricular complexes (PVC) and delayed after depolarizations 
(DADs). Autonomous activation of CaMKIIδ by phosphorylation, oxidation and O-GlcNAc 
prolongs CaMKIIδ activity in myocytes and is thought to play a critical role in cardiac 
pathophysiology (Erickson et al., 2008 & 2011). Recently, nitric oxide donors were found to 
activate CaMKIIδ, and subsequently a specific nitrosylation site on the neuronal form of 
CaMKIIδ was discovered (Erickson et al., 2015). However more work is required to confirm 







Figure 1.5 CaMKIIδ  activation in the heart. Under normal conditions the regulatory and catalytic domains are closely associated resulting in auto 
inhibition of the kinase. An increase in intracellular Ca2+ causes disruption of the kinase as Ca2+/CaM binds to the regulatory domain exposing the 
catalytic domain for substrate binding, subsequent post-translational modification (PTM) results in autonomous kinase activity (Adapted from Daniels 

























1.5 Physiological role of CaMKIIδ 
 
1.5.1 CaMKIIδ and excitation contraction coupling 
 
CaMKIIδ is involved in modulation of Ca2+ influx, as it participates in both SR Ca2+ release 
and SR Ca2+ reuptake during ECC. In response to Ca2+ signals CaMKIIδ phosphorylates the 
RyR2 at S2809 (Witcher et al., 1991), and S2815 (Wehrens et al., 2004). CaMKIIδ also 
phosphorylates PLB at T17 (Simmerman et al., 1986; Brittsan & Kranias, 2000), which in 
turn regulates SERCA2a by inhibiting SERCA2a activity when in an unphosphorylated state 
(Hook & Means, 2001; Maier & Bers, 2002). In addition, CaMKIIδ regulates sarcolemmal L-
type Ca2+-currents as well as Na+-currents (Anderson et al., 1994) (Figure 1.6, on page 24). 
 
1.5.2 CaMKIIδ and regulation of L-type Ca2+ channel 
 
CaMKIIδ is targeted to the sarcolemma by the binding sites located on the regulatory β-
subunit of the LTCC (Grueter et al., 2008). Phosphorylation of the LTCC by CaMKIIδ 
increases the ion channel open probability or facilitation, therefore allowing a greater influx 
of Ca2+ into the cytosol. It was demonstrated by Hudmon et al. (2005) that the pore forming 
alpha-subunit of the LTCC contains various anchoring sites for CaMKIIδ. They observed that 
activated CaMKIIδ was able to tether and regulate the channel’s function but also its 
deactivated state, possibly allowing it to act as a detector of Ca2+ frequency of influx. The 
action of CaMKIIδ on the LTCC is demonstrated via the ‘positive force staircase’ seen in 
cardiomyocytes that are repeatedly depolarized (Hashambhoy et al., 2009). The progression in 
the amplitude of intracellular Ca2+ demonstrates the facilitation of the LTCC as CaMKIIδ 
increases the Ca2+ entry and a slower rate of ion channel inactivation. This may possibly 
compensate for the Ca2+ dependent inactivation of the LTCC that occurs with increased 
activity (Maier & Bers, 2007). Anderson et al. (1994) confirmed the involvement of CaMKIIδ 
in the activation of the LTCC by using CaMKIIδ inhibitors to block the ion channels 






1.5.3 CaMKIIδ and regulation of sarcolemmal ion channels 
 
The ability of CaMKIIδ to associate with ion channels confers its prominent role in ECC 
coupling (Bers & Grandi et al., 2009). CaMKIIδ has been shown to have direct association 
with phosphorylation sites located on the ion channel C-terminal domain (Wagner et al., 
2006). By regulating the inactivation properties of the channel, CaMKIIδ can increase and 
prolong the voltage-dependent Na+ current (INa) that would also augment the action potential 
duration.  
 
The regulation of K+ channels via CaMKIIδ also helps to keep in balance the duration of the 
action potential. It was first reported by Tessier et al. (1999) that the CaMKIIδ inhibitor KN93 
induces a faster transient outward current (Ito) inactivation, which has previously been linked 
with arrhythmias (Antzelevitch et al., 1991; Wettwer et al., 1994). El-Haou et al. (2009) 
specified this regulation of the Kv4.3 with its associated regulatory protein synapse-associated 
protein 97 being a key attachment site for CaMKIIδ and its subsequent gating effects. Specific 
K+ channels and subtypes are subject to variable concentrations of Ca2+. Colinas et al. (2005) 
reported that Kv4.3 was effective during low L-type Ca2+ current (ICa.L) whilst Kv4.2 became 
essential during increased Ca2+ concentrations. This indicates that CaMKIIδ can also shorten 
the action potential duration by increasing Ito, which will then reduce the ICa.L. Thus CaMKIIδ 
activity would be limited due to this modification act as a form of self-regulation. 
 
 
1.5.4 CaMKIIδ and ryanodine receptor 
 
CaMKIIδ phosphorylation sites have been identified at residues S2808/2809 (Witcher et al., 
1991) and S2814/2815 of RyR2 (Wehrens et al., 2004). Studies that used isolated cardiac 
myocytes that overexpress CaMKIIδ (Maier et al., 2003) or pharmacological blockade of the 
kinase (Li et al., 1997) support the involvement of CaMKIIδ in up regulating the RyR2 and 
increasing the release of stored Ca2+ from the SR. In addition Ai et al., (2005) showed 
increased CaMKIIδ phosphorylation of RyR in a rabbit HF model of left ventricular pressure 
volume overload. However, after CaMKIIδ inhibition there was a reduction in SR Ca2+ leak 
and enhanced SR Ca2+ load. The pathological consequences of this modulation of the RyR2 
by CaMKIIδ in relation to pro-arrhythmic behaviour will be discussed in section 1.6.2. 
 
! 19 
1.5.5 CaMKIIδ and phospholamban/SR Ca2+ ATPase 
 
The increase in intracellular Ca2+ in the cardiomyocyte during contraction is balanced by 
efficient removal of Ca2+ from the intracellular space. CaMKIIδ phosphorylates PLB at T17, 
releasing its natural inhibition of the SERCA2a pump and increasing the rate of Ca2+ uptake 
into the SR (Mattiazzi et al., 2005). PLB activity is not essential for Ca2+ removal and 
subsequent relaxation of the cell (Li et al., 1998; DeSantiago, 2002). However a positive 
correlation between the phosphorylation state of the PLB T17 site and relaxation time has 
been shown (Hagemann et al., 2000), alongside SERCA2a activity and CaMKIIδ also 
showing a positive correlation between activation and relaxation (Odermatt et al., 1996). 
During times of increased stimulation, such as increased heart rate, a frequency dependent 
acceleration of relaxation is a necessity for ventricular filling. Kemi et al. (2007) investigated 
the molecular mechanisms that underlie relaxation parameters in aerobically exercised mice. 
In both cardiac tissue and isolated cardiomyocytes, they observed a decrease in PLB 
expression relative to the SERCA2a pump, but an increase in SERCA2a phosphorylation due 
to chronic CaMKIIδ activation, suggesting that the exercised mice had adapted to a CaMKIIδ 
dependent increase in Ca2+ uptake.  
 
1.5.6 Excitation-transcription coupling 
 
Alongside the role of CaMKIIδ in phosphorylating ion channels, Ca2+ handling proteins, and 
myofilament proteins, all of which occur in seconds to minutes, CaMKIIδ activation is also 
involved in gene transcription, which occurs on a much longer timescale. This role of 
CaMKIIδ on gene transcription is often referred to as excitation-transcription (ET) coupling 
and has been linked with the up-regulation of hypertrophic gene factors (Zhu et al., 2000; 
Kashiwase et al., 2005). CaMKIIδ has been shown to be involved in phosphorylation of class 
II-histone deacetylases (HDAC4 and HDAC5). When these HDACs are dephosphorylated, 
they bind to and repress hypertrophic transcription factors such as MEF2 (myocyte enhancer 
factor 2). When these HDACs are phosphorylated by CaMKIIδ or protein kinase-D (PKD), 
they are translocated out of the nucleus by 14-3-3 chaperone proteins, thereby relieving the 
repression and allowing MEF2-dependent transcriptional activation (Zhang et al., 2007; Lu et 
al., 2010). Backs et al. (2006) identified direct CaMKIIδ phosphorylation sites on HDAC4, 
whilst an indirect relationship with HDAC5 exists via the Ca2+ released by the nuclear inositol 
triphosphate receptor (IP3R) (Bossuyt et al., 2008; Wu et al., 2006). A parallel Ca2+ dependent 
ET coupling pathway involves the phosphatase calcineurin (CaN). When CaN is activated by 
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Ca2+/CaM, it dephosphorylates and drives nuclear import of nuclear factor of activated T cells 
(NFAT), which interact with other transcription factors such as GATA4 to drive hypertrophic 
gene transcription (Mattiazzi et al., 2015). 
 
1.6  Pathological role of CaMKIIδ in heart failure 
 
CaMKIIδ emerged as a potential link to HF due to its effects on Ca2+ handling proteins and 
transcriptional responses (Anderson et al., 2011; Swaminathan et al., 2012; Couchonnal et al., 
2008) (See Figure 1.6, page 24). Kirchhefer et al. (1999) and Hoch et al. (1999) were two of 
the first groups to report an up-regulation of CaMKIIδ in the left ventricle (LV) of HF 
patients with dilated cardiomyopathy. A more recent study by Sossalla et al. (2010) showed 
an increase in protein expression levels of CaMKIIδ in LV and right ventricle (RV) in HF 
patients with both dilated and ischemic cardiomyopathy. These observations indicate that 
CaMKIIδ activity is increased during ischemic injury and thus, independent of its genesis, 
CaMKIIδ activity increases in the majority of HF etiologies. The role of CaMKIIδ in HF is 
well established; however, most work to date has focused on patients with HF independent of 
diabetes. In the next paragraphs, I will examine the role of CaMKIIδ in relation to myocardial 
dysfunction, arrhythmias, apoptosis and fibrosis in non-diabetic disease states. In section 1.7 
the current knowledge on the role of CaMKIIδ in DHD will be explored. 
 
1.6.1 CaMKIIδ and myocardial dysfunction  
 
Many researchers investigating the role of CaMKIIδ in myocardial dysfunction have focused 
on either global measures of cardiac function such as echocardiography, where it has been 
shown that transgenic (TG) mice that overexpress the δc isoform of CaMKIIδ exhibit a 65% 
decrease in LV fractional shortening and premature death (Zhang et al., 2003), or in 
functional parameters of isolated cardiac muscle. An example of the latter is Sossalla et al., 
(2010), who reported an improvement in developed force in isolated RV muscle from HF 
patients after CaMKIIδ inhibition. Some research has focused on the cellular level; for 
example, TG mice overexpressing CaMKIIδ show a disturbance in their Ca2+ handling as 
demonstrated by an increase in Ca2+ spark frequency and thus CaMKIIδ induced SR Ca2+ leak 
(Maier et al., 2003). More recent studies have focused on CaMKIIδ involvement at the 
myofilament level. CaMKIIδ modulates the rates of force development and relaxation, and 
also modulates Ca2+ sensitivity, as it is involved in phosphorylation of myosin-binding 
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protein-C and TnI (Cazorla et al., 2009; Hartzell et al., 1984; Gautel 1995). There is also now 
emerging evidence to show a role for CaMKIIδ in phosphorylation of titin (Hidalgo et al., 
2013; Hamdani et al., 2013). Titin is a high molecular weight elastic protein that influences 
passive stiffness during relaxation of the heart. The mechanical properties of titin are altered 
during HF (Neagoe et al., 2002; Makarenko et al., 2004; Borbely et al., 2009; Kruger et al., 
2009; Nagueh et al., 2004) resulting in reduced diastolic performance of the heart. Hialgo et 
al. (2012) and Hamdani et al. (2013) expanded upon this and reported evidence to show that 
CaMKIIδ is involved in the hyperphosphorylation of titin on its spring elements and thus 
affects diastolic function by increasing titin-based stiffness.  
 
1.6.2 CaMKIIδ and arrhythmias 
 
Alongside the association of CaMKIIδ activation with HF and myocardial dysfunction, there 
is now abundant evidence to suggest that the alteration of Ca2+ handling proteins during up-
regulation of CaMKIIδ activity leads to the initiation of proarrhythmic electrical remodelling 
(Swaminathan et al., 2012). In particular the modulation of RyR2 by CaMKIIδ has received 
much attention in relation to pro-arrhythmic behaviour.  
 
RyR2 plays a fundamental role in the regulation of Ca2+ from the SR during contraction and 
therefore alteration in the function of RyR2 can lead to myocardial dysfunction. One such 
alteration in RyR2 function is the ‘leaky’ RyR2 (Belevych et al., 2013; Bellinger et al., 2007; 
Dobrev & Wehrens 2014; Venetucci et al., 2008). During HF the RyR2 becomes ‘leaky’ and 
therefore remains open during diastole (Shannon et al., 2003). For example, enhanced Ca2+ 
leak due to hyperphosphorylation of RyR2 at S2815 by CaMKIIδ  is linked to atrial 
fibrillation (AF) in patients undergoing coronary artery bypass or cardiac valve replacement 
(Neef et al., 2010). Impairment of diastolic RyR2 closure results in an increased frequency of 
short and tightly localized SR Ca2+ release events (Ca2+ sparks) during diastole that can act as 
an arrhythmic trigger (Fischer et al., 2014; Neef et al., 2010; Maier et al., 2003; Voigt et al., 
2012). Studies using a model of rapid pacing in mice with genetic gain-of-function mutation 
in RyR, resulting in Ca2+ leak, have shown significantly increased AF, which was reduced 
after CaMKIIδ inhibition (Chelu et al., 2009). Fischer et al. (2013) showed elevated SR Ca2+ 
leak in isolated LV cardiomyocytes from HF patients, which led to reduced systolic Ca2+ 
transients, a depletion of SR Ca2+ storage, and elevated diastolic Ca2+ levels.  Homogenized  
LV myocardium isolated from HF patients also exhibited a significant increase in CaMKIIδ-
! 22 
dependent phosphorylation of RyR2, which, when considered alongside evidence of increased 
SR Ca2+ leak, provides evidence for the pathological role of CaMKIIδ in HF and arrhythmias. 
 
Enhanced CaMKIIδ activation has also been implicated in the initiation of early atrial 
depolarizations (EADs) and DADs (Weiss et al., 2010; Westenbrink et al., 2013; Luczak et 
al., 2014). EADs occur due to dis-coordination of current activation or reactivation during 
action potential repolarization (Weiss et al., 2010). In contrast, DADs occur after 
repolarization is complete and can ultimately result in the initiation of lethal arrhythmias 
associated with long QT intervals, such as torsade de pointes (Roden et al., 1996; Anderson et 
al., 1998). It is believed that any modification to Ca2+ handling such as occurs during up-
regulation of CaMKIIδ can promote either EADs or DADs. In particular, DADs have been 
shown to occur specifically during spontaneous Ca2+ release from the SR (Venetucci et al., 
2008).   
 
Redox-dependent CaMKIIδ activation has also been linked with arrhythmias as Purohit et al. 
(2013) reported a role for oxidized CaMKIIδ in the atria of patients with AF. They also 
showed reduced susceptibility to AF in mice expressing a CaMKIIδ-resistant RyR2, further 
supporting the link between AF and oxidized CaMKIIδ phosphorylation of the RyR2. In 
addition oxidized CaMKIIδ has also been postulated as arrhythmogenic, as it has been shown 
in animal models to trigger EADs by delaying the Na+ current (Baynes & Thorpe, 1999). 
 
1.6.3 CaMKIIδ  effects on apoptosis 
 
The effect of CaMKIIδ on cell death has been investigated primarily in the context of HF 
independent of diabetes, where it has been shown to play a part in the induction of cell death 
after MI. A number of downstream mechanisms have been proposed including the activation 
of proapoptotic proteases and also transcriptional control on proapoptopic pathways (Erickson 
et al., 2011). Wright et al. (1997) showed that CaMKIIδ is involved in the activation of a 
proapoptotic protease (AP24), which results in the transmission of signals to the nucleus to 
initiate DNA fragmentation. CaMKIIδ has also been implicated in acting upstream to activate 
the TAK1-NLK mitogen-activated protein kinase (MAPK) pathway (Ishitani et al., 2003). In 
addition it has been shown that the Ca2+ signalling helps to regulate the ASK1-p38 MAPK 
cascade (Takeda et al., 2004). This pathway is involved in cytokine and stress-induced 
apoptosis as the TAK1 and ASK1 phosphorylation activates JNK and p38MAPK respectively 
! 23 
(Ishitani et al., 2003; Takeda et al., 2004). JNK is involved in the activation of the c-jun/AP-1 
pathway (Derijard et al., 1994), which is known to up-regulate proapoptotic genes 
(Dhanasekaran et al., 2008). Thus an increase in Ca2+ during cardiac stress results in 
activation of CaMKIIδ, which itself has been shown to activate ASK1 and a downstream 
signalling cascade resulting in apoptosis.  
 
CaMKIIδ has been identified as a resident protein in the mitochondria and, in fact, has been 
implicated in mitochondrial dependent pro-death pathways (Zhu et al., 2007). Chen et al. 
(2005) demonstrated that mitochondrial-triggered myocyte death is increased by activation of 
CaMKIIδ through Cav1.2 and SR Ca2+ release dependent pathways. Joiner et al. (2012) have 
more recently demonstrated that activated CaMKIIδ promotes an overload of Ca2+ in the 
mitochondria due to increased cytosolic Ca2+ and phosphorylation of the mitochondrial Ca2+ 
uniporter (MCU) current. The end result of these processes is myocardial death by promotion 
of cytochrome c release, mitochondrial swelling, and opening of the mitochondrial 
permeability transition pore (mPTP) (Westenbrink et al., 2013).  
 
1.6.4 CaMKIIδ  effects on fibrosis  
 
Myocardial fibrosis is a well-established cause of diastolic dysfunction, as the extracellular 
collagen and formation of advanced glycation end-products (AGEs) result in increased 
myocardial stiffness. CaMKIIδ modulates adult cardiac fibroblast proliferation (Martin et al., 
2014), while cardiomyocyte-specific deletion has been shown to reduce fibrotic remodelling 
in mouse models of pressure overload (Kreusser et al., 2016) and post MI (Zhang et al., 
2005). However, in contrast to these studies, Cheng et al. (2012) reported in a CaMKIIδ 
knockout (KO) model an increase in myocardial fibrosis which led to increased diastolic 
dysfunction. This observation suggests that CaMKIIδ may have an anti-fibrotic role.  
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Figure 1.6 Physiological and pathological role of CaMKIIδ in the cardiomyocyte. 
Physiological role of CaMKIIδ during normal ECC: (1) CaMKIIδ mediates the activity of  L-
type Ca2+ channel (LTCC) to allow for Ca2+ entry into the cell. (2) Phosphorylation of the 
ryanodine receptor (RyR2) to allow for Ca2+ induced Ca2+ release (CICR) and subsequent 
contraction. (3) CaMKIIδ phosphorylates phospholamban (PLB) to allow for Ca2+ reuptake 
back into the sarcoplasmic reticulum (SR) via SR Ca2+ ATPase (SERCA2a). (4) CaMKIIδ 
phosphorylates Na+/Ca2+ exchanger (NCX) to transfer Ca2+ to the extracellular space. (5) 
CaMKIIδ promotes mitochondrial permeability transition pore (mPTP) opening to allow Ca2+ 
entry into the mitochondria. Pathological consequence of CaMKIIδ: (6) 
Hyperphosphoyrlation of the LTCC can result in increased intracellular L-type Ca2+ causing 
early atrial depolarization (EADS). (7) Hyperphosphorylation of RyR2 causes SR Ca2+ leak 
possibly leading to arrhythmias and reduced myocardial performance due to reduced SR Ca2+ 
content. (8) Reduced phosphorylation of SERCA2a, can result in a reduced SR Ca2+ reuptake, 
and thus SR Ca2+ content is reduced. (9) Increased activation of NCX, which can cause an 
increase in the extrusion of Ca2+ into the extracellular space resulting in delayed after 
depolarization (DADS). (10) Alterations to the Ca2+ entry into the mitochondria can result in 
structural remodelling such as hypertrophy, fibrosis, and apoptosis. (Schematic adapted from 
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1.7 CaMKIIδ and diabetic heart dysfunction 
 
CaMKIIδ has been extensively investigated in the context of heart disease, where it has been 
shown to be a significant pathological factor, while a specific role for CaMKIIδ in the 
development of DHD is only beginning to emerge.  
 
1.7.1 CaMKII! and myocardial dysfunction in diabetic heart dysfunction 
 
As has been described in section 1.6.1, Sossalla et al. (2010) showed positive effects of 
CaMKIIδ inhibition in isolated muscle from HF patients, but no one has investigated the 
effects of CaMKIIδ inhibition on contractile function in the T2D heart. It has been shown 
however that ventricular myocytes isolated from Sprague-Dawley rats and incubated in high 
glucose medium for 1-2 days increased O-GlcNAc signalling which may underlie activation 
of CaMKIIδ  (Erickson et al., 2013). Cell shortening/lengthening and intracellular Ca2+ 
handling were measured in ventricular myocytes incubated in high glucose, and these 
myocytes had normal contractile properties but prolonged relaxation time (Ren et al., 1994). 
Ren et al., (1994) also showed a significantly slower decay of the Ca2+ transient in the high 
glucose myocytes that may contribute to impaired relaxation. In addition perforated patch-
clamp techniques were used to measure action potential duration (APD); the high glucose 
myocytes exhibited a longer APD compared to the cells in the normal glucose conditions. 
Clark et al. (2003) showed similar findings in rat cardiomyocytes subjected to high glucose 
conditions, as they observed a significantly prolonged diastolic decay phase.  
 
1.7.2 CaMKII! and arrhythmias in diabetic heart dysfunction 
 
T2D patients have a high risk for sudden cardiac death and also AF. Alongside the effects of 
CaMKIIδ on myocardial dysfunction in the T2D heart, CaMKIIδ is also an arrhythmogenic 
trigger. Erickson et al. (2013) showed in Langendorff-perfused rat hearts that exposure to 
high glucose concentrations, and thus activation of O-GlcNAc modified CaMKIIδ, induced 
potentially fatal arrhythmic events including premature ventricular complexes (PVCs) and 
DADs. Pharmacological inhibition of either O-GlcNAc modification or total CaMKIIδ 
activity ablated SR Ca2+ leak and significantly reduced the arrhythmic events. A more recent 
study from Sommese et al. (2016) reported increased pro-arrhythmogenic spontaneous Ca2+ 
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release events in a pre-diabetic animal model that were reduced after CaMKIIδ inhibition 
with KN93.   
 
1.7.3 CaMKII! effects on apoptosis in diabetic heart dysfunction 
 
Hyperglycemia is already known to be a major driving force of cell death at all stages of 
DHD (Maisch et al., 2011) as it has been shown to be involved in the release of reactive 
oxygen species (ROS) and reactive nitrogen species (RNS) (Cai et al., 2001), both of which 
can result in oxidative stress, and leads to abnormal gene expression, faulty signal 
transduction and apoptosis of cardiomyocytes (Adeghate et al., 2004). In addition, protein 
glycosylation has previously been shown to be up regulated in the diabetic heart resulting in 
impaired Ca2+ cycling and cardiac contractile function (Clark et al., 2003). A number of 
studies have also investigated apoptosis in the diabetic heart. A study by Cai et al. (2002) 
showed that hyperglycemia alone was enough to cause apoptosis in T1D mice (blood glucose 
levels >12 mmol/l). They also showed an increase in ROS generation due to high glucose 
levels, possibly through activation of the mitochondrial cytochrome c-mediated caspase-3 
activation pathway. However, a study following on from this by Backlund et al. (2004) 
demonstrated that hyperglycemia alone was not a sufficient stimulus to promote myocyte 
apoptosis. The T1D mice in this study had higher levels of blood glucose (20 mmol/l) than in 
the study by Cai et al. (2002) but did receive insulin daily. Despite these differences, 
Backlund et al. (2004) did confirm that apoptosis was enhanced and associated with LV 
enlargement and increased fibrosis post MI in the diabetic cardiomyocytes. Therefore it could 
be hypothesized that excessive activation of CaMKIIδ in the diabetic heart, induced by 
hyperglycemia alongside increases in intracellular Ca2+ and ROS, provides a potent 
environment for cell death. This effect of excessive CaMKIIδ activity in the diabetic heart on 
apoptosis is confirmed by Swaminathan et al. (2011), who reported sinoatrial node (SAN) 
apoptosis, SAN dysfunction and SAN cell death in diabetic mice. However, mice with TG 
myocardial CaMKIIδ inhibition (AC3-I mice) were protected against SAN apoptosis and 
dysfunction. Studies such as this provide vital insights into the effects of CaMKIIδ in the 
diabetic heart and the potential benefits of CaMKIIδ inhibition, but more work is still required 




1.7.4 CaMKII! effects on fibrosis in diabetic heart dysfunction 
 
Fibrotic growth is a commonly observed pathological consequence of diabetes. Lamberts et 
al., (2014) recently showed in isolated cardiac muscle from the RAA of T2D patients 
undergoing coronary artery bypass surgery, that there is preserved contractile function but a 
reduced diastolic function, demonstrated by a prolonged minimum rate of relaxation, 50% 
relaxation time and time to constant of relaxation. Despite the reduced diastolic function, they 
observed that protein expression levels of SERCA2a, the protein responsible for SR Ca2+ re 
uptake, were increased in the diabetic patients, whereas a decreased expression of PLB was 
observed. The authors attributed these unexpected findings of increased SERCA2a:PLB 
expression ratio to an increased level of atrial myocardial fibrosis, demonstrated by an 
elevated collagen deposition in the RAA of the diabetic patients.  
 
1.8 CaMKII! as a therapeutic target in diabetic heart dysfunction 
 
1.8.1 Current glucose lowering therapies  
 
Despite the above pathological manifestations of the diabetic heart being well established no 
specific diabetic heart therapy is available. This section discusses current blood glucose 
lowering therapies available as a means of reducing diabetic-induced cardiovascular risk, and 
also the potential of CaMKIIδ as a therapeutic tool in T2D patients.  
 
Current therapies for diabetic patients are targeted at lowering blood glucose with the hope 
that this approach will have the secondary effect of preventing cardiovascular disease in 
diabetic patients. Metformin works to decrease hepatic gluconeogenesis, where its primary 
target is hepatocyte mitochondria. There, it disrupts respiratory chain oxidation of complex I 
substrates such as glutamate (Brunmair et al., 2004). Metformin is the recommended first-line 
drug treatment for T2D due to its efficacy on blood glucose control without risk of 
hypoglycaemia, as well as tolerability and safety (UK Prospective Diabetes Study Group, 
1998). It has also been shown to have a positive effect on lipids, body weight, and blood 
pressure (Kirpichnikov et al., 2002). Sulfonylureas are currently used as a second-line or add-
on treatment for T2D patients. They work by increasing insulin secretion, as they act on the 
pancreatic β-cells by binding to and closing ATP dependent K+ channels, which in turn leads 
to decreased K+ influx and depolarization of the β-cell membrane (DeFronzo, 1999). This 
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cascade of events causes an increase in Ca2+ flux that results in the extrusion of insulin via 
exocytosis due to the translocation of secretory granules to the cell surface (Rorsman, 1997). 
Sulfonylureas have been shown to reduce fasting plasma glucose by an average of 2-4 
mmol/L accompanied by a decrease in HbA1c of 1-2% (Shankar et al., 2015). 
Thiazolidinediones are insulin-sensitizing drugs that have been shown to have benefits in 
glycaemic control by enhancing insulin sensitivity (Fujita et al., 1983; Soccio et al., 2014). 
Meglitinides are similar to sulfonylureas in that they act by regulating ATP-dependent K+ 
channels in pancreatic β-cells, but they are structurally different as they exert their effects via 
SUR-1 receptors (Black et al., 2007; Culy & Jarvis, 2001). Other types of drugs that are also 
used in the clinic as glucose lowering therapies include incretin-based targets like glucagon-
like-peptide-1 (GLP-1), which stimulates incretin and in turn promotes glucose dependent 
insulin secretion (Deacon, 2007). Dipeptidylpeptidase-4 (DPP-4) inhibitors prevent the 
breakdown of GLP-1, keeping incretin levels high and promoting glucose dependent insulin 
secretion. Sodium glucose cotransporter 2 (SGLT2) inhibitors such as Dapagliflozine are also 
used in the clinic to modulate glucose reabsorption in the kidney. However, despite the 
positive effects of these current drugs on glycaemic control, none of these drugs directly 
address (and some even increase) the risk of HF development in diabetic patients (Ferrannini 
& DeFronzo, 2015; Kumar et al., 2016). 
 
In addition to pharmacological agents, exercise is often recommended to patients with 
diabetes due to well-recognized health benefits such as improving glycaemic control, blood 
lipid profiles and cardiovascular health (Chudyk & Petrella RJ, 2011; Boule et al., 2001; 
McAuley et al., 2002; Cuff et al., 2003; Bordenave S et al., 2007; Brassard et al., 2007; 
Lamberts et al., 2008). However, many T2D patients are also on β-blocker medication. β-
blockers work to partially inhibit β-AR input to the heart and thus result in a reduction in 
heart rate and contractility. Therefore diabetic patients on this medication may not be able to 
reach the appropriate exercise intensities required for the cardiovascular benefits of exercise, 
suggesting that other pharmacological targets, like CaMKIIδ, may be preferable.  
!
1.8.2 CaMKII! knock-out studies 
 
The potential therapeutic effects of knocking out CaMKIIδ have been investigated in TG 
mice with global deletion of CaMKIIδ. Such studies have shown impressive results, with 
reports of protection against cardiac hypertrophy and apoptosis (Backs et al., 2009; Ling et 
al., 2009; Zhang et al., 2005). However a more recent study by Cheng et al. (2012) compared 
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a CaMKIIδ KO mouse model with a wild type mouse after being subjected to severe thoracic 
aortic banding (sTAB), and they found that the CaMKIIδ KO mice had a reduced diastolic 
function and a reduction in cardiac reserve to β-AR stimulation compared to the wild type 
mice. These contrasting findings suggest that partial inhibition, in contrast to complete 
inhibition of CaMKIIδ through pharmacological intervention, may be a preferable approach 
in the treatment of DHD.  
 
1.8.3 Pharmacological inhibition of CaMKII! 
 
Numerous CaMKIIδ inhibitors have been used in cardiac myocytes to investigate potential 
beneficial effects of CaMKIIδ inhibition on myocardial function, including the organic 
inhibitor KN93 (Maier & Bers, 2002 & 2007; Sumi et al., 1991) (Figure 1.7). KN93 
competitively inhibits CaM binding at the regulatory domain of CaMKIIδ (Ki-370 nM) (Sumi 
et al., 1991). Zhang et al. (2005) showed that chronic inhibition of CaMKIIδ with a dose of 1 
µmol/kg/day and 10 µmol/kg/day of KN93 (KN92 20 µmol/kg/day as control) for 3 weeks 
resulted in a dose dependent improvement in LV function.  
 
KN93 has been shown to have off-target effects on ion channels independent of CaMKIIδ 
actions (Gao et al., 2006; Ledoux et al., 1999; Rigg et al., 2003). Therefore a second inhibitor 
of CaMKIIδ known as autocamtide-2 related inhibitory peptide (AIP) is also widely used 
(Figure 1.7). AIP is a peptide inhibitor (substrate competitive) that blocks the catalytic 
domain and inhibits the autonomously active form of the kinase (Ishida et al., 1995). Sossalla 
et al. (2010) used both KN93 and AIP to inhibit CaMKIIδ in trabeculae isolated from the RV 
in end-stage HF patients. Inhibition of elevated CaMKIIδ activity resulted in increased 
contractility, reduced Ca2+ spark frequency and prolonged Ca2+ spark duration, and a 
significant decrease in total calculated SR Ca2+ leak. The increased SR Ca2+ load was 
attributed to reduced phosphorylation of the RyR2 at the CaMKIIδ specific binding site 
(S2815). Therefore a similar approach may be viable for diabetic patients.  
 
Other studies using CaMKIIδ inhibitors to reduce arrhythmias have also shown promising 
initial results. Chelu et al. (2009) demonstrated in a RyR2R176Q/+ mouse model a reduction in 
pacing induced AF after CaMKIIδ inhibition with KN93. Sag et al. (2009) found both cardiac 
arrhythmogenesis and SR Ca2+ leak were reduced in TG mouse models after KN93 and AIP 
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inhibition. Thus, CaMKII δ  inhibition shows promising results as a way to improve 
































Figure 1.7 Original schematic of inactive and active CaMKII!. KN93 inhibits CaMKIIδ by preventing CaM binding at the regulatory domain 
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DHD is an increasing problem worldwide and will continue to impose significant social and 
economic burdens on the health care system. CaMKIIδ and its posttranslational modifications 
play a critical pathological role in the development of heart disease, with a particular role in 
diabetes potentially emerging. Studies investigating the therapeutic benefits of CaMKIIδ 
inhibition in HF have shown promising findings of improvements in cardiac function; 
however, little is known about the effects of CaMKIIδ in T2D.  
 
1.10 Overview and scope of thesis 
 
This thesis investigates the role of CaMKIIδ in DHD. The main goal of this project was to 
determine the physiological consequences of pharmacological inhibition of CaMKIIδ in the 
T2D heart. In an ex vivo cardiac muscle preparation taken from a rat model of T2D, I 
determined the effects of acute CaMKIIδ inhibition on contractile force and contraction and 
relaxation kinetics (Chapter 3). I then investigated the effects of acute CaMKIIδ inhibition on 
Ca2+ handling in cardiomyocytes isolated from a rat model of T2D (Chapter 4).  The final part 
of this thesis aimed to measure the effects of chronic CaMKIIδ inhibition on fibrosis in a 
mouse model of T2D (Chapter 5). 
 
1.10.1 Main aims of thesis 
 
This project was divided into three key aims, which explored the effects of CaMKIIδ 
inhibition in the following contexts: 
 
i) Contraction and relaxation in T2D rat isolated cardiac muscle preparation. 
The main aim of this part of the project was to measure the effects of acute CaMKIIδ 
inhibition on cardiac muscle contraction and relaxation in the Zucker Diabetic Fatty (ZDF). I 
hypothesized that CaMKIIδ inhibition would improve contraction and relaxation in the heart 
of the ZDF rat. To test this hypothesis, I isolated cardiac tissue (trabeculae) from 20-week-old 
non-diabetic (nDM) and T2D (DM) ZDF rats and measured contraction and relaxation 
parameters. I used a pair of CaMKIIδ inhibitors (KN93 and AIP) to measure the effects of 
CaMKIIδ inhibition on contractile force and relaxation dynamics. CaMKIIδ expression and 
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activation were also measured in RV tissue via immunoblot. Additional experiments were 
also completed in the presence of isoproterenol (non-selective β-AR agonist) in order to 
measure the effects of CaMKIIδ inhibition during cardiac stress in the T2D heart.  
 
ii) Intracellular Ca2+ handling in T2D rat ventricular cardiomyocytes. 
The main aim of this part of the project was to measure the effects of CaMKIIδ inhibition on 
Ca2+ handling in the T2D rat cardiomyocyte. I hypothesized that CaMKIIδ activation would 
disrupt Ca2+ homeostasis in the T2D heart and that CaMKIIδ inhibition would reduce the 
alterations in Ca2+ homeostasis in the DM cardiomyocytes. To test this hypothesis I measured 
post-rest behaviour in isolated cardiac muscle from T2D rats, alongside the measurement of 
Ca2+ transients, SR Ca2+ load and Ca2+ spark frequency in isolated cardiac ventricular 
myocytes in the presence of CaMKIIδ inhibitors (KN93 & AIP). Experiments were also 
completed in the presence of isoproterenol (non-selective β-AR agonist) in order to measure 
the effects of CaMKIIδ inhibition during cardiac stress in the T2D heart.  
 
iii) Myocardial fibrotic remodelling in a mouse model of T2D 
The main aim of this part of the project was to measure the effects of chronic CaMKIIδ 
inhibition on fibrosis in a T2D db/db mouse model pre systolic dysfunction. As evidence has 
suggested that CaMKII δ  inhibition can both reduce and induce cardiac fibrosis, I 
hypothesized that CaMKIIδ inhibition would alter fibrotic remodelling in both the nDM and 
DM hearts. To test this hypothesis, 14-week-old db/db mice were injected with either KN92 
or KN93 every other day for 4 weeks (total of 16 injections). The animals were then 
euthanized and hearts removed for sectioning and staining to determine whether CaMKIIδ 
inhibition either reduced or induced fibrosis in the T2D myocardium. 
!
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Chapter 2.0  
Materials and Methods 
 
2.1 Animal models 
 
2.1.1 Zucker diabetic Fatty rat 
 
The ZDF rat is a leptin-resistant animal model of T2D (Phillips et al., 1996; Pick et al., 1998). 
ZDF rats homozygous for non-functional leptin receptors (fa/fa) develop obesity, 
hyperlipidemia, hyperinsulinaemia and hyperglycaemia (Ikeda et al., 1981; Leonard et al., 
2005) and will be referred to as DM throughout this thesis. However, littermates with 
homozygous dominant (+/+) or heterozygous (fa/+) genotypes remain lean and 
normoglycaemic and will be referred to as nDM throughout this thesis.  
 
2.1.2 db/db mouse 
 
The db/db mouse is a leptin-resistant animal model of T2D due to an autosomal recessive 
mutation on chromosome 4 traced to the db gene, which encodes for the leptin receptor (Chen 
& Wang, 2004; Srinivasan & Ramaro, 2007). These mice are spontaneously hyperphagic 
insulin over-secretors becoming obese, hyperinsulinaemic and insulin resistant within the first 
month of age (Srinivasan & Ramaro, 2007; Chatzigeorgiou et al., 2009). They then develop 
hyperglycemia later with a peak between 3-4 months of age (Bates et al., 2005).  
 
 
2.2 Animal bodyweight and blood glucose measurements 
 
All procedures and handling of the animals were conducted with the approval of the 
University of Otago’s Animal Ethics Committee and in accordance with the New Zealand 
Animal Welfare Act (1999). All animals were housed in a controlled environment (standard 
light cycle 07:00-19:00 & stable temperature of 21 ± 1 oC) in the University of Otago holding 
facility. ZDF rats were maintained on a Purina 5008 diet (LabDiet, St Louis, MO, USA) 
whilst db/db mice were maintained on a standard chow diet. Water was available to all 
animals ad libitum. The bodyweight of the ZDF rats was measured at 12 and 20 weeks of age 
alongside blood glucose measurements taken via tail vein blood using a glucometer and test 
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strips (ACCU-CHECK®). The bodyweight of the db/db mice was measured at 14 and 18 
weeks of age. Blood glucose measurements were taken via tail vein blood at 18 weeks of age 
before termination.  
 
The experiments with ZDF rats carried out at UC, Davis (cardiomyocyte experiments) were 
performed in accordance with NIH Guide for the Care and Use of Laboratory Animals and 
approved by the Institutional Animal Care and Use Committee of the University of California, 
Davis. ZDF rats were purchased from Charles River and maintained on a Purina 5008 diet. 
The bodyweight of the rats was measured at 18-20 weeks of age alongside blood glucose 





2.3 Echocardiography for assessment of left ventricle structure and function 
 
Echocardiography was carried out at 12 and 20 weeks of age on nDM & DM rats using an 
echocardiogram ultrasound machine (Vivid Q, General Electric (GE) Healthcare). db/db mice 
echocardiography scans were carried out at 14 and 18 weeks of age. ZDF rats at 12 and 20 
weeks of age were anaesthetized with 5% isoflurane in a gas chamber, and transferred onto a 
heat pad and maintained at 3% via a nose cone during echocardiography. The db/db mice 
were initially anesthetized with 2% isoflurane and maintained at 1.5% during 
echocardiography. All examinations were performed with the animal on its back and the chest 
area shaved (see Figure 2.1). Standard two-dimensional echocardiographic parameters were 
obtained from the parasternal short and long axis. All settings were optimized to obtain 
maximal signal-to-noise ratio and two-dimensional images to provide optimal endocardial 
delineation. Two blinded researchers independently analysed all echocardiography data, and 
their results were compared to control for potential variation in analysis. 
 
2.3.1. Left ventricle structure and systolic function 
 
In the short axis view at the level of the papillary muscle (see Figure 2.2) LV posterior wall 
thickness during diastole (LVPWd) and systole (LVPWs) were measured by measuring from 
the right ventricle (RV) septal border to the LV septal border, and the posterior wall to the 
edge of the epicardium (using built in software on echocardiography machine). LV end-
diastolic volume (LVEDV) and LV end-systolic volume (LVESV) were also calculated using 
Simpson’s biplane methodology to enable the calculation of LV ejection fraction (EF) and 
fractional shortening in accordance with ASE guidelines (Lang et al., 2015). Heart rate and 
cardiac output were measured by counting cardiac cycles from diastole to diastole.  
 
2.3.2 Left ventricle diastolic function 
 
Early (E) and atrial (A) filling velocities of the LV, and the E:A ratio were measured using 
corresponding pulsed-wave tissue Doppler (PWD) images by measuring the peak of the 
systolic, early and atrial filling waves, and calculating an average. Deceleration time (DT), a 
measure of early LV filling, was also determined from the peak of the early atrial filling wave 

















Figure 2.1 Echocardiographic set-up. Animal is placed supine on a heat pad maintained at 37 oC with its arms positioned down to spread the chest 






































Figure 2.2 Representative M-mode image for the assessment of left ventricle structural 
parameters. Inter-ventricular septal wall thickness diastole (ISVd); inter-ventricular septal 
wall thickness systole (ISVs); left ventricular end-diastolic diameter (LVEDD), left 
ventricular end-systolic diameter (LVESD); left ventricular posterior wall thickness diastole 



















Figure 2.3 Representative pulse-wave Doppler image for the assessment of left ventricle 
diastolic function. Early (E) and atrial (A) filling velocity and deceleration time (DT) of the 









2.4 The isolated rat cardiac muscle - trabeculae 
 
2.4.1 Excision of the heart and isolation of right ventricle cardiac muscle 
 
Male nDM & DM rats were anaesthetized by an intraperitioneal injection of sodium 
pentobarbital (60 mg/kg-1). The depth of anaesthesia was deemed surgically appropriate when 
the pedal reflex was absent. The animals were placed in a supine position and the thoracic 
cage was opened via an incision above the xiphoid process and lengthwise cuts through the 
ribs on either side of the sternum. The xiphoid process was clamped and the sternum flexed 
backwards. The aortic arch was located and momentarily gripped with forceps to allow for 
excision of the heart. The heart was rapidly removed and placed in a modified Krebs-
Henseleit buffer (KHB) (NaCl 118.5 mM, KCl 4.5 mM, MgCl2.6H2O 1 mM, NaH2PO4.H20 
0.33 mM, NaHCO3 25 mM, glucose 11 mM, CaCl2 1.4 mM) previously oxygenated with 
carbogen (95 % O2- 5% CO2). The heart was then immediately mounted on a simplified 
Langendorff setup and the aorta retrogradely perfused with KHB. The RV was opened up (see 
Figure 2.4 A & B) and a suitable cardiac muscle (trabecula) was dissected under the 
microscope. For immersion and mounting of the heart and for dissection of the cardiac 
muscles, the KCl and CaCl2 concentrations in the KHB were, respectively, increased and 
decreased to 6.5 and 1.0 mM to prevent spontaneous beating of the heart. 
 
Muscles were isolated from the RV free wall as isolating the muscle can often result in 
damage of the muscle therefore as the trabeculae are much more pronounced in the RV free 
wall compared to the LV it means there is less chance of damage to the muscle during the 
isolation procedure. Han et al., (2013) investigated the difference between the left and right 
trabeculae in their energetics of contraction and concluded there was no difference in passive 




















Figure 2.4 Representative image of Zucker diabetic fatty rat heart on a simplified Langendorff set-up and isolated trabeculae. A, and B, right 
ventricle free wall; C, Trabeculae immersed in experimental bath and attached between force transducer and micromanipulator. Arrows on B denote 
suitable trabeculae. 
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2.4.2 Trabeculae experimental set-up 
 
The trabecula was then transferred to the experimental chamber, where it was attached 
between a force transducer and micromanipulator (see Figure 2.4 C) (World Precision 
Instruments). All muscles were constantly superfused with the modified oxygenated KHB and 
kept at 37 oC. The muscles were stimulated at a basal stimulation frequency of 2 Hz by two 
platinum electrodes situated in the experimental bath, which orientated on each side of the 
muscle and were connected to a Grass SD9 stimulator. The stimulus duration was set at 2 ms 































Figure 2.5 Trabeculae experimental set-up. Trabeculae are attached between a force transducer and a micromanipulator immersed in an 
experimental chamber. Oxygenated KBH buffer is pumped into the system via an inflow tube pump and passes through a heated coil. The muscle is 
superfused and the buffer pumped back out of the system via an outflow pump. Two platinum electrodes sit on either side of the muscle and stimulate 
the muscle to contract. The force transducer measures the amount of pull produced by the muscle on the hook and converts this via an amplifier into an 
electrical signal.  The amplifier also incorporates a two-channel temperature controller to ensure the temperature was kept at 37 oC. 
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2.4.3 Experimental protocol 
 
The experiments began with a stabilization period of 15-20 minutes duration. Muscle width 
and approximate depth measurements were taken to calculate cross sectional area (CSA) of 
the muscle. This was calculated using the following formula: width X thickness X π (see 
Table 2.1 for cross sectional area of trabeculae from nDM and DM muscles). After the 
stabilization period the trabeculae were gradually stretched to a muscle length at which 
maximum isometric force development was achieved, referred to as Lmax. Any muscle 
exhibiting a force below 1mN/mm2 was excluded.  
  
2.4.3.1 CaMKIIδ inhibitor superfusion and functional measurements 
 
Once the muscle was at Lmax and a steady-state twitch force was achieved, stimulation was 
stopped and CaMKIIδ inhibition was performed by perfusing trabeculae for 20 minutes with 
KN93 (2 µmol/L, Sigma-Aldrich, St Louis, MO, USA). Control experiments were performed 
using the inactive analogue KN92 (2 µmol/L, Cayman chemicals). Additional experiments 
were performed using the synthetic peptide CaMKIIδ inhibitor myristoylated AIP 
(autocamtide-2-related-inhibitor peptide, 2.5 µmol/L, TOCRIS). KN92, KN93 & AIP were all 
diluted in 100% dimethyl sulfoxide (DMSO, Millipore) to make a 10 x stock concentration 
which was then diluted down using KBH to the chosen concentration used to perfuse the 
muscle (10% DMSO, Millipore).  
 
2.4.3.2 Force frequency relationship 
 
Force frequency relationship (FFR) was obtained at steady-state twitch force conditions using 
stimulation frequencies from 2 to 6 Hz for 2 minutes each. Figure 2.6 A shows a 
representative trace of a FFR recording from LabChart.  
 
2.4.3.3 Post-rest behaviour  
 
The FFR was followed by measuring post-rest behaviour assessed by using increasing rest (no 
stimulation) intervals of 10, 30 and 120 s between beats at basal stimulation frequency of 2 
Hz. Figure 2.6 B shows a representative trace of the post-rest protocol from LabChart.  
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2.4.3.4 β-Adrenergic stimulation 
 
Trabeculae were then subjected to cardiac stress via increasing concentrations of 
isoproterenol (non-selective β-AR agonist, 10-8,-7,-6 M) for 5 minutes each and stimulated at 2 
Hz. Figure 2.6 C shows a representative trace taken from LabChart. 
 
Once the full protocol had been completed, the chosen inhibitor was washed out with KHB 
buffer for 10 minutes. The muscle was then superfused again with the second inhibitor and 
the protocol repeated in the same manner as previously described. To control for conditioning 
or washout effects, the order of inhibitor treatments was randomized. Table 2.2 provides an 
overview of the experimental protocol.  
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 Table 2.1 Cross sectional area of trabeculae 
Muscle 
characteristic 
nDM DM P value 
CSA (mm2) 3.50 ± 0.11 3.66 ± 0.10 0.70 
Lmax  (mm) 0.31 ± 0.02 0.32 ± 0.1 0.57 
CSA= cross sectional area, Lmax= length at max force. Date are mean ± SEM. Unpaired t-test: P=<0.05 was used. 
 
 
Table 2.2 Trabeculae experimental protocol 
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Figure 2.6 Representative LabChart recordings. A, Force frequency recordings; B, Post rest behaviour; C, Isoproterenol perfusion (concentrations 
are M). 
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2.4.4 Offline data analysis 
 
Data was analysed using LabChart 7.0 (ADInstruments). Peak analysis was used for the 
assessment of developed force (Fdev), relaxation from 50-90% of contraction (RT90%). Blood 
pressure analysis was used for the assessment of maximum rate of contraction (+dF/dtmax) and 
the maximum rate of relaxation (-dF/dtmax), as it is able to detect pressure signals and convert 
them to mN/mm2/s (see Figure 2.7). One minute of recordings was selected for analysis of 
FFR and for isoproterenol the last 2 minutes of the 5 minute recording time.  
 
Figure 2.7 LabChart recording of a muscle contraction showing analysis parameters. 
Developed force (Fdev); Maximum rate of contraction (+dF/dtmax); Maximum rate of 
relaxation (-dF/dtmax); Duration of relaxation from 50% peak height during the diastolic phase 







Post rest behaviour was analysed by measuring the Fdev of the first peak as indicated by the 
number 2 in Figure 2.8 after the rest period normalised to the Fdev of the peak before the rest 




Figure 2.8 LabChart recording of an example rest period for post rest behaviour at 2 Hz 
stimulation frequency. (1) Represents the beat analysed before the rest period and (2) 
represents the beat analysed after the rest period.
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2.5 Cardiomyocyte isolation 
 
Cardiomyocyte isolation was performed at the University of California, Davis in the 
laboratory of Professor Donald Bers in the Department of Pharmacology, as a core facility 
procedure. The isolation of rat ventricular cardiomyocytes was performed using Langendorff 
perfusion apparatus. Prior to isolation, perfusion apparatus was washed with detergent and 
ethanol and left overnight soaking in MilliQ water. The following day 500 ml of boiling water 
was washed through the system followed by a wash through of the perfusion buffer for 5 
minutes (see below for components). Male nDM and DM rats (18-20 weeks of age) were anti-
coagulated with intraperitioneal injection of heparin (400 mg/kg). The rats were then 
anesthetized in a gas chamber with 5 % isoflurane (100 %-oxygen). The animals were taken 
out of the gas chamber and moved onto a mask where the isoflurane was maintained at 3 %. 
After checking the depth of anaesthesia via pedal reflex the thoracic cage was opened via an 
incision above the xiphoid process and lengthwise cuts through the ribs on either side of the 
sternum. The xiphoid process was clamped and the sternum flexed backwards. The aortic arch 
was located and gripped with forceps to allow for excision of the heart. After heart excision 
the heart was briefly placed in wash solution (1x MEM, heparin 5000 IU/ML). The heart was 
then cannulated above the aortic valve and perfusion started with a flow rate of 12-14 ml/min 
for 10 minutes (NaCl 135 mM, NaH2PO4 · 2H2O 0.33 mM, KCl 5.31 mM, MgCl 1 mM, 
C3H3NaO3 2 mM, HEPES 10 mM, Na-HEPES 10 mM, glucose 5.5 mM, pH 7.4). Afterwards, 
the heart perfusion was continued with enzyme solution for 12 minutes for myocyte digestion 
(1x MEM 50 ml, taurine 62 mg, 0.01 M Ca2+ 50 µm, Liberase TH 550 µL). After enzymatic 
digestion, the heart was cut from the cannula and placed in a petri-dish containing digestion 
buffer. The heart was cut in half and the ventricles gently teased with forceps into several 
small pieces and pipetted gently up and down several times with a sterile plastic transfer 
pipette. The cell suspension was then filtered through a mesh into three 15 ml tubes and 
stopping buffer added (1x MEM 25 ml, BSA 0.5 g). The cells were allowed to settle and a 
pellet was formed. The pellet was then resuspended with increasing Ca2+ wash solutions (1 x 
MEM 50 ml, BSA 0.5 g) to remove other cell types and dead myocytes. Each portion of the 
washing solution contained Ca2+ at a gradually rising concentration, reaching the 
concentration of 1 mM in the final wash.  
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2.6 Measurement of Ca2+ in isolated cardiomyocytes 
 
2.6.1 Measurement of Ca2+ transients, Ca2+ sparks, and sarcoplasmic reticulum Ca2+ 
load 
 
Isolated cardiomyocytes were incubated on laminin-coated cover glass slides for 10 minutes 
to allow the cells to attach. The washing solution was removed and replaced with 100 µl of 
Ca2+-fluorescent dye Fluo-4AM (Molecular Probes, in a mixture of DMSO and pluronic acid 
20 %) (final concentration of Fluo4-AM is 5 M) for 25 minutes at room temperature in a dark 
room. To wash out extracellular dye, the Fluo-4AM solution was removed from the cover 
glass slides and cells incubated in Tyrode’s solution (in mM: 140 NaCl, 4 KCl, 1.1 MgCl2, 10 
HEPES, 10 glucose, 1.8 CaCl2; pH= 7.4, with NaOH) either containing: KN92 (1 µmol/L - 
Millipore), KN93 (1 µmol/L - Millipore), AIP (1 µmol/L - Tocris Bioscience) or control 
solution (Tyrode’s solution) for 10 minutes. The cover glass slide was then mounted on a 
chamber and placed into the microscope holder. Experiments were performed on a confocal 
microscope (Bio Rad, Radiance 2100, x40 oil immersion objective) and Lazersharp2000 used 
for experimental recordings. Fluo-4AM was excited with an Argon laser (488nm) and 
emission was collected at wavelengths >505 nm. Fluorescence was acquired in line-scan 
mode at 3 ms.line-1 (512 pixels per line, pixel size 166.0 x 3.342 pixels/seconds, width of the 
scan 18.07). The scanning laser line was orientated in the longitudinal axis of the cell and 
placed approximately equidistant between the outer edge of the cell and the nucleus/nuclei to 
ensure the nuclear area was not included in the scan line. During the recording, the intact 
myocytes were continuously perfused with either Tyrode’s solution for control experiments, 
or Tyrode’s solution containing KN92 (1 µmol/L), KN93 (1 µmol/L) or AIP (1 µmol/L). 
Additional experiments were performed to assess the effect of β-AR stimulation on the 
cardiac myocytes. To this end, cells were perfused with their chosen inhibitor alongside 100 
nmol/L of isoproterenol (Millipore). Ca2+ transients were evoked by field stimulation (1 Hz) 
using a Grass S48 stimulator. Stimulation was then stopped and spontaneous Ca2+ sparks were 
obtained in quiescent cells. SR Ca2+ load was assessed by rapid application of caffeine (10 
mM, Sigma Aldrich) after 30 seconds pacing to reach the steady state pacing. Application of 
caffeine allows for the assessment of SR Ca2+ load as the caffeine opens the RyR2 channels 
thereby releasing all Ca2+ ions which are stored in the SR (Smith et al., 1988; Rousseau & 




2.6.2 Offline data analysis 
 
Firefly route in PythonTM was used for analysis of the amplitude of the Ca2+ transients, time to 
peak and time constant of decay (Tau) (see Figure 2.9). SR Ca2+ content was calculated by 
measuring the background intensity of the trace and calculating (PeakF-
background/BaselineF-background)-1 using ImageJ (Wayne Rasband, National Institutes of 
Health, Bethesda, MD) (see Figure 2.10). Ca2+ sparks were analysed using Image J spark 
master plug-in. This software uses an algorithm (designed by Cheng et al., 1999) and was 
incorporated into a user-friendly interface on ImageJ by Picht et al. (2007). Ca2+ sparks are 
detected by measuring the background amplitude and then identifying sparks based off their 
deviation from the background noise (2 x). A criterion must be set prior to analysis that was at 
3.8 based on recommendations in Pitch et al. (2007). Therefore the threshold for detection of 
sparks is 3.8 times the standard deviation of the background noise over the mean value of the 
background. This particular criteria setting of 3.8 has been shown to have a high sensitivity 
and low frequency of false-positive detections (Picht et al., 2007). The program also allows 
for the analysis of extended kinetics to measure Ca2+ spark amplitude, full width at half 
maximum (FWHM), and full duration of half maximum (FDHM). Figure 2.11 shows an 
example of a confocal line scan analysed for Ca2+ sparks and a surface plot demonstrating the 































Figure 2.9 Ca2+ transient analysis in cardiomyocytes. A, Representative line scan; B, Example plotted profile from Image J; C, Representative 
individual twitch showing analysis parameters; D, Calculation of Ca2+ transient amplitude. Peak amplitude was obtained by measuring the height of the 
plotted profile twitch. 
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Figure 2.10 Sarcoplasmic reticulum (SR) Ca2+ load analysis in cardiomyocytes. A, Representative line scan showing the application of caffeine; B, 
Representative plotted profile, C, Calculation of SR Ca2+ load. Peak amplitude was obtained by measuring the height of the plotted profile twitch. 
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Figure 2.11 Ca2+ spark analysis in cardiomyocytes. A, Representative line scan showing 
Ca2+ sparks; B, Representative single Ca2+ spark; C, Ca2+ spark plotted profile showing spark 
amplitude and full width at half max (FWHM, µm) and full width at half duration (FDHM, 

















































2.7 Sodium dodecyl sulphate and western blotting 
 
2.7.1 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
 
Acrylamide gels of various percentages (see table 2.3) were formed using gel moulds with 1.5 
mm spacers. The resolving gel solution was allowed to polymerise for 1 hour, with a flat 
resolving gel solution surface achieved by the overlay of milliQ-H2O. After 1 hour, the 
overlaying milliQ-H2O was removed and a 15 well comb (thickness 1.5 mm) was placed in 
the gel moulds. Loading of the stacking gel solution to form protein-loading wells followed 
this, and the gel was left to set for 1 hour. 
 
2.7.2 Homogenisation of cardiac tissue 
 
RV tissue from nDM and DM rats, and DM and nDM mice was homogenized in lysis buffer 
containing: 50 mM Tris-HCl, pH 7.5, 3% SDS, phenyl methyl sulfonyl fluoride (PMSF, 100 
mM), cOmplete protease inhibitor (Sigma-Aldrich, 1X) and phosphatase inhibitor 
(PhosSTOP, Sigma-Aldrich, 1X). Protein concentration was determined by absorbance at 280 
nm.  
 
In anticipation of the trabeculae being isolated from the RV, cardiac tissue from this area of 
the heart was used for the measurement of expression and activation status of CaMKIIδ in the 
T2D heart. There is no evidence to suggest any difference in CaMKIIδ expression between 
the LV and RV as Sossalla et al., (2010) measured CaMKIIδ phosphorylation in trabeculae 
from both ventricles of the heart and showed no difference.  
 
2.7.3 Western blotting 
 
Table 2.4 outlines conditions for each protein of interest. In brief, homogenized samples were 
combined with 5X sample buffer (Resolving gel buffer 0.31 M, glycerol 50 %, SDS 10 %, 
DTT 0.5 M, bromophenol blue 0.05 %) and then denatured on a heat block followed by 
loading of protein onto a polyacrylamide gel of the appropriate percentage. Electrophoresis 
was then performed followed by the wet tank transfer of the protein onto a membrane 
(running buffer: glycine 1.92 mM, Tris 30.2 mM, SDS 10 %; transfer buffer: glycine 1.92 
mM, Tris 0.25 mM, SDS 10 %). This was followed by blocking the membrane with 5 % non-
fat milk in Tris-buffered saline (50 mM Tris, 150 mM NaCl, pH 7.6) containing 0.05 % 
! 56 
Tween (TBS-T). The membrane was then incubated with primary antibodies for varying time 
periods (see table 2.4 and 2.5). After washing 4x 5 minutes with TBS-T, membranes were 
incubated with horseradish peroxidase- conjugated (HRP) anti-rabbit or anti-mouse (β-actin 
HRP conjugated). This was followed by 3X 20 minutes washes with 1X TBS-T. 
Chemiluminescent detection was performed with Supersignal west-pico (Thermo Fisher) and 
imaged using a Syngene gel doc system, Gene Tools (syngene) was used to obtain density 
measurements for each protein band. For RyR2 and RyR2 S2814 blots were stripped with low 
pH (2.0) buffer and re-probed. They were first probed with antibody for RyR S2814, once this 
was complete and the blot was imaged it was stripped with a low pH buffer (glycine 25 mM, 
SDS 1 %, distilled water 400 ml), at room temperature for 10 minutes. This was followed by 
3x 10 minute TBST washes, and 1x 5 minute in TBS. The membrane was then imaged again 
to ensure all stripping of antibodies was complete. Blocking the membrane with 5% non-fat 
milk in Tris-buffered saline for 30 minutes and re-probing with primary antibody as described 





Total CaMKIIδ, phosphorylated CaMKIIδ, PLB and PLB T17 (CaMKIIδ phosphorylation 
site) density values were normalized to those of GAPDH. The ratio of phosphorylated 
CaMKIIδ to total CaMKIIδ and the ratio of PLB T17 to total PLB was then calculated. RyR2 
and RyR2 S2814 (CaMKIIδ phosphorylation site) values were normalized to β-actin. The 




















Ingredients Stacking gel Resolving gel Supplier 
 4 % (µL) 6 % (µL) 
 
10 % (µL) 
 
12 % (µL) 
 
 
MilliQ-H2O (µL) 2516 4632 3832 3432 Merck Millipore 
Tris/HCl (1.5 M, pH 8.8) - 2000 2000 2000 Biofroxx 
Tris/HCl (0.5 M, pH 6.8) 1000 - - - Biofroxx 
40 % Acrylamide (µL) 400 1200 2000 2400 Merck Millipore 
10 % SDS (µL) 40 80 80 80 Merck Millipore 
TEMED (µl) 4 8 8 8 Merck Millipore 
Note: Different percent acrylamide gels were used to separate proteins: CaMKIIδ  (Calmodulin-dependent protein kinase II, 10%), RyR2 (ryanodine 




Table 2.4 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis and western blot protocols for proteins of interest 
 
Protein of interest 
 CaMKIIδ CaMKIIδ  
T287 
PLB PLB  
T17 










95 95 100 100 37 37 95 95 
Protein 
loading (µg)  
40 40 40 40 70 70 40 70 
% Gel 10 10 10 10 6 6 10 10 
Running time 
(minutes) 
100 100 100 100 360 360 100 100 
Membrane PVDF PVDF PDVF PVDF Nitrocellulose Nitrocellulose PDVF PVDF 
Transfer time 
(minutes) 








90 90 90 90 90 90 90 n/a 
Note: PVDF: Polyvinylidene difluoride, β-actin HRP conjugated. 
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Primary antibody Concentration Species Supplier Secondary 
antibody  
CaMKIIδ       
(MW= 50 kDA) 




CaMKIIδ  T287 
(MW= 50 kDa) 
1:1000 Rabbit Abcam Anti-rabbit HRP 
(1:2500, abcam) 
RyR2               
(MW= 450 kDa) 
1:1000 Mouse Abcam Anti-mouse HRP 
(1:20000, abcam) 
RyR2 S2814     
(MW= 450 kDa) 
1:2000 
Rabbit 
Abcam Anti-rabbit HRP 
(1:10000, abcam) 
 
PLB                
(MW= 15 kDa) 
1:5000 Mouse Badrilla Anti-mouse HRP 
(1:20000, abcam) 
PLB T17          
(MW= 15 kDa) 
1:5000 Rabbit Badrilla Anti-rabbit HRP 
(1:20000, abcam) 
GAPDH          
(MW= 37 kDa) 
1:10000 Mouse Genetex Anti-mouse 
(1:2500) 
β-actin             




Note: Primary anti-bodies CaMKIIδ, CaMKIIδ T287, PLB, PLB T17, GAPDH & β-actin were 
prepared in TBS. RyR2 & RyR2 S2814 were prepared in PBS with 20 % FBS (vol/vol) and 0.02 % 
NaN3 (w/vol). The primary anti-body solutions were reused and store at 4oC. Secondary anti-body 
solutions were prepared in TBS and also reused and stored at 4 oC. MW= molecular weight. kDa= 
kilodaltons. 
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2.8 Chronic CaMKIIδ inhibition in db/db mice 
 
 
2.8.1 KN92 and KN93 injections 
 
At 14 weeks of age nDM and DM db/db mice were subcutaneously injected with either KN92 
(20 µmol/kg (APExBio) 10 % DMSO) or KN93 (10 µmol/kg, (APExBio) 10 % DMSO) every 
other day for 4 weeks (see Figure 2.12). Concentrations were informed by previous studies 
(Zhang et al., 2005) that reported a dose-dependent CaMKIIδ inhibition by KN93. They 
observed that daily injections of 10 µmol/kg KN93 produced similar effects on LV 
contraction measurements as the genetically CaMKIIδ-inhibited AC3-I mice (Kaurstad et al., 
2010). Echocardiography scans for structural parameters were carried out at 14 weeks pre-
treatment and at 18 weeks post-treatment.   
 
 
Figure 2.12 Experimental timeline for CaMKIIδ inhibition in db/db mice. 
18 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 19 20 21 22 23 24 25 26 27 28 








18 weeks of age 
28 days 
•  KN93/KN92 injection 
every other day 
= Injection of KN93 (10 µmol/kg) / KN92 (20 µmol/kg) 
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2.8.2 Animal termination 
 
At 18 weeks animals were euthanized via urethane overdose. The heart was then extracted 
and placed in PBS followed by being sectioned off for analysis. RV tissue was placed in 4% 
formalin and later used for measurements of fibrosis via Masson’s Trichrome stain. A portion 
of RV tissue was also snap frozen in liquid nitrogen for protein analysis. 
 
2.8.3 Cryopreservation and sectioning 
 
RV cardiac tissue was placed in 4 % formalin for 24 hours, followed by 24 hours in PBS. The 
tissue was then placed in 30 % sucrose to cryoprotect the tissue. Once the tissue had sunk to 
the bottom of the tube (> 24 hours) it was removed from the 30 % sucrose and covered in 
Tissue-Tek optimum cutting temperature (OCT) solution and snap frozen in liquid nitrogen. 
The samples were then stored at -80 oC until sectioning. Frozen sections were cut using a 
microtome (8 µm) enclosed in a refrigerated compartment, a cryostat, set at -20 oC and picked 
up onto standard glass slides, followed by storage at -80 oC. 
 
2.8.4 Masson’s Trichrome staining for fibrosis 
 
Masson’s trichrome stain involves using three dyes that selectively stain muscle, collagen 
fibers, fibrin and erythrocytes. Frozen 8 µm tissue sections were removed from the -80 oC and 
brought to room temperature for 10 minutes. Tissue sections were then placed in 10 % neutral 
buffered formalin for 2 minutes to post-fix. Samples were rinsed in distilled water followed 
by incubation in Bouin’s solution for 1 hour at 60 oC. Bouin’s solution is used as a mordant in 
order to link the dye to the targeted tissue components. Tissue sections were then washed well 
in distilled water until no yellow was left on the sections. They were then incubated in 
Celestine blue for 5 minutes, which acts to solidify the bond connection with the 
haematoxylin. Slides were then rinsed in distilled water followed by incubation in Gill’s 
haematoxyiln for 3 minutes to stain the nuclei. Tissue sections were then rinsed with running 
water for 2 minutes and placed in Scott’s Solution for 2 minutes. This converts the soluble red 
haematoxylin to an insoluble blue due to an alkaline pH. Samples were again washed in 
running water for 1 minute, followed by incubation in 0.5 % acid fuchsin, which attaches to 
the muscle fibers, for 5 minutes. Samples were rinsed in distilled water, followed by 1 % 
phosphomolybdic acid, which competes with the acid fuschin and then slides were drained. 
The slides were then placed in 2 % methyl blue solution for 2 minutes, which stains larger 
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molecules like collagen. Tissue sections were then rinsed in distilled water followed by 
incubation in 1% acetic acid for 1 minute in order to differentiate the stain. Slides were then 
rinsed and placed between two pieces of filter paper and dried. The samples were rapidly 
dehydrated for 30 seconds in 100 % ethanol and cleared in xylene. The tissue sections were 
then covered with cover slips (22x50mm) mounted with DPX mounting medium. Within each 
batch of slides processed, one control slide with mouse skin was included to act as a positive 
control due its high collagen content.  
 
Images of each tissue section were taken using a slide scanner (Leica Biosystems) set at X40 
zoom magnification. Aperio image scope software (Leica Biosystems) was then used to 
extract out the images to allow for analysis. Photoshop Pro software was used for analysis 
where it was able to calculate the total number of pixels in the image, followed by a pixel 
count for the collagen. This was then divided by the total pixel count and multiplied by 100 to 
give a percent collagen deposition.  
 
2.9 Statistical Analysis  
 
All numerical data are presented as mean values + SEM. Graphpad Prism (version 6.0) and 
statistical package for Social Sciences (SPSS v24.0, Chicago, IL), was used for all statistical 
analysis. An independent t-test was used for comparison of Total CaMKIIδ, PCaMKIIδ T287, 
RyR2, RyR2 S2814, PLB and PLB T17 data. When data did not meet assumptions of 
normality a non-parametric Mann-Whitney test was used. One-way between groups analysis 
of variance (ANOVA) was used for analysis of bodyweight, blood glucose and 
echocardiographic measurements. To analyze differences between the nDM and DM rats and 
the effect of CaMKIIδ inhibition from the isolated cardiac muscle and cardiomyocyte 
experiments, and also the Masson’s trichrome stain in the db/db mice, a two-way between 
groups ANOVA was used, with P< 0.05 indicating statistical significance. Echocardiography 
data from the db/db mice in chapter 5.0 was analyzed using a two-way between groups 
ANOVA, with P< 0.05 indicating statistical significance. When data did not meet the 
assumptions of normality a log transformation was performed. When data did not meet the 
homogeneity of variance but did meet normality an independent t-test was used with the P 
value multiplied by the number of t-tests ran to account for family wise error (Field, 2005). A 
chi-squared test was used for the analysis of nominal data collected on spontaneous 
contractions in isolated cardiac muscle and Ca2+ waves in cardiomyocytes, with P< 0.05 
indicating statistical significance.  
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Chapter 3.0  
Contractile performance in the type 2 diabetic heart and the 




As described in chapter 1, CaMKIIδ plays a pivotal role in myocardial contraction and 
relaxation through regulation of a number of Ca2+ handling proteins. However during the 
progression of HF this role of CaMKIIδ takes on more of a pathological form. Relatively little 
is known about the potential pathological role of CaMKIIδ in relation to contractility in the 
T2D; therefore, this chapter will explore the hypothesis that CaMKIIδ inhibition will be 
beneficial in preserving the reduced contractility in the T2D heart. 
 
3.1.1 Diastolic dysfunction as an early marker of diabetic heart dysfunction 
 
One of the early manifestations of cardiac dysfunction in T2D patients is reduced diastolic 
performance, which later progresses to systolic dysfunction and ultimately HF (Zarich, 1989; 
Piccini, 2004; Boyer et al., 2004; Hayat et al., 2004; Marwick, 2006). Diastole is described by 
Brutsaert et al. (1980) as the time period where the myocardium is no longer generating force 
and subsequently returns to an unstressed length and force. Diastolic dysfunction is assessed 
clinically through echocardiography, where tissue Doppler techniques are applied to measure 
ventricular filling velocities during diastole. An E:A ratio is calculated, which represents the 
ratio of the peak velocity of flow in the LV in early diastole (the E wave) to peak velocity of 
flow in the LV in late diastole caused by atrial contraction (the A wave). The E wave 
represents the pumping of blood out of the left atria into the LV. However during this stage a 
small amount of blood will remain in the atria, and thus towards the end of diastole, the atria 
pump the remaining blood out of the atria and into the ventricle (A wave). A normal E:A ratio 
is typically between 1.5 to 2.0. The first stage of diastolic dysfunction is impaired relaxation 
where the E:A ratio is reversed, and the E wave will be smaller than the A wave. The second 
stage of diastolic dysfunction is pseudonormalisation where the E:A ratio appears normal, but 
other characteristics such as deceleration time of the e wave and structural parameters can 
unmask the pseudonormal state. The third stage of diastolic dysfunction is restrictive filling, 
where the E:A ratio is often above 2:0. During this stage cardiac filling during diastole is 
restricted and thus less blood is available for contraction (Zile & Brutsaert, 2002). 
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It has been observed that 27%-70% of asymptomatic T1D patients show some form of 
diastolic abnormality (Paillole et al., 1989; Zarich et al., 1988; Ward & Crossman, 2014). 
Despite these patients being classified as not having any clinical signs of HF, even at this 
early stage of DHD there are changes in myocardial Ca2+ handling and expression of Ca2+ 
regulating proteins (Reuter et al., 2008; Lamberts et al., 2014; Bussey et al., 2015). Therefore, 
given that CaMKIIδ regulates a number of Ca2+ handling proteins involved in contraction 
(LTCC, RyR2) and relaxation (PLB & SERCA), CaMKIIδ is an ideal candidate to investigate 
during the early manifestations of DHD in the T2D heart.  
 
3.1.2 CaMKII! and type 2 diabetic heart dysfunction 
 
CaMKIIδ is upregulated in HF patients with systolic (and diastolic) dysfunction, while 
inhibition of the kinase results in improved contractility (Sossalla et al., 2010).  To date very 
little research has been done to investigate the effects of CaMKIIδ inhibition on cardiac 
dysfunction in the T2D heart. What we do know though is that CaMKIIδ is activated during 
HF, where increases in intracellular Ca2+ and oxidative stress modify CaMKIIδ into its 
autonomous pathological active form (Luczak et al., 2014; Anderson et al., 2011; Couchonnal 
& Anderson, 2008). Interestingly the T2D heart, even prior to systolic dysfunction, is exposed 
to a similar cellular milieu (high intracellular Ca2+ levels and increased oxidative stress) to 
that observed in HF patients. Thus, the diabetic environment could modify CaMKIIδ into an 
autonomous pathological form even prior to systolic dysfunction, further establishing 
CaMKIIδ as a potential therapeutic target in the T2D heart before the onset of systolic 
dysfunction.   
 
3.1.3 Aims and hypothesis 
 
The overall aim of this study was to investigate whether there is reduced contractility in the 
T2D heart during the early stages of global diastolic dysfunction. In addition, the effects of 
CaMKIIδ inhibition on contraction and relaxation properties in the T2D heart were measured. 
I hypothesized that in an isolated cardiac muscle there will be reduced force production and 
contraction and relaxation rates in the DM trabeculae compared to the nDM, which would be 
consistent with the development of HF observed clinically in diabetic patients Further, I 
hypothesized that CaMKIIδ inhibition would restore contractility in the DM muscle.  
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To address these hypotheses, the first aim of this study was to establish the age at which ZDF 
rats develop a clear diabetic phenotype but retain preserved EF with no signs of systolic 
dysfunction, as this time point is ideal for pharmacological intervention to investigate the 
potential effects of CaMKIIδ inhibition. Thaung et al., (2015) have previously shown that at 
20 weeks of age the ZDF rat is chronically hyperglycemic but not yet exhibiting alterations in 
function associated with systolic heart failure. Therefore to confirm this previous observation, 
echocardiography scans were conducted at 12 and 20 weeks for the assessment of LV 
structure and function, as well as E:A ratio, a measure of cardiac relaxation often used in the 
clinic as the first point of diagnosing diastolic dysfunction in T2D patients.  
 
The second aim of this study was to measure the expression and activation status of CaMKIIδ 
in RV tissue from rats at 20 weeks of age via Western blot. For the third aim of the study, ex 
vivo measurements of cardiac contraction and relaxation were made in isolated trabeculae 
from the RV of ZDF rats. Two pharmacological inhibitors of CaMKIIδ, KN93 and AIP, were 
used to determine the involvement of CaMKIIδ activity on contractility in the isolated cardiac 
muscle.  
 
The T2D heart has increased cardiac sympathetic input but reduced responsiveness to β-AR 
stimulation (Thaung et al., 2015). Chronic elevation of cardiac sympathetic input can further 
exacerbate cardiac diabetic complications. Therefore I tested the additional hypothesis that 
inhibition of CaMKIIδ may alter the functional response associated with β-AR stimulation in 
the DM heart. To this end, isolated cardiac muscles were also superfused with increasing 
doses of isoproterenol (non-selective β-AR agonist 10-8 - 10-6 M) in the presence of the 





In this section the animal characteristics and echocardiography data at 12 and 20 weeks of age 
are described. Levels of CaMKIIδ expression and activation at 20 weeks of age measured via 
western blot are shown. Isolated cardiac muscle (trabeculae) from the RV was used for the 
measurement of contractility in the diabetic heart before and after perfusion with CaMKIIδ 
inhibitors (KN93 & AIP). In addition the response to isoproterenol, (non-selective β-AR 
agonist) was used to investigate the β-AR response in the isolated cardiac muscle. Due to the 
complex nature of the functional data and experiments a brief interpretation of the data is 
included in each paragraph to support reasoning and flow of the experimental results, and an 
extended interpretation of data is provided in the discussion. 
 
3.2.1 Animal characteristics 
 
 
Table 3.1 lists body weight, blood glucose, and other basic characteristics for the DM and 
nDM rats at 12 and 20 weeks of age. Both the nDM and DM rats had a significantly higher 
body weight at 20 weeks compared to 12 weeks of age. The DM rats had a significantly 
higher body weight compared to the nDM rats at both 12 and 20 week of age, consistent with 
the observation that ZDF rats develop a phenotype that mimics obesity. Blood glucose was 
also significantly elevated in the DM rats compared to the nDM at 12 and 20 weeks of age, 
with the DM rats also exhibiting a significant increase in blood glucose from 12 to 20 weeks 
of age. Heart weight, tibia length and the ratio between the two parameters (heart weight/tibia 
length) at 20 weeks showed no significant difference between the nDM and DM rats (Table 
3.1).  Overall this data indicates that the DM rats have an increase in body weight and 













Table 3.1 Animal characteristics in 12 and 20 week-old male non-diabetic (n= 10) and 
type 2 diabetic rats (n= 10) 
 
Parameter 12 weeks 20 weeks Condition 
effect 
(P value) 
 nDM DM nDM DM  
Body weight (g) 296.6 ± 6.9 375.3 ± 36.7 387.2 ± 7.9 # 442.9 ± 46.2 # * <0.001 
Blood glucose 
(mmol/L) 
8.6 ±1.9 16.8 ± 2.5 8.2 ± 0.6  25.0 ± 2.5 # * <0.001 
 
 
Heart weight (g) n/a n/a 1.92 ± 0.06 1.94 ± 0.04 0.96 
Tibia length (mm) n/a n/a 32.34 ± 0.61 32.32 ± 0.67 0.98 
HW:TL (mg/mm) n/a n/a 0.06 ± 0.001 0.06 ± 0.002 0.75 
nDM= non diabetic; DM= type 2 diabetic ZDF rats; HW: heart weight/tibia length, n/a= measurements not taken 
at this age. Data are expressed as mean ± SEM. For comparison of age (#) and condition effect between nDM & 
DM at 12 weeks & 20 weeks of age in body weight and blood glucose two between groups ANOVA, # = 
P<0.05, * = P <0.05. For comparison of tibia length, heart weight, and heart weight: tibia length a paired t-test, * 




3.2.2 Echocardiographic measurements 
 
 
Echocardiography data in both the nDM and DM at 12 and 20 weeks of age can be seen in 
Table 3.2. There was no significant difference in LVPWs, LVPWd, EF and LVESV or peak 
early and late mitral inflow velocities between the nDM and DM rats at either 12 or 20 weeks 
of age. There was a significant increase in LVEDV in the DM rats compared to the nDM at 
20 weeks of age, and a trend towards an increase in E:A ratio that did not reach the level of 
significance (P=0.08). Taken together, these measurements indicate that neither of the rat 
cohorts have a significant systolic dysfunction phenotype at 20 weeks of age, with mild 
diastolic dysfunction as indicated by the findings in the LVEDV and E:A ratio. Overall the 
functional measurements indicate that the DM rats have preserved EF at 20 weeks of age and 












Table 3.2 Echocardiography data in 12 and 20 week-old male non-diabetic (nDM) (n= 
10) and type 2 diabetic rats (n= 10) 
 
Parameter 12 weeks 20 weeks Condition 
effect 
(P value) 
 nDM DM nDM DM  
LVPWs (mm) 3.1 ± 0.1 3.1 ± 0.1 2.9 ± 0.1 3.0 ± 0.1 0.60 
LVPWd (mm) 2.5 ± 0.1 2.5 ± 0.2 2.3 ± 0.1 2.7 ± 0.1 0.18 
EF 77.2 ± 1.9 78.6 ± 1.2 72.2 ± 1.9 69.9 ± 3.9 0.84 
LVESV (ml) 0.2 ± 0.0 0.2 ± 0.0 0.3 ± 0.0 0.5 ± 0.1 0.21 
LVEDV (ml) 0.8 ± 0.1 1.0 ± 0.0 1.1 ± 0.1 1.4 ± 0.2 * 0.04 
E:A 1.9 ± 0.1 2.0 ± 0.1 1.8 ± 0.1 2.0 ± 0.1 0.08 
E vel (cm/s) 59.2 ± 1.3 54.3 ± 2.2 55.1 ± 2.3 57.1 ± 3.0 0.52 
A vel (cm/s) 31.0 ± 1.5 27.4 ± 1.5 31.7 ± 2.1 29.2 ± 2.3 0.11 
 
nDM= non-diabetic; DM= type 2 diabetic ZDF rats; LVPWs= left ventricle posterior wall thickness systole; 
LVPWd= left ventricle posterior wall thickness diastole; EF= ejection fraction; LVESV= end systolic volume; 
LVEDV= end diastolic volume. Data are expressed as mean ± SEM. For comparison of condition effect between 






3.2.3 CaMKII! expression and activation 
 
Having established the DM rat model has preserved EF at 20 weeks, the expression and 
activation levels of CaMKIIδ in tissue from the RV of nDM and DM rats at 20 weeks of age 
were measured (Figure 3.1 A). RV tissue was used in anticipation that this tissue type would 
be used to isolate trabeculae for measurements of contractility. Total CaMKIIδ expression 
was unchanged in the RV tissue from the DM rats compared to the nDM rats (0.95 ± 0.08 vs. 
1.15 ± 0.1, nDM vs. DM; Figure 3.1 B), while CaMKIIδ phosphorylation at the T287 site was 
significantly increased in the RV tissue from DM rats (0.77 ± 0.13 vs. 1.40 ± 0.26, nDM vs. 
DM; Figure 3.1 C). Thus, enhanced cardiac CaMKIIδ activity precedes advanced HF in the 














































Figure 3.1 Western blot for total CaMKIIδ  and phosphorylated CaMKIIδ  at T287. A, 
Representative immunoblot of total CaMKIIδ, T287 phosphorylated (PCaMKIIδ) and 
GAPDH as a loading control in non-diabetic (nDM) and type 2 diabetic (DM) rat RV tissue. 
B, Quantification of total CaMKIIδ levels in nDM (n= 8) and DM (n=8) rat RV tissue. C, 
Quantification of PCaMKIIδ levels in nDM (n=8) and DM RV tissue (n=8). Data are mean + 































































3.2.4 Preserved contractile force but impaired contraction and relaxation kinetics in 
type 2 diabetic rat cardiac muscle at basal stimulation frequencies (2 Hz)  
 
Prior studies have reported reduced contractility in trabeculae from human patients with HF 
(Sossalla et al., 2010) or diabetes (Lamberts et al., 2014). I therefore hypothesized that basal 
contractility would be impaired in cardiac tissue from DM rats. Developed force (Fdev), speed 
of contraction (dF/dtmax), speed of relaxation (dF/dtmin) and relaxation time from 50-90% of 
peak contraction (RT90%) were measured in RV trabeculae isolated from nDM and DM 
hearts and stimulated at a low basal frequency of 2 Hz in the presence of the CaMKIIδ 
inhibitor KN93. To control for any potential off-target effects of KN93, all trabeculae were 
also tested in the presence of the control compound KN92. The effects of CaMKIIδ inhibition 
with AIP, a peptide inhibitor of CaMKIIδ, were also investigated.  
 
Table 3.3 shows average data in nDM and DM RV trabeculae in KN92 and KN93 conditions. 
There was no significant main effect for condition or treatment observed in Fdev; however, 
there was a significant interaction (P <0.01). Further post hoc analysis revealed a significant 
difference between the nDM KN92 and nDM KN93 (P= 0.04), with the nDM after CaMKIIδ 
inhibition (KN93) exhibiting a significantly reduced Fdev. There was a significant main effect 
of diabetes on dF/dtmax (P= 0.02), dFdtmin (P= 0.03) and RT90% (P= 0.03), with the DM 
exhibiting a reduced dF/dtmax and dF/dtmin and a slower RT90%. No significant main effect of 
CaMKIIδ inhibition with KN93 was observed in any of the parameters (see table 3.3).  
 
Therefore at a low pacing frequency of 2 Hz the DM cardiac muscles exhibited reduced 
cardiac function, but CaMKIIδ inhibition with KN93 had no significant effect. It must also be 
noted that the nDM exhibited a significantly reduced Fdev after CaMKIIδ inhibition with 
KN93 (Table 3.3), highlighting the important physiological role of CaMKIIδ in the healthy 
heart. This will be discussed further in chapter 6.0, and the remaining data will not address the 
impact of CaMKIIδ inhibition in the nDM cardiac muscle. Data from the nDM cardiac 
muscle in KN93 conditions can be seen in the appendix 1.1 Figure 3.i and appendix 1.2 






Table 3.3 Contraction and relaxation parameters in isolated trabeculae from the right ventricle in non-diabetic and type 2 diabetic rats with 





















nDM= non diabetic ZDF rat; DM= type 2 diabetic ZDF rat; Fdev= developed force; dF/dtmax= speed of contraction; dF/dtmin= speed of relaxation; RT90%= relaxation time from 50-
90% of peak contraction. Data are expressed as mean ± SEM. For comparison between groups and effects of CaMKIIδ inhibition with KN93 a two-way between groups ANOVA 
with Bonferroni’s multiple comparisons test, * = P< 0.05 for condition effect (nDM vs DM), # = P< 0.05 interaction effect. 
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0.03 * 0.42 
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3.2.5 CaMKIIδ  inhibition with KN93 partially restores cardiac contractility in right 
ventricle trabeculae from type 2 diabetic rats 
 
At a low pacing frequency of 2 Hz, there was no difference in the Fdev between the DM and 
nDM trabeculae, but relaxation and contraction rates were impaired in the DM trabeculae. 
However, at higher frequencies Ca2+ flux in myocytes is greatly increased and thus CaMKIIδ 
becomes more active. I therefore hypothesized that the DM cardiac muscle would have 
greater impairment of contractility at higher pacing frequencies and that CaMKIIδ inhibition 
would be beneficial in preserving contraction and relaxation parameters. Therefore the next 
step was to measure the effects of CaMKIIδ inhibition in modulating contractility of nDM 
and DM trabeculae over a range of stimulation frequencies (2-6 Hz) (see Figure 3.2 for 
representative traces.  
 
Across the range of stimulation frequencies tested there was a significant reduction in 
absolute Fdev in trabeculae from DM rats treated with KN92 compared to nDM rats (P< 0.001 
for condition effect, Figure 3.3 A). However the slope of the line for DM cardiac muscle in 
KN92 conditions was significantly different from zero (P <0.01), suggesting that despite the 
reduced Fdev the DM muscle was still able to respond to the increase in stimulation frequency. 
In addition, both dF/dtmax and dF/dtmin were significantly reduced in the trabeculae from the 
DM rats (P<0.001 for condition effect, see Figure 3.3 B & 3.4 A, respectively) demonstrating 
that both contraction and relaxation rates are severely impaired in the isolated cardiac muscle 
from the DM heart. However there was no difference between the nDM and DM trabeculae in 
RT90% even at increasing frequencies (see Figure 3.4 B).  
 
Treatment with KN93 in the DM trabeculae significantly improved Fdev across the range of 
stimulation frequencies (P <0.01), and fully restored it to levels observed in trabeculae from 
the nDM animals (nDM KN92 vs DM KN93 P= 0.74, Figure 3.3 A). While KN93 treatment 
had no effect on RT90% in the DM trabeculae (P= 0.81, Figure 3.4 B), it did significantly 
increase the speed of contraction (dF/dtmax) (P <0.01) and relaxation (dF/dtmin) (P <0.01) 
(Figure 3.3 B & 3.4 A respectively). Similar to the Fdev CaMKIIδ inhibition with KN93 in the 
DM cardiac muscle restored dF/dtmin to levels similar to that observed in the nDM KN92. 
However despite the significant improvement in dF/dtmax with KN93 a persistent difference 
between the nDM KN92 and DM KN93 was observed in the dF/dtmax (P= 0.03). Thus, 
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CaMKIIδ inhibition using KN93 reversed the impaired contractility and speed of relaxation, 
























Figure 3.2 Representative single twitches in isolated right ventricle trabeculae (KN92 & 
KN93). nDM (non-diabetic) RV (right ventricle) rat trabeculae in the presence of KN92 (solid 
black line), and the type 2 diabetic (DM) RV rat trabeculae in the presence of KN92 (dotted 






Fig 3.3 Contraction in isolated trabeculae from the right ventricle in non-diabetic (nDM) 
and type 2 diabetic (DM) rats across a range of stimulation frequencies (2-6 Hz) in the 
presence of KN92 and KN93. A, Developed force (Fdev). B, Maximum rate of contraction 
(dF/dtmax). Data are means + SEM. nDM rat KN92, solid black line, n=9 rats (10 muscles); DM 
rat KN-92, dotted black line, n=9 rats (12 muscles); DM rat KN93, solid red line, n=7 rats (8 
muscles). For all parameters two-way between groups ANOVA: * =P <0.05 condition effect 
(nDM KN92 vs DM KN92), # =P <0.05 treatment effect (DM KN92 vs DM KN93), ¶ =P 
<0.05 treatment effect (nDM KN92 vs DM KN93). 
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Figure 3.4 Relaxation in isolated trabeculae from the right ventricle in non-diabetic 
(nDM) and type 2 diabetic (DM) rats across a range of stimulation frequencies (2-6 Hz) 
in the presence of KN92 and KN93. A, Maximum rate of relaxation (dF/dtmin). B, 
Relaxation time from 50-90% of relaxation (RT90%). Data are means + SEM. nDM rat KN92, 
solid black line, n=9 rats (10 muscles); DM rat KN92, dotted black line n=9 rats (12 muscles); 
DM rat KN93, solid red line, n=7 rats (8 muscles). For all parameters two-way between groups 
ANOVA: * =P <0.05 condition effect (nDM KN92 vs DM KN92), # =P <0.05 treatment effect 
(DM KN92 vs DM KN93). 
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3.2.6 Impaired contraction and relaxation kinetics in type 2 diabetic isolated right 
ventricle trabeculae are reversed by AIP at basal stimulation frequencies (2 Hz) 
 
Having established the beneficial effects of CaMKIIδ inhibition with KN93 on contractility 
across a range of stimulation frequencies, the measurements were repeated in trabeculae from 
a separate set of animals to investigate the effects of CaMKIIδ inhibition with AIP, a peptide 
inhibitor of CaMKIIδ. KN93 inhibits CaMKIIδ activity by preventing calmodulin-binding to 
the kinase but does not inhibit autonomously active CaMKIIδ (Sumi et al., 1991), whereas 
AIP blocks the catalytic domain and inhibits the autonomously active from of the kinase. 
Therefore I hypothesized that AIP would be more effective at restoring cardiac function in 
trabeculae from DM rats, which have a cellular milieu of elevated Ca2+ and oxidative stress 
that drives autonomous activation of CaMKIIδ. To test this hypothesis, measurements were 
first made at a basal stimulation frequency of 2 Hz.  
 
Table 3.4 shows average data in nDM and DM RV trabeculae in CTRL and AIP conditions. 
There was no significant main effect of diabetes (P= 0.84) on Fdev or treatment with AIP in 
either the nDM or DM on Fdev (P= 0.41). In contrast dF/dtmax, dF/dtmin and RT90% were 
significantly impaired in the DM trabeculae, with the DM exhibiting a significantly reduced 
dF/dtmax (P < 0.01) and dF/dtmin (P= 0.03), and longer RT90% in the KN92 conditions. There 
was however a treatment effect of AIP, which significantly improved dF/dtmax (P= 0.02), 
dF/dtmin (P= 0.01) and reduced the RT90% time (P <0.01) in the nDM and DM trabeculae. As 
before, there was a significant impairment in the contraction and relaxation kinetics at low 
pacing frequency in the CTRL conditions, but unlike KN93, AIP was beneficial in restoring 
these measures of contractility. Although it did not reach statistical significance, there was 
reduced Fdev after CaMKIIδ inhibition with AIP in the nDM, a finding similar to that shown 
in the KN93 data. Further data addressing the effects of AIP in nDM trabeculae can be seen in 








Table 3.4 Contraction and relaxation parameters in isolated trabeculae from the right ventricle in non-diabetic and type 2 diabetic rats with 




















nDM= non diabetic ZDF rat; DM= type 2 diabetic ZDF rat; Fdev= developed force; dF/dtmax= speed of contraction; dF/dtmin= speed of relaxation; RT90%= relaxation time from 50-
90% of peak contraction. Data are expressed as mean ± SEM. For comparison between groups and effects of CaMKIIδ inhibition with KN93 a two-way between groups ANOVA 
with Bonferroni’s multiple comparisons test, * = P< 0.05 for condition effect (nDM vs DM). 
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0.01 * < 0.01 ** 
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3.2.7 CaMKIIδ  inhibition with AIP fully restores cardiac contractility across a range of 
stimulation frequencies in isolated RV trabeculae from type 2 diabetic rats 
 
Figure 3.5 shows representative traces of Fdev in nDM CTRL, DM CTRL and DM AIP 
trabeculae. Similar to the findings in the trabeculae treated with the KN92, there was a 
significantly reduced Fdev in the DM trabeculae in the CTRL conditions compared to the nDM 
(P<0.001, Figure 3.6 A). The slope of the line for the Fdev in the nDM trabeculae was not 
significantly different than zero (P= 0.14), indicating that force did not change in response to 
stimulation frequency. dF/dtmax and dF/dtmin were also impaired in the DM trabeculae 
(P<0.001, Figure 3.6 B & 3.7 A, respectively), along with impaired late relaxation as 
measured by RT90% (P< 0.001, Figure 3.7 B). CaMKIIδ inhibition with AIP resulted in a 
significant increase in Fdev (P <0.001) and dF/dtmax (P <0.001), with both Fdev and dF/dtmax 
fully restored to levels observed in the nDM trabeculae in CTRL conditions (Fdev nDM CTRL 
vs DM AIP P= 0.36 & dF/dtmax nDM CTRL vs DM AIP P= 0.89). Similar findings were 
observed in RT90%, with AIP significantly reducing RT90% time (P <0.001, Figure 3.7 B) 
and restoring it to the same level as the nDM in CTRL conditions (P= 0.46). DM trabeculae 
had significantly increased dF/dtmin after treatment with AIP (P <0.001), and in fact those DM 
trabeculae treated with AIP showed a significantly faster dF/dtmin rate than even the nDM 
trabeculae (P= 0.02, Figure 3.7 A). Taken together, these data are consistent with the 
hypothesis that inhibition of CaMKIIδ, and in particular the autonomously active forms of 
















































Figure 3.5 Representative single twitches in isolated right ventricle trabeculae (CTRL & 
AIP). Non-diabetic (nDM) rat right ventricle (RV) trabeculae in the presence of CTRL buffer 
(solid black line), and the type 2 diabetic (DM) rat RV trabeculae in the presence of CTRL 








Figure 3.6 Contraction in isolated trabeculae from the right ventricle in non-diabetic 
(nDM) and type 2 diabetic (DM) rats across a range of stimulation frequencies (2-6 Hz) 
in the presence of CTRL and AIP. A, Developed force (Fdev). B, Maximum rate of 
contraction (dF/dtmax). Data are means + SEM. nDM rat CTRL, solid black line, n=5 rats (13 
muscles); DM rat CTRL, dotted black line, n=6 rats (12 muscles); DM rat AIP, solid blue line, 
n=9 rats (12 muscles). For all parameters two-way between groups ANOVA: * =P <0.05 
condition effect (nDM CTRL vs DM CTRL), # =P <0.05 treatment effect (DM CTRL vs DM 
AIP). 
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Figure 3.7 Relaxation in isolated trabeculae from the right ventricle in non-diabetic 
(nDM) and type 2 diabetic (DM) rats across a range of stimulation frequencies (2-6 Hz) 
in the presence of CTRL and AIP. A, Maximum rate of relaxation (dF/dtmin). B, Relaxation 
time from 50-90% of relaxation (RT90%). Data are means + SEM. nDM rat CTRL, solid black 
line, n=5 rats (13 muscles); DM rat AIP, dotted black line n=6 rats (12 muscles); DM rat AIP, 
solid red line, n=9 rats (12 muscles). For all parameters two-way between groups ANOVA: * =P 
<0.05 condition effect (nDM CTRL vs DM CTRL), # =P <0.05 treatment effect (DM CTRL vs 
DM AIP), ¶ =P <0.05 treatment effect (nDM CTRL vs DM AIP). 
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3.2.8 Effects of CaMKII! inhibition with KN93 on contraction and relaxation in isolated 
right ventricle trabeculae from type 2 diabetic rats during β-adrenergic stimulation  
 
The T2D heart has previously been shown to have reduced cardiac β-AR responsiveness 
(Thaung et al., 2015), whilst others have reported similar findings in heart preparations from 
T1D animal models (Vadlamudi RV & McNeill JH, 1984; Atkins FL et al., 1985). In this 
study, I examined the response of the DM cardiac muscle to β-AR cardiac stress by 
measuring the functional response with increasing doses of isoproterenol (non-selective β-AR 
agonist, 10-8 - 10-6 M) at 2 Hz stimulation frequency. These measurements were also made in 
the presence of KN92 and KN93 to investigate the effects of CaMKIIδ inhibition in the 
context of β-AR stimulation. Measurements were made at 2 Hz as β-AR stimulation is a stress 
response for the trabeculae, and thus the combination of high stimulation frequency and 
isoproterenol may have been difficult to maintain over the course of the full experimental 
protocol. 
 
Figure 3.8 A shows the Fdev in nDM KN92, DM KN92 and DM KN93 trabeculae from 
baseline to increasing concentration of isoproterenol  (10-8 - 10-6 M). There was a significant 
main effect of isoproterenol with nDM KN92, DM KN92 and DM KN93 groups all 
exhibiting an increase in Fdev with increasing concentrations of isoproterenol (P <0.001). In 
contrast to reduced Fdev observed in DM trabeculae treated with KN92 without isoproterenol 
(see Figures 3.3 A & 3.6 A), perfusion with isoproterenol reduced the difference in Fdev 
between the nDM and DM, with no significant difference observed between the two (P= 0.08, 
Figure 3.8 A). Figure 3.8 B could help to explain this observation, as it shows the percentage 
change in Fdev from 2 Hz baseline at each isoproterenol dose. The DM trabeculae with no 
CaMKII δ  inhibition have a significantly greater % increase in their Fdev across all 
isoproterenol concentrations compared to the nDM cardiac muscle (P= 0.02). In particular at 
10-7 the DM trabeculae in the KN92 conditions increase their Fdev by 123% compared to 38% 
in the nDM trabeculae. At 10-6 the DM trabeculae in the KN92 conditions increase by 239% 
compared to 36% in the nDM trabeculae. These data suggest that the DM cardiac muscle is 
more sensitive to β-AR stimulation than the nDM. CaMKIIδ inhibition with KN93 reduces 
the response to isoproterenol down to 60% at 10-7 and 154% at 10-6, although this did not 
reach statistical significance (P= 0.17). In addition, the difference in the % change from 
baseline between the nDM and DM trabeculae persisted even after CaMKIIδ inhibition with 













































Figure 3.8 Contractile force during β-adrenergic stimulation in isolated right ventricle 
trabeculae from non-diabetic (nDM) and type 2 diabetic (DM) rats stimulated at 2 Hz in 
the presence of KN92 and KN93. A, Developed force (Fdev), B, % change in Fdev from 2 Hz 
baseline. Data are means + SEM. nDM rat KN92, solid black line & black bar, n= 9 rats (10 
muscles); DM rat KN92, dotted black line & white bar, n= 9 rats (12 muscles); DM KN93, solid 
red line & red bar, n= 7 rats (8 muscles). For all parameters two-way between groups ANOVA: * 
=P <0.05 condition effect (nDM KN92 vs DM KN92), ¶ =P <0.05 treatment effect (nDM KN92 
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Similar to the findings for Fdev, increasing concentrations of isoproterenol led to an increase in 
dF/dtmax (P <0.001 Figure 3.9 A) and dF/dtmin (P <0.001, Figure 3.10 A) for each group. 
However, I observed a significant impairment in dF/dtmax (P< 0.001, figure 3.11 A) and 
dF/dtmin (P <0.001, Figure 3.9 A) across the range of isoproterenol concentrations for the DM 
KN92 trabeculae compared to the nDM KN92 group. Further, CaMKIIδ inhibition with 
KN93 had no significant effect on improving either dF/dtmax or dF/dtmin in the DM trabeculae 
when compared to the DM trabeculae in the KN92 conditions (P= 0.31 & P= 0.36, 
respectively) and also the difference between the nDM and DM trabeculae persisted in both 
parameters (P= 0.01 & 0.02, respectively). 
 
Despite the DM trabeculae exhibiting a slower dF/dtmax and dF/dtmin during the isoproterenol 
challenge, a higher absolute percentage change in dF/dtmax (P= 0.20, Figure 3.9 B) and 
dF/dtmin (P value= 0.24, Figure 3.10 B) was observed across all isoproterenol concentrations, 
though these differences did not reach the level of statistical significance. Similarly, CaMKIIδ 
inhibition with KN93 did not alter the % change in dF/dtmax (P= 0.35, Figure 3.9 B) and 
dF/dtmin (P= 0.36, Figure 3.10 B). I had hypothesized that, although the DM trabeculae had a 
slower dF/dtmax and dF/dtmin, they would be able to increase their contractile and relaxation 
kinetics from baseline to a greater extent during β-AR stimulation than the nDM trabeculae, 






















































Figure 3.9 Speed of contraction during β-adrenergic stimulation in isolated right 
ventricle trabeculae from non-diabetic (nDM) and type 2 diabetic (DM) rats stimulated 
at 2 Hz in the presence of KN92 and KN93. A, Maximum rate of contraction (dF/dtmax), B, 
% change in dF/dtmax from 2 Hz baseline. Data are means + SEM. nDM rat KN92, solid black 
line & black bar, n= 9 rats (10 muscles); DM rat KN92, dotted black line & white bar, n= 9 rats 
(12 muscles); DM KN93, solid red line & red bar, n= 7 rats (8 muscles). For all parameters two-
way between groups ANOVA: * =P <0.05 condition effect (nDM KN92 vs DM KN92), ¶ =P 
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Figure 3.10 Speed of relaxation during β-adrenergic stimulation in isolated right 
ventricle trabeculae from non-diabetic (nDM) and type 2 diabetic (DM) rats stimulated 
at 2 Hz in the presence of KN92 and KN93. A, Maximum rate of relaxation (dF/dtmin), B, % 
change in dF/dtmin from 2 Hz baseline. Data are means + SEM. nDM rat KN92, black solid line 
& black bar, n= 9 rats (10 muscles); DM rat KN92, dotted black line & white bar, n= 9 rats (12 
muscles); DM KN93, solid red line & red bar, n= 7 rats (8 muscles). For all parameters two-way 
between groups ANOVA: * =P <0.05 condition effect (nDM KN-92 vs DM KN-92, ¶ =P <0.05 
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Similar to observations of dF/dtmax and dF/dtmin, the DM trabeculae exhibited an impaired 
RT90% response to isoproterenol compared to the nDM trabeculae (P= 0.01, Figure 3.11 A). 
CaMKIIδ inhibition with KN93 was not able to reverse this impairment, as there was no 
difference between the DM KN92 and DM KN93 trabeculae (P= 0.68) and the difference 
between the nDM KN92 and DM KN93 trabeculae persisted (P <0.001). The results from the 
percentage change in RT90% from baseline are shown in Figure 3.11 B.  There was no 
significant difference between the nDM and DM KN92 trabeculae across all isoproterenol 
concentrations (P= 0.14). In contrast, CaMKIIδ inhibition in the DM trabeculae significantly 
increased the % change in RT90% compared to the DM KN92 (P= 0.04). This increased % 
change in RT90% was surprising when compared to observations in Figure 3.11 A that 
RT90% decreases in the DM trabeculae in KN93 conditions. These seemingly contradictory 
results may be due to the large variance in the % change, with relatively high SEM on the DM 
KN93 group, which would suggest a great deal of variability in the response of the DM KN93 












































Figure 3.11 Late relaxation time during β-adrenergic stimulation in isolated right 
ventricle trabeculae from non-diabetic (nDM) and type 2 diabetic (DM) rats stimulated 
at 2 Hz in the presence of KN92 and KN93. A, Relaxation time from 50-90% of relaxation 
(RT90%), B, % change in RT90% from 2 Hz baseline. Data are means + SEM. nDM rat 
KN92, solid black line & black bar, n= 9 rats (10 muscles); DM rat KN92, dotted black line & 
white bar, n= 9 rats (12 muscles); DM KN93, solid red line & red bar, n= 7 rats (8 muscles). For 
all parameters two-way between groups ANOVA: * =P <0.05 condition effect (nDM KN92 vs 
DM KN92, ¶ =P <0.05 treatment effect (nDM KN92 vs DM KN93), # =P <0.05 treatment 
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3.2.9 Effects of CaMKII! inhibition with AIP on contraction and relaxation in isolated 
right ventricle trabeculae from type 2 diabetic rats during β-Adrenergic stimulation  
 
Having established the β-AR response in the DM trabeculae and the effect of CaMKIIδ 
inhibition via KN93, the next step was to investigate the effects of the peptide CaMKIIδ 
inhibitor AIP. The force frequency relationship showed AIP was able to restore Fdev to that 
measured in nDM trabeculae and, in particular AIP improved dF/dtmax and dF/dtmin to a 
greater extent than CaMKIIδ inhibition with KN93. Therefore I hypothesized that AIP would 
have a greater effect on preserving contraction and relaxation properties during the 
isoproterenol challenge.  
 
Figure 3.12 A shows the Fdev for the nDM CTRL, DM CTRL and DM AIP trabeculae at 
baseline and with increasing concentrations of isoproterenol (10-8 – 10-6 M). There was a 
significant difference in Fdev between the nDM and DM CTRL, with the nDM CTRL 
trabeculae exhibiting a significantly higher Fdev compared to the DM trabeculae in the CTRL 
conditions during the isoproterenol challenge (P <0.001). CaMKIIδ inhibition with AIP in the 
DM trabeculae significantly improved the Fdev (P= 0.02), and there was no longer any 
difference between the nDM and DM cardiac muscle (P= 0.22). In contrast to the data with 
KN92 and KN93 treatment, there was no significant main effect of increasing isoproterenol 
concentrations on Fdev in any of the conditions (nDM CTRL, DM CTRL, DM AIP, P= 0.43). 
Figure 3.12 B also shows this blunted responsiveness to isoproterenol where it can be seen 
there is no significant between the nDM CTRL and DM CTRL trabeculae (P=0.42), or any 
effect of CaMKIIδ inhibition with AIP in the DM cardiac muscle (P= 0.26) in their % change 









































Figure 3.12 Contractile force during β-adrenergic stimulation in isolated right ventricle 
trabeculae from non-diabetic (nDM) and type 2 diabetic (DM) rats stimulated at 2 Hz in 
the presence of CTRL and AIP. A, Developed force (Fdev), B, % change in Fdev from 2 Hz 
baseline. Data are means + SEM. nDM rat CTRL, black solid line & black bar, n= 5 rats (13 
muscles); DM rat CTRL, dotted black line & white bar, n= 6 rats (13 muscles); DM AIP, solid 
blue line & blue bar, n= 9 rats (12 muscles). For all parameters two-way between groups 
ANOVA: * =P <0.05 condition effect (nDM CTRL vs DM CTRL), # =P <0.05 treatment effect 
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Contractile and relaxation rates during the isoproterenol challenge in the nDM CTRL, DM 
CTRL and DM AIP trabeculae are shown in Figure 3.13 A and 3.14 A, respectively. dF/dtmax 
was significantly reduced in the DM CTRL compared to the nDM CTRL trabeculae (P 
<0.001). CaMKIIδ!inhibition with AIP significantly increased dF/dtmax (P <0.001), and AIP 
treatment restored dF/dtmax to nDM CTRL levels (P= 0.76). Figure 3.13 B shows the % 
change in dF/dtmax across all the isoproterenol concentrations in the nDM CTRL, DM CTRL 
and DM AIP trabeculae. There was no significant difference between the nDM CTRL and 
DM CTRL trabeculae (P= 0.19) in their response to the isoproterenol or effect of CaMKIIδ 
inhibition with AIP in the DM trabeculae (P=0.76). dF/dtmin was also significantly reduced in 
the DM CTRL trabeculae compared to the nDM CTRL trabeculae (P <0.001, figure 3.14 A). 
CaMKIIδ inhibition with AIP significantly improved the dF/dtmin (P <0.001), and again the 
AIP restored dF/dtmin to nDM CTRL levels (P= 0.27). Figure 3.14 B shows the % change in 
dF/dtmin across all the isoproterenol concentrations in nDM CTRL, DM CTRL and DM AIP 
trabeculae. There was no significant difference between the nDM CTRL and DM CTRL 
trabeculae in their response to the increasing concentrations of isoproterenol (P= 0.19) or any 


























































Figure 3.13 Speed of contraction during β-adrenergic stimulation in isolated right 
ventricle trabeculae from non-diabetic (nDM) and type 2 diabetic (DM) rats stimulated 
at 2 Hz in the presence of CTRL & AIP. A, Maximum rate of contraction (dF/dtmax), B, % 
change in dF/dtmax from 2 Hz baseline. Data are means + SEM. nDM rat CTRL, solid black line 
& black bar, n= 5 rats (13 muscles); DM rat CTRL, dotted black line & white bar, n= 6 rats (13 
muscles); DM AIP, solid blue line & blue bar, n= 9 rats (12 muscles). For all parameters two-way 
between groups ANOVA: * =P <0.05 condition effect (nDM CTRL vs DM CTRL), # =P <0.05 
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Figure 3.14 Speed of relaxation during β-adrenergic stimulation in isolated right 
ventricle trabeculae from non-diabetic (nDM) and type 2 diabetic (DM) rats stimulated 
at 2 Hz in the presence of CTRL and AIP. A, Maximum rate of relaxation (dF/dtmin), B, % 
change in dF/dtmin from 2 Hz baseline. Data are means + SEM. nDM rat CTRL, solid black line 
& black bar, n= 5 rats (13 muscles); DM rat CTRL, dotted black line & white bar, n= 6 rats (13 
muscles); DM AIP, solid blue line & blue bar, n= 9 rats (12 muscles). For all parameters two-way 
between groups ANOVA: * =P <0.05 condition effect (nDM CTRL vs DM CTRL), # =P <0.05 
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RT90% during the isoproterenol challenge is shown in Figure 3.15 A. Increasing 
concentrations of isoproterenol had a significant main effect of decreasing RT90% in nDM 
CTRL, DM CTRL and DM AIP trabeculae. There was a significant prolongation of RT90% 
in the DM CTRL trabeculae compared to the nDM CTRL trabeculae (P= 0.01). CaMKIIδ 
inhibition with AIP was beneficial in reducing RT90% in the DM trabeculae (P= 0.02), and 
there was no difference between the nDM CTRL and DM AIP trabeculae (P= 0.91). Figure 
3.15 B reports the % change in RT90%, which showed a significant difference between the 
nDM CTRL and DM CTRL trabeculae (P= 0.02), with the DM trabeculae exhibiting a much 
greater change in RT90% from baseline at all isoproterenol concentrations compared to the 
nDM trabeculae (Figure 3.15 B). CaMKIIδ inhibition with AIP significantly reduced the % 
change in RT90% (P <0.001), although a difference still existed between the nDM and DM 
trabeculae (P =0.01). These data suggest that AIP stabilized RT90% response during β-AR 
stimulation and that this increased responsiveness in RT90% contributed to the reversed 

















































Figure 3.15 Late relaxation time during β-adrenergic stimulation in isolated right 
ventricle trabeculae from non-diabetic (nDM) and type 2 diabetic (DM) rats stimulated 
at 2 Hz in the presence of CTRL and AIP. A, Relaxation time from 50-90% of relaxation 
(RT90%), B, % change in RT90% from 2 Hz baseline. Data are means + SEM. nDM rat 
CTRL, solid black line & black bar, n= 5 rats (13 muscles); DM rat CTRL, dotted black line & 
white bar, n= 6 rats (13 muscles); DM AIP, solid blue line & blue bar, n= 9 rats (12 muscles). For 
all parameters two-way between groups ANOVA: * =P <0.05 condition effect (nDM CTRL vs 
DM CTRL), # =P <0.05 treatment effect (DM CTRL vs DM AIP), ¶ =P <0.05 treatment effect 
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In this chapter, global LV cardiac structure and function were measured in nDM and DM rats 
at 12 and 20 weeks of age. CaMKIIδ expression and activation levels were also measured in 
RV tissue taken from nDM and DM rats at 20 weeks of age. Contractile and relaxation 
parameters were measured in trabeculae muscle isolated from the RV free wall of 20 week-
old male nDM and DM rats. The effects of CaMKIIδ inhibition on contractility both with and 
without β-AR stimulation were investigated with two separate inhibitors: KN93, which 
inhibits CaMKIIδ by blocking CaM binding at the regulatory domain, and AIP, a peptide 
inhibitor that blocks substrate binding at the catalytic domain of CaMKIIδ. I hypothesized 
that there would be reduced contractile performance in the DM isolated muscle and a reduced 
responsiveness to β-AR stimulation. In addition I hypothesized that CaMKIIδ inhibition 
would be beneficial in preserving contraction and relaxation in the DM muscle.  The main 
findings of this study can be summarized as follows: 
- Blood glucose measurements confirm the diabetic status of the DM rats at 12 and 20 
weeks of age. 
- Echocardiography data showed no signs of systolic dysfunction and only mild signs of 
diastolic dysfunction at 20 weeks of age in the DM rats.  
- Increased expression of phosphorylated CaMKIIδ was found in the RV tissue of DM 
rats. 
- Contraction and relaxation are reduced in isolated DM cardiac muscle. 
- Inhibition of CaMKIIδ with KN93 and AIP restores the force of contraction to levels 
similar to nDM across a range of stimulation frequencies. 
- Inhibition of CaMKIIδ with KN93 partially restores the speed and relaxation of 
contraction, while inhibition with AIP fully restores relaxation and contraction 
kinetics. 
- CaMKIIδ  inhibition with KN93 and AIP resulted in reduced Fdev in the nDM 
trabeculae. 
- DM trabeculae were more sensitive to β-AR stimulation in KN92 conditions 
compared to nDM trabeculae as shown by the greater % change in Fdev. 
- CaMKIIδ inhibition with KN93 and AIP partially blunted the response of trabeculae 






3.3.1 CaMKII! activation precedes systolic dysfunction in type 2 diabetic rats 
 
Diastolic dysfunction typically precedes systolic dysfunction in the T2D heart, therefore I 
wanted to ensure the animal model was not in systolic dysfunction. Echocardiography data 
showed no signs of systolic dysfunction and only mild signs of diastolic dysfunction, as 
demonstrated by the significantly increased LVEDV in the DM rats a 20 weeks of age, and a 
trend towards an increased E:A ratio (see Table 3.2). Therefore this finding and the Western 
blot data that shows an increase in the phosphorylated form of CaMKIIδ in the rats at 20 
weeks of age indicates that increases in phosphorylated (and therefore autonomously 
activated) CaMKIIδ precedes clinical indications of advanced HF. 
  
3.3.2 CaMKII !  inhibition improves contractility across a range of stimulation 
frequencies in isolated right ventricle trabeculae from type 2 diabetic rats 
 
Impaired contractility underpins reduced cardiac performance and contributes to enhanced 
susceptibility to HF in the diabetic myocardium (Lacombe at al., 2007; Ward & Crossman, 
2014). Thus, one of the goals in the treatment of diabetes is targeting cellular pathways that 
modulate cardiac contractility. The results from this study confirm that there is reduced 
contractility in the DM heart as demonstrated by the reduced Fdev, dF/dtmax and dF/dtmin in the 
DM trabeculae with no CaMKIIδ inhibition (KN92 & CTRL conditions). This reduced 
contractility is in contrast to what was observed in the echocardiography data; however, the 
trabeculae data is reflecting the contractile function independent of any autonomic input. 
Indeed, there is elevated sympathetic nerve activity to the DM heart (Thaung et al., 2015) that 
may be preserving the function of the heart in vivo, but when this input removed and 
measurements are made ex vivo in trabeculae, there is no longer any sympathetic drive to 
maintain that function.  
 
The results from this study provide the first evidence that acute inhibition of CaMKIIδ 
restores both the force and rate of contraction in ventricular trabeculae from DM rats. A 
previous study showed improvement in force generation and contraction after CaMKIIδ 
inhibition in nDM ventricular trabeculae from patients with HF, but the same study showed 
no improvement in relaxation parameters after KN93 treatment (Sossalla et al., 2010). 
Interestingly, the results from my study showed a positive effect of CaMKIIδ inhibition on 
both contraction and relaxation parameters in the diabetic myocardium (see Figures 3.2-3.7). 
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This difference in findings may be attributable to alterations in expression and/or activity of 
Ca2+ flux proteins associated with relaxation (SERCA2a, NCX) or alterations to myofilament 
function during diabetes and/or HF. For example SERCA expression is reduced in HF 
patients (Hasenfuss et al., 1994) whereas Lamberts et al. (2014) showed in diabetic patients 
with preserved EF that myocardial SERCA2a expression is increased, whilst PLB expression 
was decreased.  
 
Another important finding from this study was the observation that inhibitors that target the 
autonomously active form of CaMKIIδ (e.g. AIP) are more effective for rescuing cardiac 
function in diabetic tissue than inhibitors that prevent calmodulin-dependent activation of 
CaMKIIδ (e.g KN93). This study showed that AIP was able to restore Fdev and dF/dtmax in the 
DM trabeculae to similar levels as observed in the nDM trabeculae and even improve dF/dtmin 
to levels above that in the nDM (Figure 3.6 & 3.7). Therefore AIP was able to fully restore 
contraction and relaxation in the DM trabeculae. AIP inhibits CaMKIIδ by blocking substrate 
binding at the catalytic domain and thus inhibits the autonomously active and pathological 
form of CaMKIIδ (Ishida et al., 1995). Prolonged Ca2+ elevations at a high frequency are a 
hallmark of cardiac stress and result in autonomous activation of CaMKIIδ (Erickson et al., 
2011; 2014). Therefore as the T2D heart is known to have disturbed Ca2+ handling (Dillmann 
et al., 1980; Penpargkul et al., 1981; Pierce et al., 1981), my data are consistent with the 
interpretation that AIP is able to rescue function more fully than KN93, as AIP is able to 
inhibit the autonomous active form of CaMKIIδ. 
 
One surprising finding from this study was the reduced Fdev observed in the nDM trabeculae 
after CaMKIIδ inhibition with both KN93 and AIP (see Table 3.3 & 3.4 and Figures 3.i & 3.ii 
in the appendix). This finding indicates the important physiological role of CaMKIIδ in the 
heart and will be discussed further in chapter 6. 
 
3.3.3 CaMKII! inhibition and β-Adrenergic stimulation 
 
The T2D heart experiences chronically elevated levels of β-AR stimulation (Thaung et al., 
2015) and CaMKIIδ is activated by treatment with β-AR agonists (Curran et al., 2007; Wang 
et al., 2004). Whilst the role of CaMKIIδ during chronic β-AR signalling has been previously 
investigated (Grimm et al., 2015), its role during acute elevations of β-AR activation is 
relatively unknown. The data from these studies suggest that the DM trabeculae are more 
sensitive to the acute isoproterenol challenge as they exhibit a greater % increase in Fdev from 
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baseline compared to the nDM trabeculae (see Figure 3.8 B). Although this increase in Fdev is 
a normal physiological response to isoproterenol, if this β-AR signalling was in a chronic 
setting and the heart continued to respond with significant increases in force production, this 
process could induce structural changes in the heart such as hypertrophy and, ultimately, 
reduced cardiac performance (Port & Bristow, 2001; Najafi et al., 2016).  
 
CaMKIIδ  inhibition with KN93 blunted the increase in force production during β-AR 
signalling. However this increase in Fdev in response to isoproterenol may be resulting in an 
impaired relaxation time. At baseline RT90% is not impaired in the DM trabeculae; however, 
after isoproterenol perfusion there is a reduction in RT90% (see Figure 3.11 A). Unlike the 
positive of effects of CaMKIIδ inhibition on Fdev it appears that KN93 is not able to improve 
RT90%. This could be due to reduced phosphorylation of phospholamban (PLB), which 
would result in PLB acting as a break on SERCA and reducing the amount of Ca2+ that can be 
taken back up into the SR. This hypothesis will be tested in the next chapter.  
 
The findings from CaMKIIδ inhibition with AIP during acute β-AR signalling are different to 
what was seen with KN93. A difference in Fdev between nDM and DM under CTRL 
conditions remained from baseline and throughout all isoproterenol doses (see Figure 3.12 A). 
Only at the highest concentration of isoproterenol was there any change in the Fdev from 
baseline, although this change was still not significant. AIP was able to increase Fdev in the 
DM trabeculae. Similar findings were found in dF/dtmax and dF/dtmin (see Figures 3.13 & 
3.14). RT90% also exhibited a different profile to what was observed during 
CaMKIIδ!inhibition with KN93. RT90% was significantly slower at baseline and throughout 
all the isoproterenol concentrations. However CaMKIIδ inhibition with AIP was able to 
improve the RT90%. These findings provide evidence of CaMKIIδ activation during acute β-
AR signalling. 
 
The findings from this part of the study do highlight some questions, in particular the 
increased responsiveness to isoproterenol that was observed in the DM cardiac muscles. This 
finding contrasts to what has been previously reported in the literature of a reduced 
responsiveness to β-AR stimulation in the T2D heart (Altan et al., 2007; Daniels et al., 2010; 
Lamberts et al., 2014). This has previously been suggested to be due to reduced expression 
levels of β1-adrenoceptors in the rat heart (Dincer et al., 2001). Thaung et al., (2008) showed 
in the same model (ZDF) as that used in this study and at the same age (20 weeks) a reduced 
expression of β1-AR in LV tissue. Therefore if there is no increase in the expression of β1-AR, 
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alterations in downstream β-AR signalling may play a role in the increased responsiveness to 
isoproterenol observed in this study. PLB is activated during β-AR signalling, and thus an 
increase in the expression or phosphorylation of PLB could result in greater SR Ca2+ uptake 
during relaxation and increased SR Ca2+ content that can be released for contraction 
(Lamberts et al., 2014). Levels of PLB and SR Ca2+ content in the DM heart are investigated 
in the following chapter. However it must be noted that this increased responsiveness to 
isoproterenol in the DM trabeculae was only observed in the Fdev in the KN92 conditions, 
whereas in other parameters there was no difference in % change from baseline between the 
nDM and DM cardiac muscles. In addition during the CTRL and AIP conditions this 
increased responsiveness in the DM trabeculae was not observed, therefore indicating the 
increased responsiveness could be due to off target effects associated with KN92 and KN93, 
such as on the LTCC (Gao et al., 2006). It has been shown by Rigg et al., (2003) that KN92 
and KN93 reduce the ICa.L by 48 + 19% in patch clamp studies conducted at 0 mV voltage 
clamp command potential. Ledoux et al., (1999) also showed that KN93 had inhibitory effects 
on the K+ channel. Perhaps during acute β-AR with isoproterenol perfusion these off target 
effects are resulting in an increase in contractile force. 
 
3.3.4 Limitations  
 
There are several limitations that must be taken into account with the findings from this study. 
The use of trabeculae allows for the measurement of cardiac function independent of either 
autonomic input to the heart or any changes in metabolism. However the isolation of the 
trabeculae presents challenges that can potentially impact upon the results. The muscle must 
be carefully cut out of the RV free wall and then transferred to the experimental set-up, where 
it is attached between a force transducer and micromanipulator. At any stage during this 
procedure the muscle can be damaged, which could affect contractile function. To account for 
this limitation, any muscles exhibiting a force below 1 mN/mm2 during the 2 Hz stimulation 
frequency were excluded. In addition muscles are isolated from the RV free wall as the 
trabeculae in this chamber of the heart are much more pronounced than in the LV. Therefore 
it is easier to isolate the muscle and there is less chance of damage during the isolation steps 
of the protocol. Muscles from both nDM and DM rats are then superfused with identical 
glucose concentrations, which could normalize differences in glycemic load between the 
nDM and DM trabeculae. However it has been previously shown that the acute addition of 
high glucose levels does not affect the rate of glycolysis, and thus is unlikely to influence 
cardiac functionality (Saddik & Lopaschuk, 1991).  
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In addition, as the cardiac muscle is isolated from the RV, while the echocardiographic scans 
were performed on the LV. Imaging of the LV chamber is a more reproducible approach in 
rat hearts than the RV, partly due to the complex geometry of the RV, which has separate 
outflow and inflow portions and a main body that is ‘crencentic’ (rounded/curving) and 
truncated (Foale et al., 1986). It is therefore difficult for mathematical equations to 
reconstruct the complex geometric shape of the RV (Karamitsos et al., 2007). The approach 
of using two different heart chambers in this study may raise concerns, as the two ventricles 
have different cardiac functions (i.e. the RV is responsible for pumping blood to the relatively 
short, low pressure pulmonary circulation, whereas the LV pumps blood to the lengthy, high 
pressure systemic circulation). Importantly, past studies have found no difference between the 
ventricles in their contribution to the development of DHD (Karamitsos et al., 2007). 
Although differences in the expression of SERCA and PLB between the RA and LV in T2D 
patients has been reported by Bussey et al., (2015), a study by van der Brom (2010) in ZDF 
rats reported that LV changes were paralleled by RV alterations to insulin-stimulated glucose 
utilization and RV systolic function. In addition there are no reports of any chamber specific 
differences in CaMKII activation and expression levels. For example Sossalla et al., (2010) 
observed CaMKII expression to be increased in both the LV and RV of patients with dilated 




In conclusion this study has confirmed that CaMKIIδ is excessively activated in the T2D 
heart prior to systolic dysfunction. The data showed that contractile performance was 
decreased in the DM heart as the magnitude of force development and the kinetics of 
contraction and relaxation were diminished in the DM cardiac muscle. CaMKIIδ inhibition 
was beneficial in restoring contractile force and the speed of contraction and relaxation, 
parameters that are largely mediated by cardiac Ca2+ handling.  
 
The results from this study point towards the potential for targeting CaMKIIδ as a therapeutic 
approach in T2D patients in order to prevent subsequent HF that can arise from diabetes-
induced impairment of contractile performance. As stated previously diastolic dysfunction 
precedes systolic dysfunction in the T2D heart and the animal model used in this study had 
preserved EF. However the results from this study indicate that CaMKIIδ inhibition is 
beneficial in preserving both contractile (systolic) and relaxation (diastolic) parameters, 
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therefore indicating CaMKIIδ inhibition could also be used as a therapeutic target during the 
later stages of DHD where systolic dysfunction is apparent.  
 
As mentioned in Chapter 1.0, section 1.1, T2D is a complex disease that encompasses a 
number of molecular mechanisms that been proposed to underlie the development of cardiac 
dysfunction. Therefore the next step and the preceding chapter of this thesis will go on to 
investigate the potential mechanisms that CaMKIIδ inhibition could be acting upon in the 
T2D heart to result in the increased contractility shown in this chapter. 
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Chapter 4.0  





The experiments outlined in chapter 3 explored the hypothesis that CaMKIIδ inhibition in 
isolated cardiac muscle of DM rats would improve contractility. It was shown that there is 
decreased contractile performance in the DM heart, and that CaMKIIδ inhibition was 
beneficial in preserving contractility through parameters that are largely mediated by cardiac 
Ca2+ handling. The role of CaMKIIδ in mediating contractility suggests that altered Ca2+ 
handling may underlie the loss of contractility in the T2D heart. Therefore the next step was 
to investigate the effects of CaMKIIδ inhibition on Ca2+ handling in trabeculae and cardiac 
myocytes from DM rats to elucidate potential mechanisms for the observed improvement in 
contractility. 
 
4.1.1 Ca2+ mishandling in the type 2 diabetic heart prior to the onset of systolic 
dysfunction 
 
As described in section 1.3, impaired Ca2+ handling has been the focus of much research 
investigating the reduced contractile performance in the diabetic heart (Pierce & Russell, 
1997; Choi et al., 2002), but no consensus has emerged on the manifestations of the disturbed 
Ca2+ handling. Ca2+ drives contractile activity of the heart (Bers 2000; Bers, 2002), and thus 
any alterations in intracellular Ca2+ can result in myocardial dysfunction. The amount of Ca2+ 
released from the SR during CICR into the cytoplasm, and thus the amount of Ca2+ available 
for cross bridge formation between myofilaments, directly determines the strength of force 
generated by the myocardium. During relaxation the rate of cystolic Ca2+ via the SERCA2a 
pump back into the SR determines the pattern of relaxation, by promoting the dissociation of 
Ca2+ from troponin C (Bers, 2008). Ca2+ release and re-uptake can be measured through 
intracellular Ca2+ transients in isolated cardiac myocytes. The amplitude of the Ca2+ transient 
is generated mainly by SR Ca2+ release and directly determines the extent of contractile force 
in cardiomyocytes. Therefore an increase in the transient would reflect an increased loading 
of Ca2+ within the SR, whereas a decreased transient reflects a decreased load of Ca2+ within 
the SR, alongside deficiencies in the ability to accumulate and release Ca2+ from the SR 
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(Belke & Dilmann, 2004). A study by Reuter et al. (2008) investigated Ca2+ mishandling in 
muscle strips from T2D patients undergoing aortocoronary bypass surgery and classified the 
muscle as having no signs of cardiac failure as measured by echocardiography, and they 
reported a significantly slower intracellular Ca2+ release in the T2D patients compared to the 
nDM patients. Therefore the findings from Reuter et al. (2008) from patients at a similar stage 
in the progression of DHD as the DM rats used in my study indicates that intracellular Ca2+ 
may be playing a role in the reduced contractility observed in the isolated cardiac muscle 
from DM rats, and thus prompts the need to further investigate the effects of CaMKIIδ 
inhibition at the cellular level.   
 
 4.1.2 Ca2+ sparks and waves in diabetes 
 
While intracellular Ca2+ transients are a measure of triggered Ca2+ release and re-uptake, Ca2+ 
release can also occur spontaneously between transients, as is the case with Ca2+ sparks. Ca2+ 
sparks are events that occur due to the activity of individual RyR2 clusters generating 
localised Ca2+ release events (Bers, 2000; Bers, 2002; Chen-Izu et al., 2006). The frequency, 
amplitude and time course of Ca2+ sparks contribute to the amount of spontaneous Ca2+ leak 
from the SR. An increase in Ca2+ sparks is indicative of SR Ca2+ leak, which is often 
attributed to hyperphosphorylation of the RyR2 (Williams et al., 2011; Hain et al., 1995; 
Wehrens et al., 2004, Guo et al., 2006; Kohlhaas et al., 2006), whereas a decrease in Ca2+ 
sparks could indicate reduced SR Ca2+ load and thus decreased intracellular Ca2+ 
concentration for contraction (Bers et al., 2003). Similar to the disparity in findings for 
intracellular Ca2+ transients, studies investigating defective Ca2+ handling in the diabetic heart 
have shown both reduced (Lacombe et al., 2007; Zhao et al., 2014) and increased Ca2+ spark 
frequency in the diabetic heart (Yaras et al., 2005).  
 
Another form of spontaneous Ca2+ release is termed Ca2+ waves. Ca2+ waves occur when a 
spontaneous increase in Ca2+ concentration occurs within the cell that reaches a critical mass 
and leads to propagation of Ca2+ release throughout the cytosol in a wave-like pattern (Cheng 
et al, 1996). Attention has been paid to these waves, as evidence suggests a role for them in 
the generation of abnormal electrical activity of the heart (Capogrossi et al., 1987; Berlin et 
al., 1989; Venetucci et al., 2008). There is currently limited published data of the role of Ca2+ 
waves in the T2D heart. A recent study by Sommesse et al. (2016) showed in a pre-diabetes 
fructose based rat model that there was an increase in spontaneous contractions and waves in 
isolated cardiomyocytes, and that CaMKIIδ inhibition reduced the occurrence of waves.  
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Given the evidence that suggests there are alterations to Ca2+ homeostasis in the T2D heart 
and the prominent role CaMKIIδ plays in regulation of Ca2+ during ECC, CaMKIIδ is an ideal 
target to investigate whether altered Ca2+ handling underlies impaired contractility in the 
diabetic heart prior to systolic dysfunction. 
 
4.1.3 CaMKIIδ and defective Ca2+ handling 
 
To date most of the studies investigating the effects of CaMKIIδ inhibition on defective Ca2+ 
handling have been conducted in either HF models or genetically modified mice that over 
express CaMKIIδ. Maier et al. (2003) reported that mice overexpressing CaMKIIδ had a 50% 
decrease in mean twitch Ca2+ transient amplitude, and also a reduced SR Ca2+ content. Guo et 
al. (2006) reported that permeabilized ventricular myocytes with endogenous and exogenous 
activation of CaMKIIδ had an increased Ca2+ spark frequency and duration, which the authors 
attributed to an increase in RyR phosphorylation by CaMKIIδ. Oort et al. (2010) used a 
knock-in mouse model in which aspartic acid replaced serine at RyR2 S2814 in order to 
mimic CaMKIIδ phosphorylation of RyR2, and they observed reduced SR Ca2+ load, 
increased Ca2+ spark frequency, and increased ventricular arrhythmias. Fischer et al. (2013) 
showed an increase in SR Ca2+ leak in isolated cardiomyocytes from end-stage HF human 
patients, which they also attributed to CaMKIIδ hyperphosphorylation of RyR2. More 
recently Sommese et al. (2016) reported an increase in RyR2 phosphorylation by oxidized 
CaMKIIδ in rats receiving a fructose rich diet. Myocytes from the fructose fed rats had 
increased Ca2+ release events, which was reduced by CaMKIIδ inhibition with KN93 and 
AIP. Taken together, these studies indicate that CaMKIIδ does play a role in pathological 
handling of Ca2+ in the heart, though importantly none of them address whether this occurs in 
the T2D heart.  
 
4.1.4 Aims and hypothesis 
 
The overall aim of this chapter was to investigate whether Ca2+ handling properties are altered 
in myocytes isolated from the T2D heart and to determine the effects of CaMKIIδ inhibition 
in mitigating any potential differences. I hypothesized that the T2D heart would have reduced 
SR Ca2+ release and re-uptake and that CaMKIIδ inhibition would reverse this. I also 
hypothesized that the T2D heart will have increased phosphorylation at the CaMKIIδ sites of 
those proteins involved in SR Ca2+ release (RyR2) and re-uptake (PLB). To examine this 
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question, intracellular Ca2+ was measured during and between transients in myocytes isolated 
from rats (18-19 weeks of age) with or without diabetes. These measurements were then 
repeated in the presence of the CaMKIIδ inhibitors KN93 and AIP. Additionally, post-rest 
behaviour and spontaneous contractions were measured in isolated RV cardiac muscle from 
DM and nDM rats, as these measures reflect Ca2+ handling at the tissue level. The 
downstream effects of CaMKIIδ activation on cardiac Ca2+ handling proteins were 
investigated using Western blots for RyR2 and PLB. Finally, experiments were also 
conducted in the presence of isoproterenol to investigate the effects of CaMKIIδ on Ca2+ 




Animal characteristics for the post-rest behaviour experiments and western blot data are 
shown in Chapter 3, section 3.2.1, Table 3.1. Animal characteristics for the cardiomyocyte 
Ca2+ imaging are shown in the appendix 3, Table 4.i. There were no significant differences 
found in body weight, blood glucose or heart weight between the nDM or DM rats from the 
Otago animal facility compared to those used at UC Davis.  
 
4.2.1 CaMKIIδ inhibition on Ca2+ release and re-uptake 
 
4.2.1.1 No effect of CaMKIIδ inhibition on post-rest behaviour  
 
Post-rest behaviour was measured at increasing rest periods of 10s, 30s and 120s between 
basal beats at a 2 Hz stimulation frequency. A ratio of the first beat after the rest period in 
relation to the last beat before the rest period is considered to reflect the relation between SR 
Ca2+ uptake and loss during the rest interval (Allen et al., 1976; Bers, 1985). Figure 4.1 A-C 
shows representative traces of the staircase of contraction of the first 20 twitches after the 10s, 
30s and 120s rest intervals in the nDM and DM in the presence of KN92 and KN93, whilst 
Figure 4.1 D shows the post-rest behaviour ratio. There was a significant difference between 
the nDM and DM trabeculae (P=0.01), with the DM muscle in the KN92 conditions 
exhibiting a higher post-rest ratio compared to the nDM KN92. This finding suggests the DM 
trabeculae have a greater ability for SR Ca2+ store during a period of rest. CaMKIIδ inhibition 
with KN93 had no significant effect on the post-rest behaviour ratio in either the nDM or DM 
trabeculae (P=0.65). It can however be seen in Figure 4.1 D that the post rest behaviour ratio 
is higher in both the nDM and DM after CaMKIIδ inhibition.  
 
Representative traces of the staircase of contraction in the nDM and DM trabeculae in the 
presence of CTRL and AIP are shown in figure 4.2 A-C and the post-rest behaviour ratio 
shown in Figure 4.2 D. Again, I observed a significant difference between the nDM and DM 
trabeculae (P=0.01), with the DM cardiac muscles exhibiting a higher post rest ratio than the 
nDM cardiac muscle in the CTRL conditions. CaMKIIδ inhibition with AIP significantly 






























Figure 4.1 Post-rest behaviour in isolated right ventricle trabeculae from non-diabetic (nDM) and type 2 diabetic (DM) rats in the presence of 
KN92 and KN93. A-C, Staircase of contraction of the first 20 beats after re-stimulation at 10s, 30s and 120s. D, Post-rest ratio. Data are means + SEM. 
nDM KN92, solid black line, n=10 muscles (9 rats); nDM KN93, solid green line, n=4 muscles (4 rats); DM KN92, dotted black line, n=9 muscles (8 rats); 
DM KN93, solid red line, n=4 muscles (4 rats). For all parameters two-way between groups ANOVA: * =P<0.05 condition effect (nDM vs DM). 
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Figure 4.2 Post-rest behaviour in isolated right ventricle trabeculae from non-diabetic (nDM) and type 2 diabetic (DM) rats in the presence of 
CTRL and AIP. A-C, Staircase of contraction of the first 20 beats after re-stimulation at 10s, 30s and 120s. D, Post-rest ratio. Data are means + SEM. 
nDM CTRL, solid black line, n=12 muscles (5 rats); nDM AIP, solid green line, 4 muscles (3 rats); DM CTRL dotted black line, n=11 muscles (7 rats); DM 
AIP, blue solid line, n=10 muscles (8 rats). For all parameters two-way between groups ANOVA: * =P<0.05 condition effect (nDM vs DM), # =P<0.05 
treatment effect (DM CTRL vs DM AIP). 
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4.2.1.2 Increased % of spontaneous contractions in type 2 diabetic isolated right 
ventricle trabeculae 
 
Whilst carrying out the post-rest behaviour measurements, I observed that some muscles were 
exhibiting spontaneous contractions. These muscle twitches occur with no stimulation and are 
an indicator of arrhythmic activity. During each post rest behaviour rest interval, quantitative 
observations were made of the number of trabeculae exhibiting these spontaneous 
contractions and calculated as a percentage. I observed that in the KN92 and KN93 conditions 
no nDM cardiac muscles exhibited any spontaneous contractions, whereas 33% of DM 
muscles exhibited spontaneous contractions in the KN92 conditions and 37.5% in KN93 
conditions (see Figure 4.3 for % data and Figures 4.4 A-C & 4.5 A-C for representative traces 
of spontaneous contractions during each rest period interval in the DM KN92 and DM KN93 
conditions). Statistical analysis with chi-square revealed no significant difference in this % of 
spontaneous contractions in the DM trabeculae between the KN92 and KN93 conditions 
(P=0.85). In the CTRL and AIP it was observed that the DM cardiac muscles exhibited 
15.38% spontaneous contractions, compared to 0% of any DM muscles exhibiting any 
spontaneous contractions in the AIP conditions (see Figure 4.6 for % data and Figure 4.7 A-C 
for representative traces of spontaneous contractions in DM trabeculae in AIP conditions). 
Therefore these results suggest that inhibition of CaMKIIδ with AIP may be more beneficial 
in preventing pro-arrhythmic behaviour in the T2D trabeculae. (It must be noted that due to 
the DM exhibiting no spontaneous contractions during the AIP conditions and thus the value 














Figure 4.3 Spontaneous contractions observed in type 2 diabetic (DM) isolated right 
ventricle trabeculae in the presence of KN92 and KN93. Percentage of DM trabeculae 
exhibiting spontaneous contractions in KN92 conditions (black bar), and KN93 conditions 
(red bar). For analysis of % trabeculae exhibiting spontaneous contractions a chi-squared test 






































































Figure 4.4 Representative traces of spontaneous contractions during post-rest 
measurements in type 2 diabetic (DM) isolated right ventricle trabeculae in KN92 


























Figure 4.5 Representative traces of spontaneous contractions during post-rest 
measurements in type 2 diabetic (DM) isolated right ventricle trabeculae in KN93 











































Figure 4.6 Spontaneous contractions observed in type 2 diabetic (DM) isolated right 
ventricle trabeculae in the presence of CTRL and AIP. Percentage of DM trabeculae 







































Figure 4.7 Representative traces of spontaneous contractions during post-rest 
measurements in type 2 diabetic isolated right ventricle trabeculae muscle in CTRL 





























4.2.1.3 No effect of type 2 diabetes or CaMKIIδ inhibition (KN93 & AIP) on Ca2+ 
transient amplitude at 1 Hz 
 
 
Having observed at the isolated cardiac muscle level a higher post-rest behaviour in the DM 
trabeculae in both the KN92, as well as in CTRL conditions, alongside an increased 
occurrence of spontaneous contractions in the DM cardiac muscle, the next step was to 
investigate the intracellular Ca2+ handling at the cellular level in isolated cardiomyocytes. 
 
Ca2+ handling in the DM heart was investigated by measuring transients using a Ca2+-
fluorescent dye (Fluo-4AM) in isolated ventricular myocytes. Isolation of rat ventricular 
myocytes was performed by enzymatic digestion as described in Methods (2.5). Cells were 
imaged using a confocal microscope (Bio Rad Radiance 2100, x 40 oil immersion objective) 
and the fluorescent dye was excited with an Argon laser (488 nm) and emission collected at 
wavelengths > 505 nm as described in Methods (2.6). Myocytes were stimulated at 1 Hz; cells 
selected for data analysis had clear striation and rod-shaped form.  
 
Representative confocal line scan images and normalized Ca2+ transient traces from nDM and 
DM cardiomyocytes in KN92 and KN93 conditions are shown in Figure 4.8 A-D, with 
averaged data shown in Figure 4.9 A-C. There was no significant differences in the mean 
Ca2+ transient amplitude between the nDM and DM cells across both KN92 and KN93 
conditions (P=0.32), or any effect of CaMKIIδ inhibition in either the nDM or DM cells 
(P=0.53) (Figure 4.9 A). In contrast a significant difference was observed in time to peak 
(TTP) between the nDM and DM (P=0.02), with the DM cardiomyocytes exhibiting a slower 
TTP time compared to the nDM in the KN92 conditions (89.01 ms vs 101.79 ms). CaMKIIδ 
inhibition significantly reduced the TTP, in the DM cardiomyocytes down to 85.06 ms from 
101.79 ms (P<0.01, Figure 4.9 B). These results suggest that although there was no difference 
in the transient amplitude between the nDM and DM cells, the DM had a slower TTP which 
CaMKIIδ inhibition was able to reverse. These results demonstrate that Ca2+ transient kinetics 
can be altered in the DM cells. In contrast no significant differences in Tau (time constant of 
Ca2+ decay) between the nDM and DM cells across both KN92 and KN93 conditions 
(P=0.70), or any effect of CaMKIIδ inhibition in either the nDM or DM cells (P=0.26) was 















































Figure 4.8 Representative intracellular Ca2+ transients in non-diabetic (nDM) and type 2 
diabetic (DM) ventricular cardiomyocytes in the presence of KN92 and KN93. A, 
Representative confocal line scan images from nDM cardiomyocytes in the presence of KN92 
(left) and KN93 (right). B, Normalized Ca2+ transient in nDM cardiomyocytes in the presence 
of KN92 (black line) and KN93 (red line). C, Representative confocal line scan images from 
DM cardiomyocytes in the presence of KN92 (left) and KN93 (right). D, Normalized Ca2+ 



























































Figure 4.9 Intracellular Ca2+ transient data in the non-diabetic (nDM) and type 2 
diabetic (DM) ventricular cardiomyocytes in the presence of KN92 and KN93. A, Mean 
Ca2+ transient amplitude (ΔF/F0, where F0 is diastolic fluorescence). B, Mean time to peak 
(ms). C, Mean time constant of Ca2+ decay (Tau). Data are means + SEM. nDM KN92, black 
bar, n= 17 cells (6 rats); nDM KN93, red bar, n=15 cells (6 rats), DM KN92, black bar, n=14 cells 
(6 rats), DM KN93, red bar, n=15 cells, 6 rats). For all parameters two-way between groups 




















































These experiments were repeated with the CaMKIIδ inhibitor AIP substituting for KN-93. 
Representative confocal line scan images and normalized Ca2+ transient traces from nDM and 
DM cardiomyocytes in CTRL and AIP conditions are shown in Figure 4.10 A-D, with 
averaged data shown in Figure 4.11 A-C. There was no significant difference in the mean 
Ca2+ transient amplitude between the nDM and DM cells across both CTRL and AIP 
conditions (P=0.33), or any effect of CaMKIIδ inhibition (P=0.68) (Figure 4.11 A). There was 
also no significant difference in the TTP and Tau between the nDM and DM cells across both 
CTRL and AIP conditions (P=0.44 & P=0.16 respectively), or any effect of CaMKIIδ 






















































Figure 4.10 Representative intracellular Ca2+ transients in non-diabetic (nDM) and type 
2 diabetic (DM) ventricular cardiomyocytes in the presence of CTRL and AIP. A, 
Representative confocal line scan images from nDM cardiomyocytes in the presence of CTRL 
(left) and AIP (right). B, Normalized Ca2+ transient in nDM cardiomyocytes in the presence 
of CTRL (black line) and AIP (blue line). C, Representative confocal line scan images from 
DM cardiomyocytes in the presence of CTRL (left) and AIP (right). D, Normalized Ca2+ 
















































































Figure 4.11 Intracellular Ca2+ transient data in non-diabetic (nDM) and type 2 diabetic 
(DM) ventricular cardiomyocytes in the presence of CTRL and AIP. A, Mean Ca2+ 
transient amplitude (ΔF/F0, where F0 is diastolic fluorescence). B, Mean time to peak (ms). 
C, Mean time constant of Ca2+ decay (Tau). Data are means + SEM. nDM CTRL, black bar, 
n=17 cells (6 rats); nDM AIP, blue bar, n=13 cells (6 rats), DM CTRL, black bar, n=16 cells (6 
rats), DM AIP, blue bar, n=15 cells, 6 rats). For all parameters two-way between groups ANOVA 

















































4.2.1.4 No effect of type 2 diabetes or CaMKIIδ inhibition (KN93 & AIP) on 
sarcoplasmic reticulum Ca2+ load 
 
The results from the previous section indicate that the reduced contractility observed in the 
DM trabeculae (Chapter 3.0) cannot be attributed to reduced Ca2+ release during transients. I 
next tested the hypothesis that cardiomyocytes from DM rats have a reduction in Ca2+ store 
size, which would reduce the ability of the DM cell to produce rapid or forceful contractions. 
To measure SR Ca2+ content caffeine was applied to the cell, which causes a sudden release 
of Ca2+ from the SR and a rapid increase in intracellular Ca2+ concentration (see Figure 4.12 
A & B for representative traces). There was no significant difference in SR Ca2+ load between 
the nDM and DM cardiomyocytes in any of the conditions (P=0.43) or any effect of CaMKIIδ 
inhibition in either the nDM or DM cells (P=0.70) (Figure 4.12 C). I made similar 
observations in the CTRL and AIP conditions where there was no difference in the SR Ca2+ 
load between the nDM and DM cells (P=0.67) and no effect of CaMKIIδ inhibition with AIP 













































Figure 4.12 Sarcoplasmic reticulum (SR) content in non-diabetic (nDM) and type 2 
diabetic (DM) ventricular cardiomyocytes in the presence of KN92 and KN93. A, 
Representative normalized SR Ca2+ load in nDM KN92 (black line) and nDM KN93 (red 
line). B, Representative normalized SR Ca2+ load in DM KN92 (black line) and DM KN93 
(red line). C, Mean SR content assessed by 10 mmol/L caffeine-induced fluorescence change 
(ΔF/F0). Data are means + SEM. nDM KN92, black bar, n=12 cells (6 rats); nDM KN93, red bar, 
n=13 cells (6 rats); DM KN92, black bar, n=13 cells (6 rats), DM KN93, red bar, n=14 cells (6 
rats). For all parameters two-way between groups ANOVA, P=<0.05 was used. 
 


























































































Figure 4.13 Sarcoplasmic reticulum (SR) content in non-diabetic (nDM) and type 2 
diabetic (DM) ventricular cardiomyocytes in the presence of CTRL and AIP. A, 
Representative normalized sarcoplasmic reticulum Ca2+ load in nDM CTRL (black line) and 
nDM AIP (blue line). B, Representative normalized SR Ca2+ load in DM CTRL (black line) 
and DM AIP (blue line). C, Mean SR content assessed by 10 mmol/L caffeine-induced 
fluorescence change (ΔF/F0). Data are means + SEM. nDM CTRL, black bar, n=17 cells (6 
rats); nDM KN93, blue bar, n=14 cells (6 rats); DM CTRL, black bar, n=15 cells (6 rats), DM 
AIP, blue bar, n=11 cells (6 rats). For all parameters two-way between groups ANOVA, P=<0.05 
was used. 
















































4.2.1.5 RyR2 and PLB total levels and phosphorylation at CaMKIIδ target sites are not 
different in type 2 diabetic right ventricular tissue 
 
To further interrogate the hypothesis that disturbed Ca2+ handling is reducing contractility in 
the T2D heart, as well as the potential effects CaMKIIδ may be having on other Ca2+ 
regulatory proteins, Western blots were carried out to measure total cellular RyR2 protein and 
RyR2 phosphorylated at S2814 which is the CaMKIIδ target site, which underpins Ca2+ 
release from the SR. Total cellular PLB protein and PLB phosphorylated on its CaMKIIδ 
phosphorylation site (T17), as this is heavily involved in Ca2+ re-uptake back into the SR were 
also quantified by western blot. Tissue homogenates prepared from the RV of nDM and DM 
rats were denatured in sample buffer and subjected to SDS-polyacrylamide gel 
electrophoresis. No significant differences were observed between the nDM and DM groups 
in the levels of total (P= 0.99, Figure 4.14 B) or S2814 phosphorylated (P=0.91, Figure 4.14 
C) RyR2 in RV tissue. In addition no significant difference was found between the nDM and 
the DM RV tissue in PLB total protein (P=0.99, figure 4.14 F) or T17 phosphorylated PLB 



























































































































Figure 4.14 Western blot for ryanodine receptor (RyR2) and phospholamban (PLB) and 
their respective CaMKIIδ phosphorylation sites. A, Representative immunoblot of RyR2, 
RyR2 S2814 and β-actin as a loading control in nDM and DM right ventricle (RV) tissue. 
Blots were initially probed for RyR2 S2814 followed by stripping with low pH buffer and 
probed for RyR2. B, Quantification of total RyR2 levels in nDM (n=6) and DM (n=4) RV 
tissue. C, Quantification of RyR2 S2814 levels in nDM (n=6) and DM (n=4) RV tissue. D, 
Representative immunoblot of PLB and GAPDH as a loading control in nDM and DM RV 
tissue. E, Representative immunoblot of PLB T17 and GAPDH as a loading control in nDM 
and DM RV tissue. F, Quantification of total PLB levels in nDM (n=6) and DM (n=5) RV 
tissue. G, Quantification of PLB T17 levels in nDM (n=6) and DM (n=4) RV tissue. Data are 
means + SEM. nDM, black bars, DM white bars. Unpaired t-test for RyR2 S2814, total PLB and 
PLB T17, Mann-Whitney test for total RyR2, P=<0.05. 
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4.2.2 CaMKIIδ inhibition on pro-arrhythmic behaviour 
 
Having observed that CaMKIIδ inhibition may not be mediating its beneficial effects on 
contractility through Ca2+ release and re-uptake, I next investigated the effects of CaMKIIδ 
inhibition on pro-arrhythmic behaviour. I hypothesized that contractility is lower in the DM 
trabeculae due to spontaneous Ca2+ leak, which would disrupt optimal Ca2+ release timing and 
initiate arrhythmias.  
 
4.2.2.1 Decreased Ca2+ spark frequency in type 2 diabetic cardiomyocytes in KN92 and 
KN93 conditions  
 
Figure 4.15 A-D shows representative line scan images and plotted profiles of Ca2+ sparks 
from nDM and DM cardiomyocytes. Ca2+ spark frequency (CaSpF) was significantly reduced 
in the DM cells in the KN92 conditions compared to the nDM cells in KN92 conditions 
(P<0.001, Figure 4.16 A). There was no effect of CaMKIIδ inhibition as the difference 
between the nDM and DM cells persisted (P<0.001), and there was no significant difference 
between DM KN92 and DM KN93 cells (P=0.99). In contrast to the CaSpF findings there 
was no significant differences found between the nDM and DM cells in the KN92 conditions 
on Ca2+ spark amplitude (P=0.80), full width at half max (FWHM) (P=0.20), and full duration 
at half max (FDHM) (P= 0.77) (Figure 4.16 B-D). There was also no effect of CaMKIIδ 
inhibition with KN93 on nDM and DM on Ca2+ spark amplitude (P=0.91), FWHM (P=0.76) 





Figure 4.15 Original line scans and plotted profiles in non-diabetic (nDM) and diabetic 
(DM) ventricular cardiomyocytes in the presence of KN92 and KN93. A, nDM KN92. B, 
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Figure 4.16 Spontaneous sarcoplasmic reticulum (SR) Ca2+ release events (Ca2+ sparks) in isolated ventricular cardiomyocytes from non-
diabetic (nDM) and type 2 diabetic (DM) rats in the presence of KN92 and KN93. A, Mean SR Ca2+ spark frequency (CaSpF), B, Mean Ca2+ 
spark amplitude. C, Mean full width at half max. D, Mean full duration at half max in nDM KN92, nDM KN93, DM KN92, DM KN93. Data are means 
+ SEM. nDM KN92, black bar, n=16 cells (6 rats); nDM KN93, red bar, n=13 cells (6 rats); DM KN92, black bar, n=15 cells (6 rats); DM KN93, red bar, 
n=14 cells (6 rats). Data did not meet the assumptions of a parametric test (normality and homogeneity of variance) therefore an independent t-test was used 
















































































In contrast to the findings in the KN92 and KN93 conditions, there was no difference in 
CaSpF between the nDM and DM cells in the AIP and CTRL conditions (P=0.86) and no 
effect of AIP in the nDM (P=0.82) or DM cells (P=0.50) (see Figure 4.17 A-D for 
representative images and Figure 4.18 A for averaged data). There was also no difference 
between the nDM and DM cells in the CTRL conditions on Ca2+ spark amplitude (P= 0.52), 
FWHM (P=0.81), or FWHD (P=0.21) (Figure 4.18 B-D). Inhibition of CaMKIIδ with AIP 
also had no effect on nDM and DM cells Ca2+ spark amplitude (P=0.12 & P=0.07 
respectively), FWHM (P=0.88 & P=0.25 respectively), or FDHM (P=0.46 & P=0.11 
respectively) (Figure 4.18 B-D). However AIP did significantly increase the FDHM in the 
DM cells compared to the nDM cells in the CTRL conditions (P=0.04), a potential indication 
that CaMKIIδ inhibition with AIP was prolonging the time between the opening of the first 




















Figure 4.17 Original line scans and plotted profiles in non-diabetic (nDM) and type 2 
diabetic (DM) ventricular cardiomyocytes in the presence of CTRL and AIP. A, nDM 
























































Figure 4.18 Spontaneous sarcoplasmic reticulum (SR) Ca2+ release events (Ca2+ sparks) in isolated ventricular cardiomyocytes from non-
diabetic (nDM) and type 2 diabetic (DM) rats in the presence of CTRL and AIP. A, Mean SR Ca2+ spark frequency (CaSpF), B, Mean Ca2+ spark 
amplitude. C, Mean full width at half max. D, Mean full duration at half max in nDM KN92, nDM KN93, DM KN92, DM KN93. Data are means + 
SEM. nDM CTRL, black bar, n=15 cells (6 rats); nDM AIP, blue bar, n=12 cells (6 rats); DM CTRL, black bar, n=15 cells (6 rats); DM AIP, blue bar, n=13 
cells (6 rats). Data did not meet the assumptions of a parametric test (normality and homogeneity of variance) therefore an independent t-test was used with 
















































































4.2.2.2 Ca2+ wave propensity similar between non-diabetic (nDM) and type 2 diabetic 
(DM) cardiomyocytes, with no effect of CaMKIIδ inhibition (KN93 & AIP) 
 
Ca2+ waves indicate a spontaneous increase in intracellular Ca2+ and have been associated 
with pro-arrhythmic behaviour (Capogrossi et al., 1987). Figure 4.19 A-D shows a 
representative line scan demonstrating waves that occurred in nDM and DM cells. Figure 4.19 
E shows the % of cells that exhibited waves. Chi square analysis revealed no significant 
difference between the nDM and DM cells in the KN92 conditions (P=0.16); however, there 
was a higher % of waves in the DM cells compared to the nDM cells in the KN92 conditions 
(47% vs 23.5%, Figure 4.19). CaMKIIδ inhibition with KN93 had no significant effect on 
reducing the % of waves in the DM cells (P=0.85), with 50% of DM still exhibiting waves. 
However in the nDM cells CaMKIIδ inhibition significantly increased the % of waves 
(P=0.04), with 61.5% of cells exhibiting waves (P=0.04, Figure 4.19 E).  
 
For those cells that exhibit waves, it is also critical to consider the number of waves, an 
indication of the severity of Ca2+ mishandling and arrhythmogenic behaviour for each cell. 
When the total number of waves divided by the number of cells exhibiting waves was 
calculated, I observed a difference between the nDM and DM cells, with the DM exhibiting a 
significantly higher ratio of waves compared to the nDM cells in the KN92 conditions 
P=0.02, Figure 4.19 F). CaMKIIδ inhibition had no statistically significant effect on reducing 
the ratio of waves (P=0.65), however it can be seen in Figure 4.19 F, the ratio of waves/cells 
did decrease from 1.73 to 1.0. Therefore, CaMKIIδ inhibition with KN93 had no effect in the 
DM cells on the percentage of cells, but it did show some effect on reducing the number of 
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Figure 4.19 Wave occurrence in non-diabetic (nDM) and type 2 diabetic (DM) isolated 
cardiomyocytes in the presence of KN92 and KN93. Representative line scan of waves 
occurring during Ca2+ spark measurements in A, nDM cells in KN92 conditions; B, nDM 
cells in KN93 conditions; C, DM cells in KN92 conditions; D, DM cells in KN93 conditions; 
E, Quantitative measurement of % of cells exhibiting waves in nDM and DM cells in the 
presence of KN92 (nDM, n=6 hearts, 16 cells; DM, n=6 hearts, 14 cells) and KN93 (nDM, 
n=6 hearts, 13 cells; DM, n=6 hearts, 15 cells). F, Quantitative measurement of the total 
number of waves per number of cells exhibiting waves in nDM and DM cells in the presence 
of KN92 and KN93. nDM KN92, black bar; nDM KN93, red bar; DM KN92, black bar; DM 
KN93 red bar. For analysis of % of cells exhibiting waves, a Pearson’s chi-squared test with 
P=<0.05 was performed. For analysis of total number of waves/per number of cells exhibiting 
waves a two-way between groups ANOVA, * P=<0.05 for condition effect (nDM vs DM), # 
P=<0.05 for treatment effect (nDM KN92 vs nDM KN93).  
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Similar findings for the CTRL and AIP conditions were found during the observations of 
waves (see Figure 4.20 A-D for representative line scans of waves that occurred in each 
condition). There was no statistical significant difference observed between the nDM and DM 
cells in the CTRL conditions with 46.6% of nDM cells exhibiting waves compared to 40% in 
the DM cells (P=0.79, Figure 4.20 E). CaMKIIδ inhibition with AIP can be seen to increase 
the % of waves in the DM cells to 69.2% but this did not reach statistical significance 
(P=0.21). CaMKIIδ inhibition in the nDM cells also had no significant effect of % of waves 
(P=0.79). The ratio of total number of waves in relation to the number of cells exhibiting 
waves showed that the DM cells exhibited a significantly higher ratio of waves compared to 
the nDM cells in the CTRL conditions (P=0.04, Figure 4.20 F). CaMKIIδ inhibition with AIP 
had no significant effect of reducing this ratio of waves in the DM cells (P=0.65), and it can 










































































































Figure 4.20 Wave occurrence in non-diabetic (nDM) and type 2 diabetic (DM) isolated 
cardiomyocytes in the presence of CTRL and AIP. Representative line scan of waves 
occurring during Ca2+ spark measurements in A, nDM cells in CTRL conditions; B, nDM 
cells in AIP conditions; C, DM cells in CTRL conditions; D, DM cells in AIP conditions; E 
Qualitative measurement of % of cells exhibiting waves in nDM and DM cells in the presence 
of CTRL (nDM, n=6 hearts, 17 cells; DM, n=6 hearts, 16 cells) and AIP (nDM, n=6 hearts, 
13 cells; DM, n=6 hearts, 15 cells). F, Qualitative measurement of the total number of waves 
per number of cells exhibiting waves in nDM and DM cells in the presence of CTRL and AIP. 
nDM CTRL, black bar; nDM AIP, blue bar; DM KN92, black bar; DM KN93 blue bar. For 
analysis of % of cells exhibiting waves a chi-squared with P=<0.05. For analysis of total 
number of waves/per number of cells exhibiting waves a two-way between groups ANOVA, 
* P=<0.05 for condition effect (nDM vs DM). 
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4.2.3 CaMKIIδ inhibition on Ca2+ release and re-uptake during β-Adrenergic challenge 
 
In Chapter 3.0 I reported that DM trabeculae had greater sensitivity to isoproterenol than the 
nDM trabeculae and that CaMKIIδ inhibition with both KN93 and AIP appeared to blunt this 
response. Therefore to further investigate this response I next measured Ca2+ handling in the 
DM cardiomyocytes in response to β-AR stimulation and the effect of CaMKIIδ inhibition. 
Cardiomyocytes were perfused with 100nmol/L isoproterenol and stimulated at 1 Hz. This 
concentration of isoproterenol was similar to that used during the trabeculae experiments 
described in chapter  (10-7 M), and thus would allow for the comparison of findings. This 
concentration is also similar to that used by others investigating CaMKIIδ effects in 
cardiomyocytes (Pereira et al., 2013).    
 
4.2.3.1 No effect of type 2 diabetes or CaMKIIδ inhibition (KN93 & AIP) on Ca2+ 
transient properties at 1 Hz during β-Adrenergic challenge 
!
During the KN92 incubation the nDM and DM cells exhibited a 168.48% and 168.30% 
increase respectively in their Ca2+ transient amplitude from baseline.  Representative confocal 
line scan images and normalized Ca2+ transient traces from nDM and DM cardiomyocytes in 
KN92 and KN93 conditions are shown in Figure 4.21 A-D, with averaged data shown in 
Figure 4.22 A-C. There was no significant difference in the mean Ca2+ transient amplitude 
between the nDM and DM cells across all conditions (P=0.92), and also no significant effect 
of CaMKIIδ inhibition in either the nDM or DM cells (P=0.91) (Figure 4.22 A). The nDM 
cells did however exhibit a higher % change in the mean Ca2+ transient amplitude from 
baseline in the KN93 conditions of 227.70% compared to 123.25% in the DM (Figure 4.21). 
In addition there was no significant difference between the nDM and DM cells across all 
conditions observed in the TTP (P=0.21) and Tau (P=0.14). There was also no effect of 
CaMKIIδ inhibition on TTP in either the nDM or DM cells (P=0.69), with similar findings 























Figure 4.21 Representative intracellular Ca2+ transients in non-diabetic (nDM) and type 
2 diabetic (DM) ventricular cardiomyocytes in the during β-Adrenergic stimulation 
presence of KN92 and KN93. A, Representative confocal line scan images from nDM  
cardiomyocytes in the presence of KN92 (left) and KN93 (right). B, Normalized Ca2+ 
transient in nDM cardiomyocytes in the presence of KN92 (black line) and KN93 (red line). 
C, Representative confocal line scan images from DM cardiomyocytes in the presence of 
KN92 (left) and KN93 (right). D, Normalized Ca2+ transient in DM cardiomyocytes in the 
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Figure 4.22 Intracellular Ca2+ transient data in non-diabetic (nDM) and type 2 diabetic 
(DM) ventricular cardiomyocytes during β-Adrenergic stimulation in the presence of 
KN92 and KN93. A, Mean Ca2+ transient amplitude (ΔF/F0, where F0 is diastolic 
fluorescence). B, Mean time to peak (ms). C, Mean time constant of calcium decay (Tau). 
Data are means + SEM. nDM KN92, black bar, n= 5 cells (3 rats); nDM KN93, red bar, n=5 cells 
(3 rats), DM KN92, black bar, n=7 cells (3 rats), DM KN93, red bar, n=3 cells, (3 rats). For all 





















































Similar findings to those after CaMKIIδ inhibition with KN93 were found after using AIP. 
Representative confocal line scan images and normalized Ca2+ transient traces from nDM and 
DM rats in CTRL and AIP conditions are shown in Figure 4.23 A-D, with averaged data 
shown in Figure 4.20 A-C. The nDM and DM in the CTRL conditions exhibited a 132.80% 
and 190.80% respectively increase in their mean Ca2+ transient from baseline. In the presence 
of AIP the nDM and DM exhibited a 142.34% and 140.10 % increase in their mean Ca2+ 
transient from baseline. There was no significant difference in the mean Ca2+ transient 
amplitude between the nDM and DM across all conditions (P=0.74), and also no significant 
effect of CaMKIIδ inhibition (AIP) in either the nDM or DM cells (P=0.92) (Figure 4.24 A). 
In addition there was no significant difference between the nDM and DM cells across all 
conditions observed in the TTP (P=0.38) and Tau (P=0.37). There was also no effect of 
CaMKIIδ inhibition on TTP in either the nDM or DM cells (P=0.54), with similar findings 

















































Figure 4.23 Representative intracellular C2+ transients in non-diabetic (nDM) and type 2 
diabetic (DM) ventricular cardiomyocytes during β-Adrenergic stimulation in the 
presence of CTRL and AIP. A, Representative confocal line scan images from nDM 
cardiomyocytes in the presence of CTRL (left) and AIP (right). B, Normalized Ca2+ transient 
in nDM cardiomyocytes in the presence of CTRL (black line) and AIP (blue line). C, 
Representative confocal line scan images from DM cardiomyocytes in the presence of CTRL 
(left) and AIP (right). D, Normalized Ca2+ transient in DM cardiomyocytes in the presence of 
CTRL (black line) and AIP (blue line). 
nDM
CTRL + ISO AIP +ISO
























































Figure 4.24 Intracellular Ca2+ transient data in non-diabetic (nDM) and type 2 diabetic 
(DM) ventricular cardiomyocytes during β-Adrenergic stimulation in the presence of 
CTRL and AIP. A, Mean Ca2+ transient amplitude (ΔF/F0, where F0 is diastolic 
fluorescence). B, Mean time to peak (ms). C, Mean time constant of calcium decay (Tau). 
Data are means + SEM. nDM CTRL, black bar, n=5 cells (3 rats); nDM AIP, blue bar, n= 4 cells 
(3 rats), DM CTRL, black bar, n=7 cells (3 rats), DM AIP, blue bar, n=6 cells (3 rats). For all 
parameters two-way between groups ANOVA, P=<0.05 was used. 


















































4.2.3.2 No effect of type 2 diabetes or CaMKIIδ inhibition (KN93 & AIP) on 
sarcoplasmic reticulum Ca2+ load during β-Adrenergic challenge 
 
I demonstrated in chapter 3.0 that the DM trabeculae had a greater % change in Fdev from 
baseline in the KN92 conditions compared to the nDM trabeculae (Figure 3.8 B) and there 
was no longer any difference in Fdev between the nDM and DM trabeculae (Figure 3.8 A). 
Therefore I hypothesized that during β-AR stimulation the DM cells would have a higher SR 
Ca2+ store in KN92 conditions compared to the nDM cells, and that CaMKIIδ inhibition 
would reduce this store. Conversely, I previously observed reduced force development in the 
DM trabeculae during β-AR stimulation in the AIP conditions (Figure 3.12 A). I therefore 
hypothesized that myocytes from DM cardiomyocytes would have a reduced SR Ca2+ load 
during β-AR stimulation.  
 
Figure 4.25 A & B shows representative normalized data in nDM and DM cells in the 
presence of KN92 and KN93 during β-AR stimulation. Figure 4.25 C shows the mean SR 
Ca2+ load where it can be seen there is a significant difference between the nDM and DM 
cells in the KN92 conditions, with the DM cells exhibiting a significantly higher SR Ca2+ load 
(P <0.01). CaMKIIδ inhibition significantly increased the SR Ca2+ load in the nDM cells (P 
<0.01) but had no effect in the DM cells (P= 0.33). In contrast to those findings in the KN92 
and KN93 conditions during the β-AR stimulation there was no significant differences found 
between the nDM and DM cells in the CTRL conditions (P= 0.55) or any effect found of 
CaMKIIδ inhibition with AIP (nDM CTRL vs nDM AIP, P= 0.73; DM CTRL vs DM AIP, 
























Figure 4.25 Sarcoplasmic reticulum (SR) content in non-diabetic (nDM) and type 2 
diabetic (DM) ventricular cardiomyocytes during β-Adrenergic stimulation in the 
presence of KN92 and KN93. A, Representative normalized sarcoplasmic reticulum Ca2+ 
load in nDM KN92 (black line) and nDM KN93 (red line). B, Representative normalized SR 
Ca2+ load in DM KN92 (black line) and DM KN93 (red line). C, Mean SR content assessed 
by 10 mmol/L caffeine-induced fluorescence change (ΔF/F0). Data are means + SEM. nDM 
KN92, black bar, n=7 cells (3 rats); nDM KN93, red bar, n=4 cells (3 rats); DM KN92, black bar, 
n=7 cells (3 rats), DM KN93, red bar, n=2 cells (2 rats). Data did not meet the assumptions of a 
parametric test (normality and homogeneity of variance) therefore an independent t-test was used 
with the P value multiplied by the number of t-tests (6) to account for family wise error, 
*=P<0.008. 
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Figure 4.26 Sarcoplasmic reticulum (SR) content in non-diabetic (nDM) and type 2 
diabetic (DM) ventricular cardiomyocytes during β-Adrenergic stimulation in the 
presence of CTRL and AIP. A, Representative normalized sarcoplasmic reticulum Ca2+ load 
in nDM CTRL (black line) and nDM AIP (blue line). B, Representative normalized SR Ca2+ 
load in DM CTRL (black line) and DM AIP (blue line). C, Mean SR content assessed by 10 
mmol/L caffeine-induced fluorescence change (ΔF/F0). Data are means + SEM. nDM CTRL, 
black bar, n=4 cells (3 rats); nDM KN93, blue bar, n=4 cells (3 rats); DM CTRL, black bar, n=5 
cells (3 rats), DM AIP, blue bar, n=5 cells (3 rats). Data did not meet the assumptions of a 
parametric test (normality and homogeneity of variance) therefore an independent t-test was used 
with the P value multiplied by the number of t-tests (6) to account for family wise error, * 
=P<0.008. 
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4.2.4 CaMKIIδ inhibition on pro-arrhythmic behaviour during β-Adrenergic challenge  
 
4.2.4.1 Ca2+ spark frequency and amplitude not affected by type 2 diabetes or CaMKIIδ 
inhibition during β-Adrenergic challenge 
 
Figure 4.27 A-D shows representative line scan images and plotted profiles of Ca2+ sparks 
from nDM and DM cardiomyocytes during β-AR stimulation in KN92 and KN93 conditions. 
Averaged data of the characteristics measured of the sparks is shown in Figure 4.28 A-D. 
There was no significant difference found between the nDM and DM cells in their CaSpF 
(P=0.55), FWHM (P=0.829) and FDHM (P=0.54). However there was a significant effect of 
diabetes found on Ca2+ spark amplitude as the DM cells exhibited significantly lower 
amplitude in both KN92 and KN93 conditions compared to the nDM cells (P=0.04). 
CaMKIIδ inhibition with KN93 had no effect in the nDM and DM cells on CaSpF (P=0.32), 






Figure 4.27 Original line scans and plotted profiles in non-diabetic (nDM) and type 2 
diabetic (DM) ventricular cardiomyocytes during β-Adrenergic stimulation in the 
presence of KN92 and KN93. A, nDM KN92 + ISO. B, nDM KN93 + ISO. C, DM KN92 + 






























































Figure 4.28 Spontaneous sarcoplasmic reticulum (SR) Ca2+ release events (Ca2+ sparks) in isolated ventricular cardiomyocytes from non-
diabetic (nDM) and type 2 diabetic (DM) rats during β-Adrenergic stimulation in the presence of KN92 and KN93 A, Mean SR Ca2+ spark 
frequency (CaSpF), B, Mean Ca2+ spark amplitude. C, Mean full width at half max. D, Mean full duration at half max in nDM KN92, nDM KN93, DM 
KN92, DM KN93. Data are means + SEM. nDM KN92, black bar, n=7 cells (3 rats); nDM KN93, red bar, n=5 cells (3 rats); DM KN92, black bar, n=9 cells 
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Figure 4.29 A-D shows representative line scan images and plotted profiles of Ca2+sparks 
from nDM and DM cardiomyocytes during β-AR stimulation in CTRL and AIP conditions. 
Averaged data of the characteristics measured of the sparks is shown in Figure 4.30 A-D. 
There was no significant difference found in the nDM and DM cells across all conditions in 
CaSpF (P=0.73) or any effect of CaMKIIδ inhibition with AIP (P=0.37). In contrast there was 
a significant difference found between the nDM and DM cells in Ca2+spark amplitude 
(P<0.01), with DM cells exhibiting significantly lower Ca2+ spark amplitude compared to the 
nDM cells. CaMKIIδ inhibition with AIP had no significant effect on either the nDM or DM 
cells Ca2+ spark amplitude (P=0.51). There was no significant difference found in the nDM 
and DM cells across all conditions in FWHM (P=0.15) or any effect of CaMKIIδ inhibition 
with AIP (P=0.46). There was also no significant difference in FDHM in the nDM and DM 
cells in CTRL conditions (P=0.03, data did not meet parametric t-test assumptions and thus an 
independent t-test was run with P set at 0.008 to account for family wise errors), and no 
significant effect of CaMKIIδ inhibition on either the nDM (nDM CTRL vs nDM AIP, 




























Figure 4.29 Original line scans and plotted profiles in non-diabetic (nDM) and type 2 
diabetic (DM) ventricular cardiomyocytes during β-Adrenergic stimulation in the 
presence of CTRL and AIP. A, nDM CTRL + ISO. B, nDM AIP + ISO. C, DM CTRL + 
ISO. D, DM AIP + ISO. FU= Fluorescent units. 
C

















nDM CTRL + ISO 









































Figure 4.30 Spontaneous sarcoplasmic reticulum (SR) Ca2+ release events (Ca2+ sparks) in isolated ventricular cardiomyocytes from non-
diabetic (nDM) and type 2 diabetic (DM) rats during β-Adrenergic stimulation in the presence of CTRL and AIP. A, Mean SR Ca2+ spark 
frequency (CaSpF), B, Mean Ca2+ spark amplitude. C, Mean full width at half max. D, Mean full duration at half max in nDM KN92, nDM KN93, DM 
KN92, DM KN93. Data are means + SEM. nDM CTRL, black bar, n=6 cells (3 rats); nDM AIP, blue bar, n=3 cells (3 rats); DM CTRL, black bar, n=9 cells 
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4.2.4.2 AIP reduces waves per cell but not number of cells with waves in the type 2 
diabetic cardiomyocytes during β-Adrenergic challenge 
 
A higher percentage of waves were observed during the β-AR stimulation compared to 
baseline (see Figure 4.31 A-D for representative traces of waves β-AR stimulation). The DM 
myocytes exhibited a higher percentage of waves compared to the nDM (77% in the DM vs 
57% in the nDM); however, this difference was not statistically significant (P=0.06, figure 
4.31 E). CaMKIIδ inhibition in both the nDM and DM cells had no statistically significant 
effect on the % of waves (P=0.41 in the nDM & P=0.16 in the DM). However it can be seen 
that there was a reduction in the % of waves in the DM cells after CaMKII inhibition with 
KN93 from 77% to 40%, whereas there was a increase from 57% to 80% in the nDM cells. 
When the total number of waves divided by the number of cells exhibiting waves was 
calculated, the cardiomyocytes treated with KN92 had 2.6 waves/cell in the nDM compared 
to 7.8 waves/cell in the DM cells (Figure 4.31 F), however these differences did not reach 
statistical significance (P=0.52). CaMKIIδ inhibition with KN93 reduced the ratio of down to 
1.6 waves/cells, however this also did not reach statistical significance (P=0.36). Similar to 
the findings without β-AR stimulation, KN93 had only a small effect of reducing the 
percentage of waves, but was beneficial in reducing the number of waves per cell.   
 
Similar findings were observed in the CTRL and AIP conditions. There was no significant 
difference found in the % of waves between the nDM and DM cells in the CTRL conditions 
(P=0.22, Figure 4.32 E). CaMKIIδ inhibition with AIP had no significant effects on the % of 
waves in both nDM (P=0.62) and the DM cells (P=0.80). Figure 4.32 F shows the number of 
waves per cells exhibiting waves where it can seen that there is no significant difference 
between the nDM and DM cells in the number of waves/cells in the CTRL conditions 
(P=0.06). AIP reduced the ratio of waves in both the nDM cells from 6.5 in the CTRL 
conditions to 1.3 in the AIP conditions, and in the DM cells this ratio was reduced down from 
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Figure 4.31 Wave occurrence in non-diabetic (nDM) and type 2 diabetic (DM) isolated 
cardiomyocytes during β-Adrenergic stimulation in the presence of KN92 and KN93. 
Representative line scan of Ca2+ spark measurements in A, nDM cells in KN92 conditions; B, 
nDM cells in KN93 conditions; C, DM cells in KN92 conditions; D, DM cells in KN93 
conditions. E Qualitative measurement of % of cells exhibiting waves in nDM and DM cells 
in the presence of KN92 and KN93. E, Quantitative measurement of % of cells exhibiting 
waves in; F Quantitative measurement of the total number of waves per number of cells 
exhibiting waves. nDM KN92, black bar; nDM KN93, red bar; DM KN92, black bar; DM 
KN93 red bar. For analysis of % of cells exhibiting waves a chi-squared with P=<0.05. For 
analysis of total number of waves/per number of cells exhibiting waves a two-way between 
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Figure 4.32 Wave occurrence in non-diabetic (nDM) and type 2 diabetic (DM) isolated 
cardiomyocytes during β-Adrenergic stimulation the presence of CTRL and AIP. 
Representative line scan of Ca2+ spark measurements in A, nDM cells in KN92 conditions; B, 
nDM cells in KN93 conditions; C, DM cells in KN92 conditions; D, DM cells in KN93 
conditions. E Quantitative measurement of % of cells exhibiting waves in nDM and DM cells 
in the presence of CTRL and AIP. F, Quantitative measurement of the total number of waves 
per number of cells exhibiting waves in nDM and DM cells in the presence of CTRL and AIP. 
nDM CTRL, black bar; nDM AIP, blue bar; DM KN92, black bar; DM KN93 blue bar. For 
analysis of % of cells exhibiting waves a Chi-squared with P=<0.05. For analysis of total 





4.3 Discussion  
 
Impaired Ca2+ handling has been hypothesized to underlie reduced contractility in the T2D 
heart. However, debate of this hypothesis continues as the body of literature shows 
contrasting findings. Therefore this study sought to investigate Ca2+ handling further during 
early stage DHD in particular with a focus on the effects of CaMKIIδ inhibition on Ca2+ 
homeostasis in the T2D heart.  
The main findings from the results in this chapter can be summarized as follows: 
- DM cardiomyocytes exhibit an increased post-rest behaviour and occurrence of 
spontaneous contractions, which is reduced after CaMKIIδ inhibition with AIP. 
- No alterations to Ca2+ homeostasis occur in DM cells during Ca2+ transients.  
- DM cells have reduced CaSpF in the presence of KN92 and KN93 but an increase in 
the ratio of waves per number of cells. 
- Intracellular Ca2+ transients during β-AR stimulation are similar for nDM and DM 
myocytes, but there is an increased SR Ca2+ load in the DM cardiomyocytes in the 
KN92 conditions, which is reduced after CaMKIIδ inhibition with KN93. 
- CaMKIIδ inhibition with both KN93 and AIP during β-AR stimulation has no 
significant effect on CaSpF in the nDM and DM cardiomyocytes or any effect on 
reducing the % of waves, but AIP reduces the ratio of waves per number of cells in 
both the nDM and DM cells.  
 
4.3.1 Increased post-rest behaviour could be explained by occurrence of spontaneous 
contractions 
 
Post-rest behaviour is a method of measuring the ability of the cardiac muscle to store and 
release Ca2+. It has been previously shown in a T1D animal model there is reduced post-rest 
behaviour in isolated papillary muscles (Yu & McNeill, 1991). Therefore I hypothesized that 
the DM muscle would have a reduced post-rest behaviour ratio compared to the nDM cardiac 
muscle due to hyperphosphorylation of RyR2 by CaMKIIδ, which would result in SR Ca2+ 
leak and thus a reduced ability of the DM muscle to store Ca2+. I also hypothesized that 
CaMKIIδ inhibition would improve the post-rest ratio by reducing SR Ca2+ leak from the SR, 
as it has previously been observed in isolated cardiac muscle from human patients with 
ischemic and dilated cardiomyopathy that CaMKIIδ inhibition with KN93 and AIP is able to 
increase in the post-behaviour ratio (Sossalla et al., 2010). However what was observed in this 
study was in fact the opposite. The DM cardiomyocytes in the KN92 and KN93 conditions 
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had a significantly increased post-rest behaviour ratio compared to the nDM cells (Figure 4.1 
D). Similar findings were shown in the CTRL and AIP conditions, where the DM cells again 
exhibited a significantly higher post-rest behaviour ratio. However, whereas KN93 increased 
the post-rest ratio, CaMKIIδ inhibition with AIP reduced it and brought it down to the same 
level as the nDM (Figure 4.2 D). These findings suggest: 1) CaMKIIδ hyperactivation in the 
DM cardiac muscle may be contributing to a larger Ca2+ store, and 2) AIP is more effective at 
reducing excessive accumulation of Ca2+ in the SR during each rest period. 
 
The increase in post-rest behaviour ratio in the DM cells above that observed in the nDM cells 
could be explained by the data from the spontaneous contractions. I found that DM trabeculae 
treated with KN92 or KN93 exhibited spontaneous contractions (Figure 4.3). Spontaneous 
contractions occur due to a spontaneous release of Ca2+ ions from the SR into the cytoplasm 
(Fabiato & Fabiato, 1972; Chiesi et al., 1981; Stern et al., 1983; Fabiato et al., 1985). 
Therefore as the post-rest behaviour was higher in the DM cardiac muscles in both KN92 and 
KN93 conditions compared to the nDM cardiac muscles (Figure 4.1 D), thus suggesting a 
higher Ca2+ storage. The increase in spontaneous contractions may be due to the Ca2+ storage 
becoming so high that it increases spontaneous leak. Conversely, treatment with AIP resulted 
in reduced post rest behaviour in the DM compared to CTRL conditions (Figure 4.2 D), while 
the DM with AIP muscles exhibited no spontaneous contractions during this rest period. 
These findings suggest AIP, which inhibits the autonomously active form of CaMKIIδ is able 
to reduce the large store of Ca2+ and thus prevent spontaneous contractions from occurring. 
This also provides further evidence for a role of autonomous activation in pro-arrhythmic 
behaviour in the T2D heart.    
 
4.3.2 Reduced contractility in the type 2 diabetic heart not explained by alterations to 
Ca2+ homeostasis during Ca2+ transients 
 
Having observed at the isolated cardiac muscle level differences between the nDM and DM 
trabeculae on their post rest behaviour and effects of CaMKIIδ inhibition in the isolated cardi 
muscle I next wanted to directly assess the role of Ca2+ handling in the T2D myocardium. To 
do this isolated cardiomyocytes from nDM and DM rats were used in order to further examine 
Ca2+ release and storage directly in the cell. There was no difference in mean Ca2+ transient 
amplitude, TTP, Tau and SR Ca2+ load in the nDM or DM cardiomyocytes, nor was there any 
effect of CaMKIIδ inhibition. These findings are in agreement with previous studies that have 
shown no change in intracellular Ca2+ transients (Yu et al., 1997; Singh et al., 2006) and SR 
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Ca2+ load (Howarth et al., 2002 & 2004) in diabetic cardiomyocytes. Importantly, those 
studies were all conducted in T1D, while our model more closely resembles T2D. Therefore 
the results from the intracellular Ca2+ transients in the present study indicate that reduced 
contractile function in the T2D heart may not be due to altered Ca2+ handling during 
transients. Further the results reported here indicate CaMKIIδ inhibition is not mediating its 
beneficial effects on contraction and relaxation reported in chapter 3 through Ca2+ release and 
re-uptake mechanisms during Ca2+ transients. Therefore the next step was to investigate if 
there was any effect of CaMKIIδ inhibition between transients.  
 
4.3.3 CaMKIIδ inhibition on pro-arrhythmic behaviour 
 
CaMKIIδ has previously been linked to promoting pro-arrhythmic behaviour as demonstrated 
by increased SR Ca2+ leak (Chelu et al., 2007). Therefore it was hypothesized in this study 
that the DM cells would have an increased CaSpF, which would be reduced after CaMKIIδ 
inhibition. However this was not observed, as in the KN92 and KN93 conditions the DM has 
a significantly reduced CaSpF in both the KN92 and KN93 conditions compared to the nDM 
(Figure 4.16). This is even more surprising given that there was no difference in SR Ca2+ load 
between the nDM and DM cells across all conditions (Figure 4.12 & Figure 4.13). Therefore 
one explanation for the reduced CaSpF could be significantly increased number of waves per 
cell that occurred in the DM cells KN92 and KN93 conditions compared to the nDM cells 
(Figure 4.19 F). This could suggest that, though the nDM and DM cells have the same SR 
Ca2+ load with less CaSpF but more waves, the DM cells have a lower threshold for Ca2+ 
release from the SR, and thus waves occur. This phenomenon of an SR Ca2+ threshold is often 
referred to as store-overload-induced Ca2+ release (SOICR), which means Ca2+ spill over 
during diastole and has been shown to result in Ca2+ waves (Jiang et al., 2004; Chen et al., 
2014). Studies investigating the involvement of CaMKIIδ in SOICR have shown that 
CaMKIIδ inhibition can prevent SOICR (Yang et al., 2007), however no one has yet 
investigated this mechanism in the T2D heart. However this hypothesis is questionable when 
the findings from the CTRL and AIP conditions are considered. There was no difference 
observed between the nDM and DM cells in the CaSpF in the CTRL and AIP conditions 
(Figure 4.18 A), (also no difference in SR Ca2+ load, Figure 4.13), but the DM cells exhibited 
a significantly higher ratio of waves/cell in the AIP conditions (Figure 4.19 F). Therefore 
unlike in the KN92 and KN93 conditions, the increased ratio of waves in the DM cells cannot 
be attributed to a reduction in Ca2+ sparks. This finding also contradict the findings in the 
post-rest behaviour and spontaneous contractions shown in Figures 4.2 and 4.6, where it was 
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observed that AIP reduced the post-rest behaviour and also inhibited spontaneous contractions 
occurring in the DM isolated cardiac muscle. These findings suggested that AIP was more 
effective at reducing the SR Ca2+ load that could lead to spontaneous contractions. However 
the findings in the DM cardiomyocytes of an increased number of waves/per cells contradict 
these suggestions. Therefore further work is required to elucidate this effect of AIP on SR 
Ca2+ load and pro-arrhythmic behaviour.  
 
Therefore these findings from the Ca2+ spark measurements and those from the intracellular 
Ca2+ transients indicate that the potential benefits of CaMKIIδ inhibition on contractility may 
be exerted not on Ca2+ homeostasis during normal transients, but on the period between 
transients, suggesting a role for CaMKIIδ inhibition in reducing arrhythmogenic events. 
 
4.3.4 No effect of type 2 diabetes on Ca2+ transients during β-Adrenergic challenge but 
increased sarcoplasmic reticulum Ca2+ load in the type 2 diabetic cardiomyocytes in the 
KN92 conditions 
 
In chapter 3 during the KN92 and KN93 treatment of nDM and DM trabeculae it was shown 
that the reduced contractility observed in the DM trabeculae during the force frequency 
relationships (Figure 3.3 A) was no longer present, as there was no significant difference in 
contractile force between the nDM and DM trabeculae (Figure 3.8 A). This observation may 
be attributed to the ability of the DM muscle to increase force from baseline to a greater 
extent than the nDM muscle in response to β-AR stimulation (Figure 3.8 B). The findings 
from this part of the study support those in the trabeculae experiments there was no difference 
in the intracellular Ca2+ transients between the nDM and DM cells during β-AR stimulation. 
However SR Ca2+ load was increased in the DM cells compared to the nDM cells in KN92 
conditions. Therefore the increased SR Ca2+ load could explain the greater % in Fdev in the 
DM cells during β-AR stimulation in KN92 conditions. KN93 reduced the % change in Fdev 
from baseline in the DM cardiac muscles (Figure 3.8 B) and it also reduced the SR Ca2+ load 
in the DM cells. In contrast during the CTRL and AIP experiments in chapter 3.0 the reduced 
contractility in the DM cardiac muscle was maintained during the β-AR stimulation (Figure 
3.14 A), and the DM trabeculae were not able to increase their force in response to 
isoproterenol to the same extent as the DM trabeculae in the KN93 conditions (Figure 3.12 
B). This is in line with the findings from the SR Ca2+ load during β-AR stimulation in this 
study where there was no difference between the nDM and DM cells across all conditions or 
any effect of CaMKIIδ inhibition (Figure 4.26 C). 
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Contrasting findings were shown in the analysis of Ca2+ sparks and waves during β-AR 
stimulation where there was no difference found in CaSpF, amplitude or FWHM and FDHM 
on comparison of KN92 and KN93 treatment. This is an interesting as the SR Ca2+ load was 
significantly increased in the DM cells in the KN92 conditions compared to the nDM cells 
therefore it would be expected that the DM cells would exhibit a higher number of Ca2+ 
sparks. Although this difference did not statistical significance it can be seen in Figure 4.31 E 
and F that the DM cells in the KN92 conditions did show a higher % of cells exhibiting waves 
and also a higher waves/cells compared to the nDM cells in the KN92 conditions, which were 
both reduced in the DM cells after CaMKIIδ inhibition with KN93. These results suggest that 
CaMKIIδ inhibition with KN93 is beneficial on reducing the occurrence of waves and 
severity of waves during β-AR stimulation. Similar findings were shown after CaMKIIδ 
inhibition with AIP, which drastically reduced the ratio of waves/cells (Figure 4.32 F). This 
effect of AIP on the ratio of waves is different to that observed at baseline, where AIP was 
shown to increase the ratio of waves/cells. Therefore these findings that CaMKIIδ inhibition 
during β-AR reduces the severity of waves further indicates CaMKIIδ involvement in acute β-
AR stimulation. 
 
These findings and also the findings in the waves at baseline discussed in section 4.3.3 bring 
up a key question as to what is causing these waves in the DM cells as the western blot data in 
this chapter shows no difference between the nDM and DM RV tissue in their total RyR2 
protein population or the proportion of RyR2 protein activated at the CaMKIIδ site S2814 
(Figure 4.14 A-C). Traditionally hyperphosphoyrlation of the RyR2 by CaMKIIδ has been 
proposed as a mechanism of increased CaSpF (Wehrens et al., 2004), however the association 
between RyR2 and Ca2+ waves is a not so clear. We know that Ca2+ waves occur when the SR 
content reaches a critical SR threshold (SOICR) (Jiang et al., 2004; Chen et al., 2014), and 
SOICR is determined by the open probability of the RyR2. However it has also been shown 
that Ca2+ waves can occur due to rapid inhibition of SERCA (Keller et al., 2007; Venetucci et 
al., 2008). Keller et al. (2007) reported in cardiomyocytes that had rapid inhibition of SERCA 
via a photolabile inhibitor a decrease in the propagation velocity of waves. The authors 
interpreted this finding, as showing that Ca2+ uptake into the SR ahead of the propagating 
wave is required to trigger release, thus suggesting that stimulation of SERCA would promote 
the occurrence of Ca2+ waves (Venetucci et al., 2008). However it has also been shown that 
overexpression of SERCA may be anti-arrhythmogenic, as it has been reported to decrease 
the occurrence of Ca2+ dependent after-contractions (Davia et al., 2001) and reperfusion 
! 166 
arrhythmias (Del Monte et al., 2004). Therefore as it has previously been shown that 
myocardial SERCA expression is increased in the T2D heart even at an early stage in the 
progression of T2D (Fredersdorf et al., 2012) this suggests that SERCA may be playing a role 




From the standpoint of study design, it is important to note that the results from the post-rest 
behaviour in the isolated cardiac muscle would have been acutely sensitive to the condition of 
the muscle at the time of measurement. In addition the rest intervals used during this protocol 
were 10s, 30s and 120s in order to compare the findings with the literature also investigating 
CaMKIIδ inhibition on post-rest behaviour (Sossalla et al., 2010). However Sossalla et al. 
(2010) conducted their investigations in human isolated trabeculae whereas this study used rat 
tissue. The rat cardiac muscle is characterised by faster Ca2+ uptake than in humans, as Bers 
(2000 & 2002) explains that SERCA2a activity is higher in the rat ventricle than in the 
human, and thus Ca2+ removal through Na+/Ca2+ exchange is lower, which results in a balance 
of 92% for SR Ca2+ and 1% of slower systems. This suggests that future studies may identify 
further differences in post-rest behaviour between nDM and DM tissue or in samples treated 
with CaMKIIδ inhibitors using shorter rest-intervals. The post-rest behaviour measurements 
were carried out at 2 Hz stimulation frequency, which equates to 120bpm. This rate is 
relatively low for rats, as their heart normally beats at around 350-400bpm. I reported that 
there were no differences between the nDM and DM in their developed force at 2 Hz (Table 
3.3). Therefore, future studies may focus on post-rest behaviour at a higher contraction 
frequency that would be more closely matched to the rat heart. It would be expected that the 
post-rest behaviour would increase with increasing stimulation frequencies (Blinks & Koch-
Weser, 1961; Rosin & Farah et al., 1955). However Pieske et al. (1999) showed in non-failing 
and failing human myocardium that even at higher stimulation frequencies, there was an 
increase in the post-rest behaviour, but the increase in stimulation frequency did not change 
the difference in findings between the non-failing and failing myocardium. Therefore even if 
a higher stimulation frequency was used in this study it may not have been possible to see any 
difference in the findings between the nDM and DM cardiac muscles. The stimulation 
frequency is particularly relevant when investigating effects of CaMKIIδ, as CaMKIIδ is 
frequency dependent and thus is more active at higher heart rates (De Koninck & Schulman, 
1998; Kushnir et al., 2010; Wu et al., 2012). A similar limitation can be applied to the 
findings from the isolated cardiomyocytes which were stimulated at 1 Hz frequency. Again, 
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future studies may examine the effects of CaMKIIδ inhibition on Ca2+ homeostasis in DM 
myocytes paced at a higher frequency. Finally, I reported on the effects of isoproterenol on 
Ca2+ handling in myocytes isolated from DM and nDM rats. Many of the cells that received 
isoproterenol died shortly after perfusion, an indication that they were acutely sensitive to β-
AR stimulation in isolation. β-AR sensitivity depressed n values for cells treated with 
isoproterenol and may have affected the Ca2+ measurements, particularly in the DM cells. 
This distinction is critical because the β-AR receptor distribution is known to be altered in 
both the T1D heart (Dincer et al., 2001 & 2003; Okatan et al., 2015) and T2D heart (Jiang et 




In conclusion this study has shown that Ca2+ homeostasis is altered between transients but not 
during transients in the DM cardiomyocytes. Also DM cardiac muscle and cardiomyocytes 
exhibit pro-arrhythmic behaviour as demonstrated by the spontaneous contractions and Ca2+ 
waves. CaMKIIδ inhibition with KN93 and AIP was able to reduce this behaviour, providing 
further evidence of early CaMKIIδ involvement in arrhythmogenic activity in the T2D heart. 
 
Therefore the results from this further indicate the potential of CaMKIIδ inhibition as a 
therapeutic strategy to relieve the cardiac dysfunction in the T2D heart. However CaMKIIδ 
inhibition can be harmful as shown by the figures 3.i A and 3.ii A in the appendix, where 
CaMKIIδ inhibition with KN93 and AIP in the nDM cardiac muscle resulted in a reduced 
contractile force. But it can also be seen in figure 3.v there were no detrimental effects of 
CaMKIIδ inhibition in human trabeculae isolated from the RAA of two nDM patients with 
preserved EF. Therefore if CaMKIIδ is to ever be utilized in the clinic, a study involving 
chronic inhibition must be conducted to be sure that CaMKIIδ inhibition does not exacerbate 











The effects of CaMKII! inhibition on cardiac fibrosis in the type 




Acute CaMKIIδ inhibition was beneficial in preserving contractile force and the speed of 
contraction and relaxation in isolated cardiac trabeculae from DM rats, as reported in chapter 
3.0. However CaMKIIδ inhibition resulted in reduced contractile force in nDM rat trabeculae. 
Taken together, these observations suggest that CaMKIIδ inhibition may be a potential 
therapeutic approach for the treatment of DHD, but also that the physiological consequences 
of CaMKIIδ inhibition must be thoroughly understood to prevent deleterious consequences in 
the clinical setting. Therefore this chapter explores the effects chronic of CaMKIIδ inhibition 
in a mouse model of T2D (db/db mouse) on cardiac fibrosis, a pathological process that has 
been linked both positivity and negatively to CaMKIIδ activation.  
 
5.1.1 Fibrosis in the type 2 diabetic heart  
 
Fibrotic remodelling is characterised as an accumulation of extracellular matrix (ECM) 
proteins (collagen & elastin) by cardiac fibroblasts (CFs) (Rossi et al., 1998; Swynghedauw et 
al., 1999; Manabe et al., 2002; Brown et al., 2005; Khan & Sheppard et al., 2006; Martos et 
al., 2007). ECM proteins provide a structural scaffold for cardiomyocytes, distribute 
mechanical forces through the cardiac tissue, and mediate electric conduction (Travers, et al., 
2016). Therefore any disruption to the homeostasis of the ECM proteins can result in 
abnormal electric activity and mechanical dysfunction of the heart (Wu et al., 1998; de 
Bakker et al., 1990), in particular reduced relaxation due to an increase in mechanical 
stiffness. 
 
The heart has limited regenerative capacity, and thus when faced with injury the myocardial 
response involves the removal of necrotic cardiomyocytes followed by fibrotic scar tissue 
replacement in order to preserve myocardial structural and functional (Sutton & Sharpe, 2000; 
Talman & Ruskoaho, 2016). Fibrotic scar tissue replacement occurs when CFs within the 
connective tissue convert to an activated form (myofibroblasts) and secrete elevated levels of 
ECM proteins to promote a profibrotic environment (Travers et al., 2016). While this process 
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is known to occur after cardiac injury, hyperglycemia itself also induces a similar response, as 
it promotes high levels of advanced glycation end-products (AGEs), which directly act to 
stimulate the production and modification of ECM proteins (Goldin et al., 2006).  
 
The T2D heart is characterised by chronic hyperglycemia, and fibrosis is considered one of 
the key factors involved in the reduced diastolic dysfunction observed in these patients 
(Asbun & Villarreal, 2006). However despite fibrosis now being well established as occurring 
relatively early on in the development of DHD, there remains no specific therapy to prevent it 
in this setting.  
 
5.1.2 Potential involvement of CaMKII! in hypertrophic and fibrotic remodelling 
 
CaMKIIδ plays a role in regulating pathological cardiac hypertrophy. TG animal models 
overexpressing CaMKIIδ have exhibited cardiomyoycyte hypertrophy through the induction 
of the fetal gene program, resulting in dilated cardiomyopathy with ventricular dysfunction, 
loss of intracellular Ca2+ and eventual premature death (Zhang et al., 2002; Zhang et al., 2003; 
Maier et al., 2003). Ramirez et al. (1997) was the first to show in vitro that the nuclear splice 
variant CaMKIIδB activates the hypertrophic responsive gene atrial natriuretic factor (ANF) 
in primary cardiomyocytes. Subsequent work from this group and others found two further 
hypertrophic marker genes up-regulated in CaMKIIδ TG mouse hearts; brain natriuretic 
peptide (BNP), which is expressed in both the atria and ventricles, and β-myosin heavy chain 
(β-MHC), which is confined to the atria (Ronkainen 2007; Zhang et al., 2007; Barry et al., 
2008). Calmodulin, which is involved in the activation of CaMKIIδ, is also a key regulator of 
cardiac hypertrophy. Overexpression of calmodulin in the hearts of TG mice induces 
hypertrophy, which is prevented after treatment with the calmodulin antagonist W-7 in 
cultured cardiomyocytes (Passier et al., 2000). Colomer & Mean (2000) demonstrated that TG 
overexpression of calmodulin led to an increase in ANF promoter activity. A further proposed 
mechanism by which CaMKIIδB alters cardiomyocyte growth and activates the hypertrophic 
gene expression response is phosphorylation of class II histone deacetylases (HDACs) (Little 
et al., 2007), in particular HDAC4 and HDAC5 (Backs et al., 2006; Zhang et al., 2007; 
Bossuyt et al. 2008). The phosphorylation of HDACs results in the depression of myocyte 
enhancer factor 2 (MEF2), resulting in MEF2 mediated transactivation of hypertrophic 
marker genes (Passier et al., 2000; Zhang et al., 2002 & Zhang et al., 2007).  
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Less is known about the involvement of CaMKIIδ in fibrosis. Martin et al. (2014) reported 
that CaMKIIδ is present in fibroblasts and that inhibition of CaMKIIδ (AIP) does reduce 
fibrotic remodelling. Fibrosis is well established to occur in the T2D heart and studies such as 
Martin et al. (2014) report a role for CaMKIIδ in the development of fibrosis; so the effects of 
CaMKIIδ inhibition on fibrotic remodelling in the T2D heart must be delineated before this 
approach can be adapted to the clinic.  
 
5.1.3 Aims and hypothesis 
 
The overall aim of this chapter was to investigate the effects of chronic CaMKIIδ inhibition 
on fibrosis in the nDM and DM heart using a mouse model of T2D, the db/db mouse. I 
hypothesized that T2D mice would have increased cardiac fibrotic remodelling compared to 
nDM mice, and further that CaMKIIδ inhibition would alter fibrotic remodelling in both the 
nDM and DM hearts. To test this hypothesis nDM and DM db/db mice at 14 weeks of age 
were separated into 4 groups, (1) nDM KN92, (2) nDM KN93, (3) DM KN92 and (4) DM 
KN93. Each group was treated for 4 weeks with an injection of either KN93 (CaMKII 
inhibitor, 10 µmol/kg) or KN92 (control, 20 µmol/kg) every other day (injection doses based 
off findings from Zhang et al., 2005). At 18 weeks of age an echocardiography scan was 
conducted to assess global LV cardiac structure and function in each of the groups. The 
animals were then euthanized and measurements made of fibrosis present in the RV using 
Masson’s trichrome stain. The expression levels of CaMKIIδ in each treated group were 




In this section the echocardiographic data from nDM and DM db/db mice at 14 weeks of age 
prior to CaMKIIδ inhibition and at 18 weeks of age post CaMKIIδ inhibition treatment is 
described. Western blot data from the nDM and DM RV cardiac tissue at 18 weeks of age is 
also shown. Masson’s trichrome staining shows the effects of CaMKIIδ inhibition on fibrosis 
in the nDM and DM RV tissue.  
 
5.2.1 Significantly increased blood glucose, body weight and heart weight in type 2 
diabetic mice at 18 weeks of age 
 
Table 5.1 shows the animal characteristics from the nDM and DM mice at 18 weeks of age 
post KN92 or KN93 treatment. The DM mice exhibited a significantly higher body weight 
(P<0.001), blood glucose (P<0.001), heart weight (P<0.001) and significantly lower heart 
weight/body weight ratio (P<0.001) in both the KN92 and KN93 conditions compared to the 
nDM mice. However there were no significant differences between the nDM and DM mice in 
their tibia length and heart weight/tibia length ratio. There was a significant effect of 
CaMKIIδ inhibition observed on heart weight/body weight ratio, which increased in both the 
nDM and DM mice (P=0.01). However there was no significant effect of CaMKIIδ inhibition 
on any of the other parameters (Table 5.1). 
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nDM= non diabetic; DM= type 2 diabetic db/db mice; HW= heart weight; TL= tibia length; BW= body weight. Data are mean ± SEM. For comparison of nDM and DM and effects 














effect (P value) 
Treatment 
effect (P value) 
Body weight (g) 
 
29.84 ± 0.91  26.03 ± 0.83 58.69 ± 1.72  56.79 ± 1.64  < 0.001 * 0.11 
Blood glucose (mmol/L) 8.75 ± 0.40   8.31 ± 0.68 30.81 ± 1.82  30.96 ± 0.66  < 0.001 * 0.26 
HW (mg) 105.54 ± 0.62  105.38 ± 0.92 115.11 ± 1.17  114.69 ± 0.92  <0.001 * 0.86 
TL (mm) 
 
15.08 ± 0.18 15.4 ± 0.19 15.55 ± 0.26  15.43 ± 0.24  0.25  0.74 
HW:BW (mg/g) 
 
3.58 ± 0.11 4.09 ± 0.13 1.97 ± 0.06 2.08 ± 0.05 <0.001 * 0.01 * 
HW:TL (mg/mm) 7.01 ± 0.10 6.85 ± 0.13 7.42 ± 0.17  7.43 ± 0.15  0.01 0.73 
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5.2.2 Echocardiography reveals no effect of type 2 diabetes or CaMKII! inhibition on 
left ventricle structure and function  
 
Table 5.2 shows the echocardiography data from nDM and DM mice at 14 weeks of age pre 
treatment, and at 18 weeks post-treatment. The mice were divided into their respective groups 
and injected every other day for 4 weeks with either KN92 or KN93. I hypothesized that at 14 
and 18 weeks of age there would be no signs of systolic dysfunction in the DM mice. The 
echocardiography data revealed no significant difference in any of the LV structural or 
functional parameters between the nDM and DM mice at 14 and 18 weeks of age. CaMKIIδ 
inhibition had no effect on any of the structural or functional parameters, as there remained no 
significant difference between the nDM and DM mice across all of the parameters measured 
(Table 5.2). The DM mice had no signs of any systolic dysfunction regardless of CaMKIIδ 
inhibition. 
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Table 5.2 Echocardiographic assessment of left ventricle structure & function in non-diabetic and diabetic mice at 14 and 18 weeks of age 
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Parameter Week nDM KN92 nDM KN93 DM KN92 DM KN93 Condition effect Treatment 
effect 
ISVd (mm) 14 1.12 ± 0.06 1.14 ± 0.01 1.28 ± 0.09 1.32 ± 0.07 0.49 0.74 
18 1.27 ± 0.05 1.14 ± 0.01 1.30 ± 0.16 1.18 ± 0.03   
ISVs (mm) 14 1.55 ± 0.07 1.52 ± 0.05 1.64 ± 0.08 1.62 ± 0.07 0.50 0.999 
18 1.66 ± 0.06 1.50 ± 0.02 1.68 ± 0.13 1.65 ± 0.06   
LVIDd (mm) 14 3.77 ± 0.12 3.55 ± 0.07 4.23 ± 0.51 3.70 ± 0.21 0.77 0.52 
18 3.79 ± 0.12 3.33 ± 0.10 4.12 ± 0.24 3.92 ± 0.33   
LVIDs (mm) 14 2.64 ± 0.11 2.53 ± 0.07 3.20 ± 0.52 2.80 ± 0.29 0.12 0.75 
18 2.70 ± 0.12 2.34 ± 0.02 3.22 ± 0.30 2.91 ± 0.40   
LVPWd (mm) 14 1.22 ± 0.04 1.18 ± 0.04 1.40 ± 0.08 1.34 ± 0.09 0.35 0.97 
 18 1.24 ± 0.04 1.25 ± 0.07 1.39 ± 0.21 1.34 ± 0.04   
LVPWs (mm) 14 1.24 ± 0.06 1.11 ± 0.05 1.30 ± 0.08 1.28 ± 0.10 060 0.76 
 18 1.25 ± 0.07 1.21 ± 0.08 1.35 ± 0.20 1.25 ± 0.01   
LVEDV (ml) 14 0.14 ± 0.01 0.11 ± 0.00 0.22 ± 0.08 0.13 ± 0.02 0.74 0.29 
 18 0.14 ± 0.01 0.10 ± 0.01 0.18 ± 0.03 0.16 ± 0.04   
LVESV (ml) 14 0.05 ± 0.01 0.04 ± 0.00 0.12 ± 0.05 0.06 ± 0.02 0.09 0.32 
 18 0.05 ± 0.01 0.03 ± 0.00 0.09 ± 0.03 0.07 ± 0.03   
FS % 14 30.20 ± 1.68 28.73 ± 1.35 25.99 ± 3.30 25.59 ± 3.77 0.35 0.48 
 18 28.89 ± 1.27 29.54 ± 2.42 21.75 ± 3.44 26.72 ± 4.68   
EF % 14 63.40 ± 2.47 62.01 ± 2.04 56.73 ± 5.44  55.61 ± 5.93 0.28 0.63 
 18 62.30 ± 2.05 63.37 ± 3.64 50.66 ± 6.66 57.86 ± 7.42   
SV (ml) 14 0.08 ± 0.00 0.07 ± 0.00 0.11 ± 0.03 0.07 ± 0.01 0.09 0.26 
 18 0.09 ± 0.01 0.06 ± 0.01 0.08 ± 0.01 0.09 ± 0.01   
CO (l/min) 14 0.03 ± 0.00 0.03 ± 0.00 0.04 ± 0.00 0.03 ± 0.00 0.15 0.57 
 18 0.03 ± 0.00 0.03 ± 0.00 0.03 ± 0.00 0.03 ± 0.01   
HR (bpm) 14 367.93 ± 13.47 403.712 ± 14.08 377.275 ± 17.08 375.51 ± 12.69 0.83 0.98 
 18 379.75 ± 15.27 384.14 ± 9.45 348.74 ± 37.34 394.27 ± 8.75   
R-R interval (s) 14 165.44 ± 6.49 150.50 ± 4.93 160.64 ± 7.13 160.96 ± 5.83 0.71 0.83 
 18 159.89 ± 5.90 156.48 ±3.84 179.36 ± 22.93 152.41 ± 3.39   
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nDM= non-diabetic; DM= type 2 diabetic db/db mice; ISVd= inter ventricular wall thickness diastole; ISVs= inter ventricular wall thickness systole; LVIDd= LV internal diameter 
diastole; LVIDs= LVinternal diameter systole; LVPWs= LV posterior wall thickness systole; LVPWd= LV posterior wall thickness diastole; LVEDV= LV end diastolic volume; 
LVESV= LV end systolic volume; FS= fractional shortening; EF= ejection fraction; SV= stroke volume; CO= cardiac output; HR= heart rate. nDM KN92 14 weeks (n=11); nDM 
KN92 18 weeks (n=9); nDM KN93 14 weeks (n= 10); nDM KN93 18 weeks (n=4); DM KN92 14 weeks (n=6); DM KN92 18 weeks (n=6); DM KN93 14 weeks (n=6); DM KN93 
18 weeks (n=6). Data are mean ± SEM. For comparison of nDM & DM and the effect of treatment two-way between groups mixed ANOVA, P=<0.05 was used. 
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5.2.3 CaMKII! expression is not up-regulated in right ventricle tissue from 18 week old 
type 2 diabetic mice 
 
Having not observed any signs of systolic dysfunction between the nDM and DM animals at 
18 weeks of age the next step was to investigate CaMKIIδ expression in the db/db RV cardiac 
tissue. As it has been previously established that CaMKIIδ expression is increased during HF, 
quantifying the expression level of CaMKIIδ would further establish the HF phenotype in the 
db/db mice at 18 weeks of age. I hypothesized that there would be no change in the CaMKIIδ 
expression between the nDM and DM animals at 18 weeks of age. To test this hypothesis 
Western blots were performed using RV cardiac tissue from the db/db mice at 18 weeks of 
age. Figure 5.1 A shows a representative blot for total CaMKIIδ protein and the house 
keeping protein GAPDH in nDM KN92, nDM KN93, DM KN92 and DM KN93 treated 
tissue. There was no significant effect of diabetes on the total CaMKIIδ protein (Figure 5.1 B, 









































Figure 5.1 Western blot for total CaMKII! in right ventricle tissue from non-diabetic 
(nDM) and type 2 diabetic (DM) mice at 18 weeks of age treated with KN93 or its 
inactive analogue KN92. A, Western blot of total CaMKIIδ and GAPDH as a loading control 
in nDM and DM mouse right ventricle tissue. Total CaMKIIδ and GAPDH samples are from 
the same gel. B, Quantification of total CaMKIIδ levels in RV tissue nDM and T2D (DM) 
mice treated with either KN92 or KN93. Date are mean + SEM. nDM KN92, black bar, n=6 
mice; nDM KN93, red bar, n=6 mice; DM KN92, black bar, n=6 mice; DM KN93, red bar, 
n=5 mice. For all comparison of nDM and DM values and the effect of CaMKIIδ inhibition a 







































5.2.4 CaMKII! inhibition had no effect on fibrotic remodelling in non-diabetic and 
diabetic right ventricle tissue 
 
Having established that global LV structure and function were unchanged between the nDM 
and DM mice and that CaMKIIδ inhibition had no effect on these parameters, the next step 
was to investigate fibrotic remodelling at the tissue level. Masson’s trichrome stain was used 
for the assessment of collagen in tissue sections taken from the RV in nDM and DM animals 
at 18 weeks of age. Figure 5.2 A-D shows representative images of tissue sections from nDM 
KN92, nDM KN93, DM KN92 and DM KN93 treated RV tissue stained using Masson’s 
trichrome, with any collagen present stained blue. I observed no significant difference in RV 
collagen staining between the nDM and DM animals (P=0.34). Further, and contrary to my 
initial hypothesis, CaMKIIδ inhibition with KN93 neither enhanced nor reduced collagen 





Figure 5.2 Masson’s trichrome staining in right ventricle tissue from non-diabetic 
(nDM) and type 2 diabetic (DM) animals at 18 weeks of age treated with the CaMKII! 
inhibitor, KN93, or its inactive analogue, KN92. A, nDM KN92. B, nDM KN93. C, DM 
KN92. DM, KN93. E, Percent collagen deposition in each experimental group. Data are mean 
± SEM. nDM KN92, black bar, n=12 mice; nDM KN93, red bar, n=11 mice; DM KN92, 
black bar, n=8 mice; DM KN93, red bar, n=8 mice For comparison of nDM and DM and 
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In this chapter the effects of CaMKIIδ inhibition in the db/db mouse model of T2D were 
investigated. Mice were treated for 4 weeks from the age of 14 to 18 weeks of age every other 
day with KN93 (10 mg/kg), which inhibits CaMKIIδ by blocking calmodulin binding at the 
regulatory domain, or KN92 (20 mg/kg), the inactive analogue of KN93. At 14 weeks of age 
an echocardiography scan was carried out to assess baseline global LV structure and function. 
This was followed by an echocardiography scan at 18 weeks to assess the effects of CaMKIIδ 
inhibition on LV structure and function. Western blots were also carried out to quantify the 
total expression of CaMKIIδ in the RV of the nDM and DM mice at 18 weeks of age, 
alongside Masson’s trichrome stain to measure the extent of fibrosis.  
I hypothesized that CaMKIIδ inhibition would alter fibrotic remodelling in the nDM and DM 
mouse heart. The main findings of this study can be summarized as follows: 
- No signs of systolic dysfunction at 14 or 18 weeks of age in the DM mouse heart, or 
any effect of CaMKIIδ inhibition on whole heart structure or function 
- No effect of diabetes or CaMKIIδ inhibition on fibrotic remodelling in the nDM or 
DM mouse heart 
 
5.3.1 Absence of fibrosis in the right ventricle of type 2 diabetic mice at 18 weeks of age 
suggests CaMKII! is not involved in early fibrotic remodelling in this model 
 
As mentioned in previous chapters, diastolic dysfunction is one of the early signs of DHD and 
is often accompanied by fibrotic remodelling. Lamberts et al. (2014) reported an increase in 
collagen deposition in RAA tissue taken from a cohort of T2D patients undergoing coronary 
artery bypass surgery with preserved EF. The results from this study show that between the 
ages of 14 and 18 weeks there is no difference in the LV structure and systolic function 
between the nDM and DM mice or any effect of CaMKIIδ inhibition. No data pertaining to 
the diastolic function was collected in this study, and therefore no conclusion can be drawn on 
the diastolic function of the DM mice at this stage. However the results do confirm that the 
DM mice did not have a HF phenotype, and thus treatment with the CaMKIIδ inhibitor, 
KN93, was conducted prior to the onset of systolic dysfunction and did not accelerate its time 
course. These findings are in contrast to a report by Pereira et al. (2006), which showed 
functional impairment in 15 week old db/db mice as indicated by a reduced fractional 
shortening. However, other groups have reported similar findings to this study, including no 
signs of systolic dysfunction but a trend towards diastolic dysfunction in mice at 16 weeks of 
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age (Huynh et al., 2010). This disparity in findings could be due to the echocardiography 
scans that are required for these measurements, as different levels of isoflurane may have 
been used, which would have an effect on cardiac function (Constantinides et al., 2011)  
 
In the present study no difference was found between the nDM and DM mice in their fibrotic 
remodelling in tissue taken from the RV (Figure 5.2) after treatment with KN92. This 
observation was contrary to the initial hypothesis; previous groups have reported fibrotic 
remodelling in db/db mice at a similar age to that used in this study (Huynh et al., 2014). 
However the absence of fibrosis in the DM RV tissue could be explained by reports from 
others. Van Heerebeek et al. (2008) suggested that increased cardiomyocyte resting tension 
(Fpassive), not fibrosis, is the mechanism responsible for diastolic stiffness in the diabetic heart 
when LVEF is preserved. This increase in Fpassive means that the sarcomeres are stretched 
beyond their optimal resting length of 2.2 µm, and thus they are not able to fully adhere to the 
length-tension relationship in cardiac muscle. During the relaxation phase, the cardiac muscle 
is not able to generate as much tension, suggesting that the resting length is lower, which 
results in a weaker contraction. Titin has been shown to play a role in modulating Fpassive as an 
isoform shift from N2A to N2B results in greater stiffness in the heart (LeWinter & Granzier. 
2010; Helmes et al., 1999; Trombitas et al., 1999; Cazorla et al., 2000; Borbely et al., 2009). 
 
Therefore as CaMKIIδ has been linked with hyperphosphorylation of titin’s spring elements 
(Hamdani et al., 2013; Hidalgo et al., 2013), this could suggest that CaMKIIδ may have an 
effect on myofilament dynamics rather than accumulation of collagen during the early stages 
of DHD.  
 
5.3.2 Chronic CaMKII! inhibition as a therapeutic intervention prior to the onset of 
systolic dysfunction 
 
Another goal of this study was to investigate the efficacy of chronic CaMKIIδ inhibition in 
the nDM and DM heart. CaMKIIδ inhibition negatively impacts upon Fdev in isolated cardiac 
muscle from nDM rats (Chapter 3.0), evidence of the important physiological role CaMKIIδ 
plays in the heart. If CaMKIIδ inhibition is ever to be used in the clinic the ideal time point at 
which to use CaMKIIδ inhibitors in the progression of DHD would need to be established. In 
addition it has also been reported that chronic CaMKIIδ inhibition may actually induce 
fibrosis (Cheng et al., 2012). The results from this study show that there is no effect of 
chronic CaMKIIδ inhibition in the nDM heart on LV structure and function and fibrosis in the 
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RV. This indicates that although acute CaMKIIδ inhibition may have effects on contractile 
force, chronic inhibition was safe as it resulted in no functional or remodelling effects in the 
nDM heart.  
 
There have been other studies that have investigated at chronic CaMKIIδ inhibition in the 
heart; however, they have predominately focused on HF models. Zhang et al. (2005) 
generated a genetically modified mouse model, the AC3-I mouse that exhibited a 40% 
reduction in total CaMKIIδ activity without completely abolishing activation of CaMKIIδ. 
Post MI, the AC3-I mouse model exhibited reduced fibrotic remodelling, suggesting that 
CaMKIIδ inhibition could be used as a therapeutic approach in targeting adverse myocardial 
remodelling. However studies conducted since have provided evidence to show the potential 
negative effects of CaMKIIδ inhibition. Cheng et al. (2012) showed in a complete CaMKIIδ 
KO that there was an increase in fibrosis after thoracic aortic banding, pointing to a potential 
anti-fibrotic role for CaMKIIδ. Others have shown that in healthy mouse models, chronic 
CaMKIIδ inhibition results in a blunted response in cardiomyocyte contractility (in particular 
that of fractional shortening) and intracellular Ca2+ handling in response to exercise training 
after CaMKIIδ inhibition (Kaurstad et al., 2012), therefore suggesting potentially deleterious 
effects of CaMKIIδ inhibition. However the findings from the current study suggest that, in 
early diabetes, CaMKIIδ inhibition did not accelerate fibrotic growth. This difference in 
findings could be due to a difference in models, as the study by Cheng et al. (2012) was 
conducted in a KO model, whereas in this study the KN93 injections would have mimicked 
the AC3-I model which as mentioned above has been shown by Zhang et al. (2008) to reduce 
fibrosis post MI. Therefore, perhaps CaMKIIδ partial inhibition may be favorable than 




There are several limitations that must be taken in account with the findings from this study. 
Firstly Masson’s Trichrome stain is widely used for the assessment of collagen in cardiac 
tissue (Kuhn et al., 2007; Yoon et al., 2010; Chen et al., 2011) it is not specific for the type of 
collagen. Masson’s Trichrome stain is based on three dyes, of which Light Green or Aniline 
Blue is used to colour the collagen. As well as phosphomolybdic acid, which is able to bind to 
collagen. As the binding of these dyes is based on base-acid interactions, they therefore are 
not specific for collagen (Jong et al., 2012). Therefore it would have been useful to have used 
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another stain such as picrosirius red or even gene expression measurements of collagen to 
support the findings from the Masson’s Trichrome stain.  
 
KN93 inhibits CaMKIIδ by blocking calmodulin binding at the regulatory domain (Sumi et 
al., 1991) and is widely used in studies investigating CaMKIIδ inhibition (Anderson et al., 
1998; Bell et al., 2015; Sommesse et al., 2016). However one limitation of using KN93 in 
vivo is that it is not cardiac specific. In the heart CaMKIIδ is the predominant isoform, but 
CaMKIIδ is also expressed in many other tissue types (Kennedy & Greengard, 1981; 
Srinivasan et al., 1994; Uemura et al., 1995), particularly in the brain, where it is involved in 
learning and memory processing (Braun & Schulman, 1995; Hudmon & Schulman, 2002; 
Coultrap & Bayer, 2012; DeKoninck & Schulman, 1995), and in skeletal muscle, where it is 
involved in Ca2+ handling during exercise (Woodgett et al., 1983; Bayer et al., 1998; Damiani 
et al., 2000; Rose & Hargreaves, 2003; Rose Et al., 2006). Therefore the KN93 injections may 
have had off-target effects outside of the cardiovascular system that could still have impacted 
cardiac function. As no significant difference in whole-heart function was observed in 
echocardiography scans, such effects were likely minimal. 
 
The use of the inhibitors also highlights the need for a second control group i.e. a group 
injected with saline (10% DMSO). Although KN92 is considered the appropriate control for 
KN93 as its mimics the same off-target effects as KN93, KN92 itself may have affected the 
nDM and DM heart. Therefore it may be useful to incorporate a second control group injected 
with saline to establish any potential effect of KN92 on structural remodelling.  
 
In addition this study focused on the RV and did not investigate any potential effects in the 
LV. The RV has a much thinner wall than the LV and therefore the fibrotic remodelling that 
occurs in each chamber could differ. However it was shown by Daniels et al. (2009) that there 
is no difference between the RV and LV in connective tissue growth factor, and therefore the 
findings in the RV are likely to mimic those in the LV.  
 
One further limitation is the use of different sexes of mice in this study. It is well established 
that pre-menopausal women have a decreased cardiovascular risk compared to males due to 
circulating levels of estrogen, with this cardio-protective effect of estrogen diminishing during 
post-menopause (Bittner, 2009; Coylewright 2008; Kim et al., 2009; Reckelhoff et al., 2010; 
Yang et al., 2011). Alongside these differences in cardiovascular risk between males and 
females, males are more likely to suffer from DHD but the development of DHD has a greater 
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impact on HF risk in females. As stated in chapter 1, section 1.1, HF is twice as high in males 
with diabetes and five times higher in females with diabetes (Kannel & McGee, 1979; 
Marwick 2006). It has also previously been reported that isolated cardiomyocytes from 
female rats maintain lower Ca2+ levels than males (Curl et al., 2001; Farrell et al., 2010). 
Given the prominent role CaMKIIδ plays in Ca2+ handling in the heart, this evidence suggests 
that CaMKIIδ could have a sex specific effect during diabetes. Bell et al., (2015) recently 
investigated this potential sex specific effect of CaMKIIδ and indeed confirmed a difference 
between males and females exists in CaMKII activation pathways. The authors reported a 
significantly reduced activation of CaMKIIδ (as measured by Western blot for PCaMKIIδ 
T287) in female cardiomyocytes at baseline, alongside a sex difference in the extent of splice 
variant post-translational modifications during acute ischemia/reperfusion injury. In our 
experiments, cohorts were assigned to maintain equal male:female ratios between groups as 
much as was possible and based on animal availability, but potentially confounding effects of 




In conclusion this study has shown that fibrosis was not present in the DM heart at 18 weeks 
of age, and that there were no detrimental effects of CaMKIIδ inhibition on global LV 
structure and function or on fibrosis in either the nDM or DM heart. However further work is 
required to fully understand the effects of chronic CaMKIIδ inhibition in the diabetic heart.  
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6.1 Summary of key findings 
 
The overarching objective of this project was to evaluate the role of CaMKIIδ in the T2D 
heart and to investigate the efficacy of CaMKIIδ inhibition in preventing DHD. This thesis 
describes the first work to the best of our knowledge focused on CaMKIIδ effects in the T2D 
heart. 
 
For my first aim, I initially hypothesized that CaMKIIδ activation would be increased in the 
DM heart prior to systolic dysfunction. Indeed, CaMKIIδ activation was increased in the DM 
RV tissue prior to systolic dysfunction, as demonstrated by an increase in phosphorylated 
CaMKIIδ measured by Western blot. I next hypothesized contractile force and contraction 
and relaxation kinetics would be impaired in the DM isolated cardiac muscle, which would be 
improved by CaMKIIδ inhibition with either KN93 or AIP. The DM cardiac muscle did have 
reduced contractility as indicated by reduced Fdev, dF/dtmax and dF/dtmin, CaMKIIδ inhibition 
with KN93 and AIP was beneficial in preserving these measures of contractility. Finally, I 
hypothesized that DM cardiac muscle would have a reduced responsiveness to β-AR stress, 
and thus contractile force, speed of contraction and relaxation would be reduced compared to 
nDM muscle in the presence of isoproterenol. Further, I hypothesized that CaMKIIδ 
inhibition with KN93 and AIP would restore the contractile and relaxation parameters in the 
DM trabeculae during β-AR stimulation to the same level as that in the nDM trabeculae. In 
the KN92 and KN93 conditions this hypothesis was partially accepted as the dF/dtmax and 
dF/dtmin and RT90% were all significantly impaired in the DM trabeculae. However there was 
no difference between the nDM and DM in their contractile force, and the DM had a 
significantly greater % change in their Fdev from baseline, indicating the DM had an increased 
responsiveness to isoproterenol. CaMKIIδ inhibition with KN93 had no effect on any of the 
parameters. In contrast during the CTRL and AIP conditions the DM trabeculae did exhibit a 
reduced contractile force, as well as reduced dF/dtmax and dF/dtmin, and RT90%. CaMKIIδ 
inhibition with AIP did significantly improved all these parameters.  
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The next step was to investigate potential mechanisms that could underlie the reduced 
contractility and beneficial effects of CaMKIIδ inhibition in the T2D heart. As CaMKIIδ 
regulates cardiomyocyte Ca2+ handling, which is known to be disturbed in the T2D heart 
(Reuter et al., 2008), I chose to focus on alterations to Ca2+ homeostasis in myocytes from 
T2D animals. I hypothesized that, in isolated cardiac muscle, post-rest behaviour (a measure 
of SR Ca2+ release and re-uptake) would be reduced in the DM cardiac muscle and that 
CaMKIIδ inhibition would improve this. However, this hypothesis was rejected as the DM 
trabeculae in both KN92 and CTRL conditions exhibited a significantly higher post-rest 
behaviour, which was increased further with KN93 but reduced back down to the same level 
as the nDM in the AIP conditions. I next hypothesized that, in isolated cardiomyocytes from 
the DM rat heart, there would be altered Ca2+ handling, reduced SR Ca2+ load and an increase 
in Ca2+ spark frequency, and that CaMKIIδ inhibition with KN93 and AIP would bring these 
variables back to the same level as the nDM trabeculae. This hypothesis was also rejected, as 
there was no difference in intracellular Ca2+ transients and SR Ca2+ load between the nDM 
and DM cells. There was a difference observed in the CaSpF between the nDM and DM 
myocytes, with the DM cells exhibiting a significantly higher CaSpF in the KN92 conditions. 
CaMKIIδ inhibition had no effect on altering this difference, particularly in the AIP treatment 
conditions. The reduced CaSpF frequency in the DM cardiomyocytes may be explained by an 
increase in the ratio of waves/cell in the DM cells, which was increased in both the KN92 and 
CTRL conditions. There was no significant effect of KN93 or AIP on reducing waves/cell.  
 
Having observed no difference in the Fdev between the nDM and DM during β-AR stimulation 
but a greater % change in Fdev from baseline in the KN92 and KN93 conditions, I 
hypothesized that there would be no difference in the intracellular Ca2+ transients between the 
nDM and DM myocytes after treatment with isoproterenol, but SR Ca2+ load would be 
increased in the DM cardiomyocytes in KN92 and KN93 conditions. Indeed, Ca2+ transient 
amplitude was similar between the nDM and DM myocytes after isoproterenol treatment, 
consistent with my previous observations in trabeculae. Thus, this hypothesis was accepted. 
In contrast, in the CTRL conditions the reduced contractile force observed between the nDM 
and DM at baseline in the isolated muscle was maintained during β-AR stimulation, CaMKIIδ 
inhibition with AIP restored contractile force. Finally, I hypothesized that the DM 
cardiomyocytes in the CTRL conditions would have a reduced intracellular Ca2+ transient and 
a reduced SR Ca2+ load compared to nDM CTRL myocytes. This hypothesis was rejected, as 
there was no difference observed in the Ca2+ transients or SR Ca2+ load. There was no 
difference observed in CaSpF across any of the conditions in either the nDM and DM cells. 
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However CaMKII inhibition with KN93 and AIP resulted in a striking reduction of the 
waves/cell in the DM cardiomyocytes but, presumably due to small n values for a couple of 
these conditions, this difference did not quite reach statistical significance (P=0.06).  
 
One other key aspect of the reduced function in the T2D heart other than alterations in 
intracellular Ca2+ handling is an accumulation of collagen (Kass et al., 2004; Lamberts et al., 
2014), which can cause fibrosis and result in the heart becoming stiffer and impair relaxation 
(Badenhorst et al., 2003; van Heerebeek et al., 2008; Janicki et al., 2002). This means that the 
heart is not able to fill with blood as effectively during the relaxation stage and thus the 
contractile force generated during systole is reduced. A role for CaMKIIδ in pathological 
cardiac hypertrophy in response to myocardial injury is well established (Ramirez et al., 
1997), whereas as a role for CaMKIIδ in fibrosis has only recently been discovered (Martin et 
al., 2014). Therefore it was hypothesized that there would be an increase in fibrotic 
remodeling in RV tissue taken from db/db mice at 18 weeks of age compared to age matched 
nDM mice, and that CaMKIIδ inhibition would alter fibrotic remodeling in the nDM and DM 
hearts. This hypothesis was rejected, as there was no differences found between the nDM and 
DM in their fibrotic remodelling, or any effect of CaMKIIδ inhibition. 
 
Overall the findings of this study indicate that CaMKIIδ inhibition is beneficial for preserving 
contractility isolated DM cardiac muscle. However, the mechanisms underlying reduced 
contractility in the DM heart are complex and not fully explained by alterations to 
intracellular Ca2+ handling or fibrosis.  
  
6.2 Is CaMKIIδ a potential therapeutic target in the type 2 diabetic heart? 
 
As the main objective of this study was to investigate the physiological effects of CaMKIIδ 
inhibition in the T2D heart, this discussion will focus on how the findings from this study 









6.2.1. Translating findings from animal models to humans 
 
The animal models used for these studies, the ZDF rat and the db/db mouse, are both models 
of T2D. They are both leptin receptor deficient, and thus the rodents become hyperphagic 
leading to obesity and hyperglycemia. They are both widely used animal models in T2D 
research but, like with any animal model, there are a number of limitations when comparing 
to human conditions (Milani-Nejad et al., 2014). As the rodents are leptin receptor deficient 
the animals are subject to lipotoxicity more so than humans would be and this can further 
exacerbate cellular dysfunction (Bugger & Abel, 2009). Despite this both the ZDF and db/db 
models closely mirror what is observed in the human diabetic myocardium. For example 
Daniels et al., (2012) reported ZDF rats show typical characteristics of T2D patients, 
including elevated blood glucose and HbA1c levels from the age of 14 weeks, and this 
progression of diabetes is coupled with development of diastolic dysfunction. db/db mice 
have impaired Ca2+ handling, as demonstrated by decreased systolic and diastolic levels of 
Ca2+, decreased rates of Ca2+ decay and, increased Ca2+ leakage from the SR (Belke et al., 
2004). Meanwhile, Pereira et al., (2006) reported reduced Ca2+ transients, L-type Ca2+ current 
and SR Ca2+ in db/db mice. Therefore given this evidence, the findings in this study are useful 
for examining the physiological effects of CaMKIIδ inhibition and could potentially be 
translated into clinical approaches for T2D patients. In addition, as both the ZDF and db/db 
animals were used at a stage at which systolic dysfunction is not present but early signs of 
diastolic dysfunction are observable, these models mimic clinical observations in T2D 
patients and thus further the potential connection to human patients.  
 
6.2.2 How is CaMKIIδ inhibition improving contractility 
 
It is important to interrogate the mechanisms of CaMKII inhibition to further understand the 
potential efficacy in the clinic. CaMKIIδ is vital in regulating a number of the Ca2+ handling 
proteins during contraction and relaxation (Maier & Bers; Couchonnal & Anderson, 2009), 
and therefore Ca2+ release and reuptake are dependent on CaMKIIδ activation. It has been 
hypothesized by many that CaMKIIδ inhibition mediates beneficial effects through this 
mechanism, and this has been confirmed in HF studies (Sossalla et al., 2010). However the 
results provided in chapter 4 in this thesis do not follow this same trend. The intracellular 
Ca2+ transients and SR Ca2+ load showed no alterations in Ca2+ handling in the DM 
cardiomyocytes at either baseline or during β-AR stimulation, and there was no effect of 
CaMKIIδ inhibition. These data indicate that both T2D and CaMKIIδ inhibition had no effect 
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on altering Ca2+ handling and thus this is not responsible for the reduced contractility in the 
DM trabeculae or beneficial effects shown on contractility. However there were alterations in 
the DM cells during the Ca2+ spark measurements, where there was an increased CaSpF 
frequency observed and also an increased ratio of waves/cells. CaMKIIδ inhibition had no 
effect on the CaSpF parameters but it did reduce the ratio of waves/cells, therefore indicating 
that CaMKIIδ inhibition has a positive effect on reducing waves, which are building blocks 
for cardiac arrhythmias (Berlin et al., 1989; Capogrossi et al., 1987; Stuyvers et al., 2000). 
This is an important point to consider in terms of the use of CaMKIIδ inhibition in the clinic. 
Diabetic patients are known to have a higher risk of arrhythmias, in particular AF (Benjamin 
et al, 1994; Krahn et al., 1995; Nichols et al., 2009; Aksnes et al., 2008). Erickson et al., 
(2013) showed that acute glucose elevations similar to diabetic patients activates CaMKIIδ 
and leads to arrhythmic events. This observed arrhythmogenic activity was reduced when 
CaMKIIδ activity was blocked, providing direct evidence of the role of CaMKIIδ in 
arrhythmias in the diabetic heart and the potential therapeutic benefits on arrhythmogenic 
activity.  
 
The increase in waves/cell in the DM cells also indicates that the time in between transients 
that may be key to the reduced contractility observed in the DM cells, and the effects of 
CaMKIIδ inhibition. Figure 4.i in the appendix 2 could provide an insight into these observed 
effects between the transients, as it shows the Fdev in the DM trabeculae in the KN92 and 
KN93 conditions, in those muscles that had spontaneous contractions and those that did not. 
As these spontaneous contractions occurred during the post rest period and thus in between 
transients, looking at the difference in the contractile force between those that had 
spontaneous contractions and those that didn’t could provide an indication that the reduced 
contractility may be contributing to the events occurring during the transients. It can be seen 
in the KN92 conditions that there is a significantly reduced Fdev in those muscles that 
exhibited spontaneous contractions compared to those that didn’t (P<0.01), whereas in the 
KN93 conditions there is a significantly increased Fdev in those muscles exhibiting 
spontaneous contractions compared to those that did not (P=0.01). Therefore it could be 
hypothesized that the overall reduced contractile force that is observed in the DM muscles in 
the KN92 conditions in Figure 3.3 A in chapter 3 is due to the pro-arrhythmic behaviour that 
these muscles are exhibiting and thus, as the spontaneous contractions indicate some 
alteration in the Ca2+ handling, these muscles in particular have a reduced SR Ca2+ load and 
reduced developed force. In comparison, as the overall developed force in the DM trabeculae 
in the KN93 conditions is improved in Figure 3.3 A in chapter 3 and the graph in appendix 2, 
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Figure 4.i, shows an increase in the Fdev in those exhibiting spontaneous contractions indicates 
that even in muscles that exhibit pro-arrhythmic behaviour CaMKIIδ inhibition is able to 
restore their contractile force. In addition there was a significant difference between the DM 
KN92 and DM KN93 cardiac muscles with spontaneous contractions (P= 0.02), indicating 
that CaMKIIδ inhibition with KN93, despite having no effect on the % of trabeculae 
exhibiting spontaneous contractions (see Figure 4.3 in chapter 4), is able to preserve the 
contractile force in these muscles exhibiting pro-arrhythmic behaviour.  
 
Another mechanism in the T2D heart that could be playing a role in reduced contractility and 
which CaMKIIδ could act on is fibrotic remodeling. Acute CaMKIIδ inhibition would not 
have any effect on fibrosis; therefore, chapter 5 describes results of chronic inhibition applied 
in a mouse model of T2D (db/db mouse). There was no difference in the level of fibrosis 
between the nDM and DM hearts or any effect of CaMKIIδ inhibition. These findings 
indicated that there was no adverse effect of CaMKIIδ inhibition, which is a positive finding 
in relation to translating CaMKIIδ inhibition into the clinic. However, these experiments do 
not leave us with a mechanistic explanation for the observation that CaMKII inhibition 
improves contractility, which requires further investigation. Future studies could focus more 
on potential alterations at the myofilament level. We already know that alterations to titin can 
have an impact on contractility in particular passive stiffness and thus diastolic function. It 
has previously been shown that titin’s mechanical properties are altered in HF (Neagoe et al., 
2002; Makarenko et al., 2004; Borbely et al., 2009; Kruger et al., 2009; Nagueh et al., 2004) 
and it has also been suggested to play a role in diastolic dysfunction in DHD (Kruger et al., 
2010). It is also known that CaMKII is involved in phosphorylation of titin on its spring 
elements (Hialgo et al., 2012 & Hamdani et al., 2013). Therefore as it has previously been 
shown that there is depressed cardiac myofilament function in the T2D heart (Jweied et al., 
2005), the potential of CaMKIIδ modulation of titin in the T2D heart could be an interesting 
area to explore in regards to reduced contractility.  
 
One of the main objectives of this thesis was to investigate CaMKIIδ inhibition in the T2D 
heart and the mechanisms behind it. The results have shown that pro-arrhythmic behaviour 
may be the main mechanism CaMKIIδ inhibition is acting on to improve contractility. It also 
poses the question of what decreased contractility of myocytes explain to us about DHD. As 
previously stated the majority of the literature attribute reduced contractile function in the 
diabetic heart to fibrotic remodeling which makes the ventricular wall stiff and less flexible 
and thus affects relaxation (Badenhorst et al., 2003; van Heerebeek et al., 2008; Janicki et al., 
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2002). However this study has shown changes to the fundamental ways that cardiomyocytes 
generate force.This is a really important point to consider because if each myocyte is weaker, 
they then need to contract more often to produce the same amount of blood flow, thus putting 
the heart under more stress, resulting in the transition to HF phenotype reported in diabetic 
patients (Kannel & McGee, 1979; Marwick, 2006).  
 
6.2.3 Does CaMKIIδ inhibition in the non-diabetic heart tell us something about its 
efficacy in the clinic? 
 
The results in chapter 3.0 provide strong support for the use of CaMKIIδ inhibitors in T2D 
patients, as both KN93 and AIP were able to improve contractile force and the speed of 
contraction and relaxation. However one important finding of this study was that CaMKIIδ 
inhibition with KN93 in healthy nDM rats results in reduced Fdev across the stimulation 
frequencies tested. Why CaMKIIδ inhibition would reduce contractility in the healthy heart is 
not fully understood. However my findings do confirm a role for CaMKIIδ in the positive 
modulation of inotropy in the healthy heart. Therefore it could be hypothesized that, in the 
nDM heart, CaMKIIδ inhibition is resulting in a reduction in Ca2+ release from the SR via 
reduced phosphorylation of RyR2 and thus there is less Ca2+ available for contraction. 
CaMKIIδ inhibition would also prevent phosphorylation of PLB. In its unphosphorylated 
state PLB acts as a break on SERCA2a to reduce Ca2+ reuptake in the SR. Therefore meaning 
there would be less Ca2+ re-uptake during relaxation and thus there is less Ca2+ in the SR to be 
released during CICR. In addition CaMKIIδ inhibition would result in less sensitivity in the 
LTCC, which would result in a slower initiation of Ca2+ transients, and thus less Ca2+ entering 
the cell. KN93 has also been shown to have off-target CaMKII-independent effects on ion 
channels, and thus the combination of inhibiting CaMKIIδ and the off target effects may have 
a greater impact in the nDM heart than in the DM heart. However these findings in the nDM 
trabeculae become a little less clear when we look at what happens in the AIP conditions. 
There is again a significantly reduced Fdev; however, CaMKIIδ inhibition with AIP results in 
an improved dF/dtmax and dF/dtmin in the nDM cardiac muscle. Therefore it could be 
hypothesized that the overall Ca2+ flux is lower, which results in reduced force development, 
and thus it takes less time to get to peak of contraction and back due to the contraction itself 
being so much smaller. 
 
These findings in the nDM trabeculae indicate that, if CaMKIIδ inhibition is ever to be used 
in the clinic, the time point in the progression of the disease would have to be established to 
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avoid any negative influence on contractile properties. This is particularly important when we 
consider findings from exercise based studies that have investigated CaMKIIδ inhibition. 
Exercise is a key component in diabetic therapeutic programs due to cardiovascular benefits, 
including improved strength of the respiratory and cardiac muscles, and thus improved 
utilization of oxygen and pumping efficiency of the heart (Banzer et al., 2004; Bourkhis et al., 
2015; Horden et al., 2012; Boule et al., 2003). However Kemi et al. (2007) reported that the 
combination of exercise and acute CaMKIIδ inhibition in healthy mice resulted in an 
abolishment of training-induced increases in fractional shortening. The authors attributed this 
finding to the fundamental targets that CaMKIIδ acts upon in the heart, including L-type Ca2+ 
channel, RyR2 and SERCA2a, all of which play a major part in ECC. Thus any alteration in 
Ca2+ handling proteins would affect cardiac output, which is a major determinant of oxygen 
transport and could therefore diminish aerobic training adaptations. Kaurstad et al., (2012) 
extended the work by Kemi et al., (2007) using a chronic model of CaMKIIδ inhibition in 
healthy mice and also reported a blunted response in cardiomyocyte contractility and 
intracellular Ca2+ handling in response to exercise training after CaMKIIδ inhibition. Thus, 
up-regulation of CaMKIIδ activity during exercise is required for the modulation of training-
induced cardiac adaptation in healthy mice. Kaurstad et al., (2012) suggested that chronic 
inhibition such as that used in their study might have even progressed to systolic dysfunction 
and failure if CaMKIIδ inhibition was continued. These previous findings suggest that 
therapeutic strategies incorporating CaMKIIδ inhibition would need to be adopted with 
consideration for exercise rehabilitation programs to ensure CaMKIIδ inhibition is not 
reducing the potential benefits of exercise in T2D patients.  
 
Importantly, the animals used in the studies by Kaurstad et al., (2012) and Kemi et al., (2007), 
as well as the nDM rats in my study were all healthy. One potential hypothesis that follows 
from these observations is that CaMKIIδ inhibition is deleterious in the healthy myocardium. 
If true, that hypothesis suggests that CaMKIIδ inhibition may be a safe therapeutic strategy 
for both nDM and DM patients that are progressing towards HF. In support of this hypothesis 
I have included figure 3v in the appendix, which shows contractility measurements from 5 
muscles isolated from the RAA of 2 nDM patients with preserved EF undergoing coronary 
artery bypass surgery. KN93 did not impair the contractility of this tissue, suggesting that 





6.3 Future directions 
 
6.3.1 Modifications of CaMKIIδ in the type 2 diabetic heart 
 
In this study the effects of CaMKIIδ autophosphorylation were studied as a starting point for 
investigating the potential benefits of CaMKIIδ inhibition in the T2D heart. However, as 
detailed in chapter 1 CaMKIIδ is known to be modified by a number of post-translational 
modifications (oxidation, O-GlcNAcylation, nitrosylation). In particular O-GlcNAcylation is 
relevant in T2D due to the high glucose levels present.  
 
O-GlcNAc is synthesized via the hexosamine biosynthesis pathway (HBP), which is activated 
upon glucose entering the cell (Chatham & Marchase, 2010). Therefore, the elevated plasma 
glucose levels in T2D patients potentially suggest a possible mechanistic link between protein 
O-GlcNAcylation and DHD (McLarty et al., 2013). Torres and Hart (1984) were the first to 
identify the modification of threonine residues of nuclear and cytoplasmic proteins by O-
GlcNAc in intact lymphocytes. Since then, much work has been published elucidating the role 
of O-GlcNAc modification in many biological processes, including nuclear transport, 
transcription and translation, cytoskeletal organization, signal transduction, proteasomal 
function and cell survival, and most recently cardiac dysfunction (Hart, 1997; Comer & Hart, 
1999; Zachara & Hart, 2004 & 2006; Wells et al., 2003). However, the exact role of O-
GlcNAc in mediating DHD, and specifically O-GlcNAc modification of CaMKIIδ is not fully 
understood (McLarty et al., 2013). Medford et al., (2012) reported that a ‘western diet’ high in 
saturated fat and sugar, which has long been associated with T2D, results in increase O-
GlcNAcylation of cardiac proteins. Interestingly, glucose deprivation is also known to trigger 
an increase in O-GlcNAc levels (Taylor et al., 2008). Zou et al., (2012) demonstrated that in 
neonatal rat ventricular myocytes (NRVMs), glucose deprivation was a profound stimulus for 
increasing protein O-GlcNAc levels, and in fact, CaMKIIδ played a role in mediating this 
effect. As diabetic patients are subject to periods of both hyper- and hypoglycemia, these 
studies suggest a critical role for O-GlcNAc activation in DHD.  
 
The effects of O-GlcNAc modification on Ca2+ handling proteins have been investigated by 
Hu et al., (2005), who showed a decreased level of SERCA2a expression as well as decreased 
phosphorylation of the SERCA2a modulator, PLB, in hearts from mice with streptozotocin 
(STZ)-induced diabetes (T1D), a potential explanation for the observed cardiac dysfunction in 
these mice. However, when an adenovirus overexpressing O-GlcNAcase, which acts to 
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reduce cellular O-GlcNAcylation, was delivered into the hearts of the STZ-diabetic mice, 
there was a 40% increase in SERCA2a expression, alongside a 50% reduction in PLB protein 
expression, but a twofold increase in the phosphorylated form. Thus, in these mice, there was 
an increase in the SERCA2a/PLB ratio and SERCA2a activity, resulting in improvement of 
contractility in the diabetic myocytes. This negative effect of O-GlcNAc modification has 
also been shown in rat cardiomyocytes treated with PUGNAc, a compound that enhances 
protein O-GlcNAcylation, where there was a disruption of the association between PLB and 
SERCA, resulting in impaired Ca2+ reuptake into the SR and a slower rate of cardiomyocyte 
relaxation (Yokoe et al., 2010).  
 
Erickson et al., (2013) were the first to identify a specific O-GlcNAc modification of 
CaMKIIδ and reported a novel mechanism of O-GlcNAc-modified CaMKIIδ activation at the 
Ser279 in the diabetic heart. It was shown in this study that pharmacological inhibition of O-
GlcNAc modified CaMKIIδ attenuate SR Ca2+ leak and significantly reduced arrhythmic 
events. The results of this study suggest important novel pathways mediated by O-GlcNAc 
modification of cardiac Ca2+ regulatory proteins that could be particularly important in the 
context of hyperglycemia in the T2D heart. While Erickson et al., (2013) showed significant 
anti-arrhythmogenic benefits from inhibition of O-GlcNAc-modified CaMKIIδ, other studies 
have demonstrated that enhanced O-GlcNAc modification within the heart can have 
beneficial effects. During ischemia/reperfusion in rats, for example, increased protein O-
GlcNAc levels provide protection against ischemic injury (Liu et al., 2007). When the heart 
experiences severe acute stress, such as hypoxia, ischemia and oxidative stress, O-GlcNAc 
modification of proteins may act as a signal to mediate/alleviate pathological consequences 
(Zachara et al., 2004; Zou et al., 2007 & 2009). This dual effect of O-GlcNAcylation 
demonstrates both potential pathological and cardioprotective roles, and suggests that O-
GlcNAc signaling must be carefully balanced to maintain proper cardiac function, an 
equilibrium that may be critically disrupted in the altered metabolic environment of the T2D 
heart.  
 
As well as O-GlcNAcylation emerging as a potential mediator of CaMKIIδ activation 
oxidation is also another modification of CaMKIIδ that could be critical in the T2D heart. 
Purohit et al., (2013) has recently shown a role for oxidized CaMKIIδ in the atria of patients 
with AF. This group also showed in mice expressing a CaMKIIδ-resistant RyR a reduced 
susceptibility to AF induction, thus further supporting the link between AF and oxidized 
CaMKIIδ phosphorylation of the RyR. In addition oxidized CaMKIIδ has also been 
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postulated as an arrhythmogenic trigger, as it has been shown in animal models to trigger 
EADs by delaying the sodium current (Song et al., 2008). Swaminathan et al., (2011) showed 
that oxidized CaMKIIδ acts as a biomarker in patients for sinus node dysfunction, as patients 
demonstrated increased SA node cell death and fibrosis. In addition to a decreased intra-atrial 
conduction velocity and reduced spontaneous beating rate in the right atrium. In terms of 
investigations oxidative stress modifying CaMKIIδ in diabetes very little research has been 
conducted. One study that has investigated it demonstrated that in patients who have MI, the 
diabetic patients had elevated levels of ox-CaMKIIδ compared to the nDM patients. Therefore 
suggesting ox- CaMKIIδ contributes to the well-established increased mortality in diabetic 
patients after MI. The authors also suggested a link between the hyperglycemia that is 
characteristic of diabetes, and mortality after MI. This was attributed to an increase in 
mitochondrial reactive oxygen species, which was shown to lead to excessive ox- CaMKIIδ 
activation, SAN cell dysfunction and apoptosis (Swaminathan et al., 2011).  
 
Therefore as it is well established that the T2D heart is exposed to both hyperglycaemia and 
oxidative stress, which are postulated to contribute to disease complications (Baynes & 
Thorpe, 1999; Jay et al., 2006). More investigations are required to elucidate the role of these 
other modifications of CaMKIIδ in the T2D heart. This could be achieved by Western blots 
using specific antibodies, and also the use of inhibitors such as Trolox, a vitamin E derivative 
for oxidized CaMKIIδ and diazonorleucine, a metabolic inhibitor for O-GlcNAc modified 
CaMKIIδ. 
 
6.3.2 Different stages of diabetic heart dysfunction 
 
As well as addressing the other modifications of CaMKIIδ, the stage of DHD would also be 
an area that could be addressed in the future. This current study used animals that were pre 
systolic dysfunction and the results show that acute CaMKIIδ inhibition was beneficial at this 
stage in the T2D heart. However, what about those patients that are at a later stage in the 
development of DHD? The results from this study showed that CaMKIIδ inhibition was 
beneficial for both contraction and relaxation parameters which suggest that CaMKIIδ 
inhibition could also be beneficial at later stages in DHD where systolic dysfunction is 
present. It will however be important to repeat these experiments at a later stage of DHD, 
where possibly the other mechanisms of CaMKIIδ activation (O-GlcNAc and oxidation) may 
be acting in synergy to further exacerbate the pathological effects of CaMKIIδ activation. In 
addition the observation that inhibition of CaMKIIδ has been shown to be beneficial post MI 
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(Zhang et al., 2007) suggests that even in the later stages of DHD it could be a therapeutic 
target. 
 
If these studies were to be conducted it would also be interesting to investigate whether partial 
inhibition of CaMKIIδ in diabetes to levels of activity consistent with healthy individuals 
would be preferable to complete inhibition. This could even be extended to incorporate some 
form of exercise treatment as Stolen et al., (2009) showed that aerobic interval training 
resulted in reduced levels of CaMKIIδ and improved cardiac function in T2D mice compared 
to their sedentary counterparts, which had increased cardiac CaMKIIδ expression and reduced 
cardiomyocyte contractile function and Ca2+ handling. This is particularly relevant from a 
preventative medical care point of view, as more and more evidence is being providing of the 
beneficial effects of exercise (Warburton et al., 2006; Pedersen & Saltin, 2015), not just on 
cardiovascular health (Flynn et al., 2009; Maltais et al., 1996; Demopoulous et al., 1997) but 
on indices of skeletal muscle (McCartney et al., 1993; Pollock et al., 2000) and mental health 
(Cooney et al., 2013; Conn 2010; Bartley et al., 2013; Galper et al., 2006) and general 
enhancement of the quality of life (Bize et al., 2007). Therefore CaMKIIδ inhibition may be a 
useful acute treatment in patients followed by a transition to a long-term plan of exercise.  
 
6.3.3 Specific inhibitors 
 
The observation of improved contractility in the T2D muscle after CaMKIIδ inhibition with 
KN93 and AIP is very promising. However if CaMKIIδ inhibition is ever to be used in the 
clinic, much more specific inhibitors will be required. KN93 is neither isoform nor tissue-type 
specific and thus would have deleterious off-target effects via the two CaMKII isoforms 
within the brain. AIP is more specific than KN93; however, it is a peptide inhibitor and thus 
breaks down within the body. Therefore further research would be required to design a 
selective inhibitor that is safe and effective for therapeutic use, in addition to being isoform 
and organ specific. Fortunately, such CaMKIIδ inhibitors are currently in development 




DHD is an increasing problem worldwide and will continue to impose health, social and 
economic burdens on society. Here, we identify CaMKIIδ activation as a novel mediator of 
cardiac contractility in the T2D heart. Thus, the work in this thesis provides novel evidence 
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that can be extended to further investigate the therapeutic potential of CaMKIIδ inhibition in 
the T2D heart. 
! 198 
APPENDIX 1 



























Fig 3.i Contraction and relaxation in isolated right ventricle trabeculae from non-diabetic (nDM) rats in the presence of KN92 and KN93. A, 
Developed force (Fdev). B, Maximum rate of contraction (dF/dtmax). C, Maximum rate of relaxation (dF/dtmin). D, Relaxation time from 50-90% of 
relaxation (RT90%). Data are means + SEM. nDM rat KN92, solid black line, n=9 rats (10 muscles); DM rat KN93, solid red line, n= 6 rats (9 muscles). For 
all parameters two-way between groups ANOVA: * = P< 0.05 treatment effect (nDM KN92 vs nDM KN93). 






























































































Fig 3.ii Contraction and relaxation in isolated right ventricle trabeculae from non-diabetic (nDM) rats in the presence of CTRL and AIP. A, 
Developed force (Fdev). B, Maximum rate of contraction (dF/dtmax). C, Maximum rate of relaxation (dF/dtmin). D, Relaxation time from 50-90% of 
relaxation. Data are means + SEM. nDM rat CTRL, solid black line, n=5 rats (13 muscles); nDM rat AIP, solid blue line, n=8 rats (15 muscles). For all 
parameters two-way between groups ANOVA: # = P< 0.05 treatment effect (nDM CTRL vs nDM AIP. 
















































































































Figure 3.iii Contraction and relaxation in isolated right ventricle trabeculae from non-
diabetic (nDM) rats in the presence of KN92 and KN93 during β-Adrenergic 
stimulation. A, Developed force (Fdev). B, % change in Fdev from 2 Hz baseline. C, Speed of 
contraction (dF/dtmax). D, % change in dF/dtmax from 2 Hz baseline. E, Speed of relaxation 
(dF/dtmin). F, % change in dF/dtmin from 2 Hz baseline. G, Relaxation time from 50-90% of 
relaxation (RT90%). H, % change in RT90% from 2 Hz baseline. Data are means + SEM. 
nDM rat KN92, solid line & black bar, n = 9 rats (10 muscles); nDM KN93, solid line, red bar, n= 
6 muscles (5 rats). For all parameters two-way between groups ANOVA: # = P< 0.05 treatment 
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Figure 3.iv Contraction and relaxation in isolated right ventricle trabeculae from non-
diabetic  (nDM) rats in the presence of CTRL and AIP during β-Adrenergic stimulation. 
A, Developed force (Fdev). B, % change in Fdev from 2 Hz baseline. C, Speed of contraction 
(dF/dtmax). D, % change in dF/dtmax from 2 Hz baseline. E, Speed of relaxation (dF/dtmin). F, 
% change in dF/dtmin from 2 Hz baseline. G, Relaxation time from 50-90% of relaxation 
(RT90%). H, % change in RT90% from 2 Hz baseline. Data are means + SEM. nDM rat 
CTRL, solid black line & black bar, n = 5 rats (13 muscles); nDM AIP, solid blue line, blue bar, 
n= 14 muscles (5 rats). For all parameters two-way between groups ANOVA: * = P< 0.05 
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Figure 3.v Contration and relaxation in isolated trabeculae taken from the right atrial appendage in non-diabetic (nDM) patients undergoing 
coronary artery by pass surgery in the presence of KN92 and KN93. A, Developed force (Fdev). B, Maximum rate of contraction (dF/dtmax). C, 
Maximum rate of relaxation (dF/dtmin). D, Relaxation time from 50-90% of relaxation (RT90%). Data are means + SEM.  nDM KN92, solid black line, n 
=2 patients (5 muscles), nDM KN93, solid red line, n= 2 patients, 5 muscles. Note: RAA was removed under normothermic conditions before cross clamping 
bypass surgery. Immediately after removal, all specimens were placed in a sealed vial containg a modified, low Ca2+ (0.5 mM) KHB ((mM: 118.5 NaCl, 4.5 
KCl, 1.4 CaCl2, 0.3 NaH2PO4, 1.0 MgCl26H2O, 25 NaHCO3 and 11 glucose) with 6.5 mM KCl previously well oxygenated with carbogen (95% oxygen and 
5% carbon dioxide).  
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Appendix 2.1- Contractile force in isolated right ventricle trabeculae from type 2 
diabetic rats in those that exhibited spontaneous contractions and those that did not, in 
KN92 and KN93 conditions. 
 
 
Figure 4.i Contractile force in type 2 diabetic isolated right ventricle trabeculae in those 
that exhibited spontaneous contractions and those that did not in KN92 and KN93 
conditions. Developed force (Fdev). Data are means + SEM. DM KN92 no spontaneous 
contractions, solid black line, n= 9 muscles (8 rats), DM KN92 with spontaneous contractions, 
black dotted line, n= 4 muscles (4 rats), DM KN93 no spontaneous contractions, solid red line, n= 
4 muscles (4 rats), DM KN93 with spontaneous contractions, dotted red line, n= 4 muscles (4 
rats). For all parameters two-way between groups ANOVA: * = P< 0.05 DM KN92 no 
spontaneous contractions vs DM KN92 with spontaneous contractions, # = P< 0.05 DM KN93 no 
spontaneous contractions vs DM KN93 with spontaneous contractions, // = P< 0.05 DM KN92 
with spontaneous contractions vs DM KN93 with spontaneous contractions.  
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Appendix 3.1- Animal characteristics from ZDF rats used for cardiomyocyte 
experiments at University of California, Davis 
 
 
Table 4.i. Animal characteristics in 18-19-week old male non-diabetic (6) and type 2 diabetic 










nDM= non diabetic rats; DM= T2D rats; HW: heart weight; TL: Tibia length. Data are 
expressed as mean ± SEM. For comparison of all parameters between nDM & DM an 
independent t-test with non-parametric Mann-Whitney was used when appropriate, *= P 
<0.05. For comparison of animal characteristics in nDM and DM animals at 20 weeks of age 
from the University of Otago breeding facility (see Table 3.1) and those from the University 
of California, Davis breeding facility an independent t-test with non-parametric Mann-
Whitney was used when appropriate, Δ= P <0.05. 
!
Parameter nDM DM 
Body weight (g) 382.92 ± 6.48 438.44 ± 12.40 * 
Blood glucose 
(mmol/L) 
9.65 ± 0.16 27.16 ± 1.70 * 
Heart weight (g) 1.81 ± 0.09 1.83 ±0.07 
Tibia length (mm) 25.93 ± 0.33  Δ 25.6 ± 0.21  Δ 
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